

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

A Systematic Assessment of Cochrane Reviews and Systematic Reviews Published in High-Impact Medical Journals Related to Cancer

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020869
Article Type:	Research
Date Submitted by the Author:	28-Nov-2017
Complete List of Authors:	Goldkuhle, Marius; Uniklinik Koln, Department I of Internal Medicine Narayan, Vikram; Minneapolis Veterans Administration Health Care System, Urology Section; University of Minnesota, Department of Urology Weigl, Aaron; Uniklinik Koln Klinik I fur Innere Medizin Dahm, , Philipp ; Minneapolis Veterans Administration Health Care System, Urology Section; University of Minnesota, Department of Urology Skoetz, Nicole; University Hospital of Cologne , Cochrane Haematological Malignancies Group; Department I of Internal Medicine
Keywords:	methodological systematic review, AMSTAR, quality assessment

SCHOLARONE™
Manuscripts

Peer Review Only

1
2
3
4
5
6 **A Systematic Assessment of Cochrane Reviews and Systematic Reviews Published in High-**
7 **Impact Medical Journals Related to Cancer**
8
9
10
11
12
13
14
15

16 Marius Goldkuhle, Masters Student;¹ Vikram M. Narayan, House Officer;² Aaron Weigl,
17 Research Associate;¹ Philipp Dahm, Professor;² and Nicole Skoetz, MD Senior Lecturer¹
18
19
20

21 ¹Department of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937
22 Cologne, Germany
23

24 ²Minneapolis Veterans Administration Health Care System and Department of Urology,
25 University of Minnesota, Mayo Memorial Building, 420 Delaware St SE, MMC 394,
26 Minneapolis, MN 55455, US
27
28

29 **Correspondence to:**
30

31 Marius Goldkuhle, B.Sc.
32

33 Kerpener Str. 62
34

35 50937 Cologne, Germany
36

37 Email: marius.goldkuhle@uk-koeln.de
38

39 Phone: +49 221 478-96648
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: To compare cancer-related systematic reviews (SRs) published in the Cochrane Database of SRs (CDSR) and high-impact journals, with respect to type, content, quality, and citation rates.

Design: Methodological SR with assessment and comparison of SRs and meta-analyses. Two authors independently assessed methodological quality using an Assessment of Multiple Systematic Reviews (AMSTAR) –data based extraction form. Both authors independently screened search results, extracted content-relevant characteristics, and retrieved citation numbers of the included reviews using Clarivate Analytics Web of Science database.

Data sources: Cancer-related SRs were retrieved from the CDSR, as well as from the ten journals which publish oncologic SRs and had the highest impact factors, using a comprehensive search in the CDSR and MEDLINE.

Eligibility criteria for selecting studies: We included all cancer-related SRs and meta-analyses published from January 2011 to May 2016. Methodological SRs were excluded.

Results: We included 346 applicable Cochrane reviews and 215 SRs from high-impact journals. Cochrane reviews consistently met more individual AMSTAR criteria, notably with regards to an a-priori design (RR 3.89; 95% CI 3.10 to 4.88), inclusion of the grey literature and trial registries (RR 3.52; 95% CI 2.84 to 4.37) in their searches, and the reporting of excluded studies (RR 8.80; 95% CI 6.06 to 12.78). Cochrane reviews were less likely to address questions of prognosis (RR 0.04; 95% CI 0.02 to 0.09), use individual patient data (RR 0.03; 95% CI 0.01 to 0.09), or be based on non-randomised controlled trials (RR 0.04; 95% CI 0.02 to 0.09). Citation rates of Cochrane reviews were notably lower than those for high-

1
2
3
4
5
6 impact journals (Cochrane reviews: mean number of citations 6.52 (range 0 to 143); High-
7 impact journal SRs: 74.45 (0 to 652)).

8
9
10
11 **Conclusions:** When comparing cancer-related SRs published in the CDSR versus those
12 published in high-impact medical journals, Cochrane reviews were consistently of higher
13 methodological quality, but were cited less frequently.
14
15

16
17
18
19
20
21 **Strengths and limitations of this study**

22
23 -Unique cross-disciplinary comparison of systematic reviews in oncology including over 550
24 SRs.
25

26
27
28 -Methodological assessment using AMSTAR, a validated and widely used tool to evaluate the
29 quality of systematic reviews.
30

31
32
33 -It was not feasible to blind the authors of this study to the source journal of a given review,
34 which may have potentially biased the assessments.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

Introduction

The care of patients with cancer continues to be a clinical research priority as documented by an increasing number of publications of different types including systematic reviews (SRs). In fact, in recent years, oncology has been the medical discipline with the highest number of publications and the numbers continue to rise.¹ The large number of oncology-related research studies poses a tremendous challenge for patients, healthcare providers, and health policymakers alike when seeking to stay abreast of a particular oncologic topic. SRs follow reproducible methods to identify relevant studies for a given question, apply pre-defined and explicit eligibility criteria, perform assessments of the validity of findings, and systematically present the results. In this context, SRs can be helpful in summarizing the current best evidence for a particular clinical question to support both individual decision-making and in serving as the basis for clinical practice guidelines.^{2 3} Cochrane is widely known for having developed many of the methodological standards based on which SRs should be conducted. These standards are specified in the 2016 updated Methodological Expectations of Cochrane Intervention Reviews (MECIR). However, a large number of oncology-related SRs are currently published by clinical journals, high-impact medical journals, oncology focused journals, as well as subspecialty journals. As the number of SRs has steadily increased over the past two decades, their methodological rigor has been drawn into scrutiny.⁴⁻⁶ To date, no study has formally assessed the methodological quality of oncology-related SRs which assume such a prominent place in the medical literature.

In this study, we therefore sought to formally assess the methodological quality, type, content, and citation rates of oncology related SRs, comparing SRs published in high-impact medical journals with those published in the Cochrane Database of SRs (CDSR).

Methods

The design and eligibility criteria of this project were based on an a priori written protocol. Study reporting is provided in accordance with the PRISMA statement. However, as a methodology-focused review, it was not eligible for a registration in the International Prospective Register Of Systematic Reviews (PROSPERO).

Patient involvement:

Given its methodologic focus, we did not evaluate patient-related outcomes. Therefore, we also chose not to involve patients' input in its design. However, the clear intent of this study is to indirectly benefit the welfare of patients by promoting the development and dissemination of high quality systematic reviews.

Eligibility criteria:

We selected all Cochrane reviews that examined questions related to oncology. We furthermore identified all cancer related SRs published in the highest impact medical journals, as defined by the InCites™ Journal Citation Report® 2014, from the same time period via an electronic database search. To reflect contemporary reviews, we chose the five year period between January 2011 and May 2016 as the study timeframe. We did not apply restrictions with regards to study design or meta-analytic methods, and also included SRs without a meta-analysis. We broadly included studies related to all types of cancer.

The ten journals with the highest impact factors that published SRs on cancer topics were: *A Cancer Journal for Clinicians*, *New England Journal of Medicine*, *The Lancet*, *JAMA*, *Lancet Oncology*, *Journal of Clinical Oncology*, *The BMJ*, *Nature Reviews Clinical Oncology*,

1
2
3
4
5
6 *Journal of the National Cancer Institute*, and *Cancer Research*. We did not apply any
7
8 language restrictions, however the selected journals published exclusively in English. We
9
10 excluded SRs with a methodological focus. For our examination, we used the original English
11
12 version of each Cochrane review (given that foreign language translation exists for many
13
14 Cochrane reviews). In cases where one or more updates of previously published Cochrane
15
16 reviews existed, we based our assessment on the most recently published version within the
17
18 defined timeframe.
19

20 21 *Study identification and selection*

22
23 We identified all cancer-related Cochrane reviews in the CDSR from January 2011 to
24
25 May 2016 using the built in “Browse by topic” database function with the options “Cancer”
26
27 and “Stage: Review.” In a parallel step, we conducted a comprehensive literature search of
28
29 SRs published in the ten highest-impact journals from the same time-period on June 1st,
30
31 2016. An information specialist developed the search strategy for MEDLINE using the
32
33 following search terms: Cancer, leukaemia, tumor, tumour, leukemia, lymphoma, myeloma,
34
35 solid, neoplasm, meta-analysis, systematic review, publication dates: 2011 to 2016. We used
36
37 the following MeSH terms: Neoplasm by Histologic Type and Neoplasms by Site. The full
38
39 search strategy is provided in the *appendix*. Two authors independently (MG, VN) and in
40
41 duplicate performed title and abstract screening, full text screening, and ultimately,
42
43 selection of reviews to be included. We resolved discrepancies by discussion with one of two
44
45 other authors (NS, PD).
46

47 48 *Quality assessment*

49
50 We evaluated methodological quality with the Assessment of Multiple Systematic
51
52 Reviews (AMSTAR) checklist, by Shea, et al.⁷ The checklist consists of 11 items and was
53
54
55
56
57
58
59
60

1
2
3
4
5
6 specially developed to assess the methodological quality of SRs and meta-analyses. In cases
7
8 where AMSTAR combined several items into one criterion, we separated these out into 20
9
10 individual items for the sake of transparency but readjusted them into single items for the
11
12 AMSTAR scoring. A complete list of items can be found in the *appendix*; answer options were
13
14 “yes,” “no,” and “not applicable.” Methods like sensitivity- and subgroup-analyses, or funnel
15
16 plots for the assessment of publication bias require a minimum quantity of studies. For
17
18 example, meaningful interpretations of funnel plots require a threshold of at least ten
19
20 studies.⁸ In SRs where there was evidence that these secondary analyses were planned, but
21
22 not be meaningfully conducted, this criterion was rated as fulfilled. Two authors (MG, VN)
23
24 performed the quality assessments independently and in duplicate. We resolved
25
26 disagreements by discussion and with a third author (NS, PD).
27
28

29 *Data extraction and extracted items*

30
31 The included studies were then reviewed in detail as part of a clinical content
32
33 analysis. We extracted the review type, the study design of the included studies, and review
34
35 question (e.g. therapeutic, diagnostic, or prognostic) of included studies. We chose the
36
37 following items to reflect the review content: Cancer type (e.g. breast, lung, colorectal, but
38
39 also “cancer in general”, “mixed” (but not in general) and “other” (e.g. liver metastases or
40
41 male breast cancer), intervention (e.g. chemotherapy, “new drug” (targeted therapies, such
42
43 as monoclonal antibodies and small molecules)), radiotherapy, surgery, supportive (e.g.
44
45 interventions for cancer-related pain, rehabilitation after cancer treatment, interventions for
46
47 depression in cancer patients, or adjuvant bisphosphonate treatment for cancer patients), or
48
49 not applicable (if prognostic, diagnostic or epidemiological review question), population
50
51 (adults, children or both), the number of included studies, and the number of included
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 patients. A complete list of the 17 criteria can be found in the *appendix*. To ensure the
7
8 completeness of our assessment we obtained and formally considered any additional
9
10 information from all (online) supplements and appendices. Two authors (MG, VN)
11
12 independently extracted this data using a previously piloted form. The data extraction form
13
14 was designed a priori with consensus of four authors (MG, VN, NS, PD). Discrepancies were
15
16 once again resolved through discussion and third author arbitration if necessary (NS, PD).
17

18 19 *Citations*

20
21 We gathered the citation counts for both Cochrane reviews and high-impact journal
22
23 reviews using the Clarivate Analytics Web of Science database. Citations counts were
24
25 assessed on February 15th, 2017 by two authors independently (AW, MG). For updates of
26
27 Cochrane reviews, we considered the citations of the respective update(s) and added
28
29 citations from the original review, as long as the original review and any updates were
30
31 published within the predefined timeframe of our study.
32

33 34 *Data synthesis and analysis*

35
36 For dichotomous variables, we determined rates, and for continuous variables, we
37
38 calculated median and interquartile range (IQR), or mean and range. To compare the quality
39
40 of both groups, we used risk ratios and the corresponding 95% confidence intervals. We
41
42 defined an event as fulfilling a given quality indicator and have presented this data in forest
43
44 plots. All statistical analyses were undertaken using Review Manager Version 5.3.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Search results

As shown in the study flowchart (Figure 1), our search for oncology-related Cochrane reviews identified 412 records, of which 346 were determined to be cancer related and appropriate according to our selection criteria. Our electronic database search for high-impact SRs identified 738 records, of which 215 were ultimately included, excluding seven reviews at the full-text stage which focused on methodological issues (Figure 2).⁹⁻¹⁵ The references of the included articles are provided in the *online appendix*.

Quality

In general, reviews published by Cochrane met each quality criterion to a greater extent than reviews published in high-impact journals (Figure 3). Cochrane reviews were more likely to report an a priori design, including the definition of the review question and a planned inclusion and exclusion criteria before conducting the review (both with a risk ratio of 3.89; 95% confidence interval (CI) 3.10 to 4.88) (AMSTAR Item 1). Differences also existed in the inclusion of unpublished and non-English literature; Cochrane reviews were more likely to include unpublished (risk ratios (RR) 3.52 (95% CI 2.84 to 4.37) and non-English studies) (RR 3.23 (95% CI 2.64 to 3.95)) (Item 4). Included studies were listed relatively equally between the two (RR 1.10; 95% CI 1.05 to 1.14) comparators, whereas a list of excluded studies, at least those rejected in the course of full-text screening, were provided almost nine times more often by Cochrane reviews (RR 8.80; 95% CI 6.06 to 12.78) (Item 5). Further, a quality assessment of the included studies (using tools such as Cochrane's Risk of Bias, the Jadad scale, or the Newcastle-Ottawa scale) were undertaken over twice as frequently in Cochrane reviews (RR 2.17; 95% CI 1.88 to 2.50) (Item 7). A meta-analysis was

1
2
3
4
5
6 conducted in 67% (227/346) of Cochrane reviews and in 80% (173/215) of high-impact
7
8 journal SRs. A sensitivity analysis based on study quality or risk of bias was more commonly
9
10 reported in Cochrane reviews (RR 4.17; 95% CI 3.07 to 5.67). Almost 23% (53/227) of
11
12 Cochrane reviews planned to undertake, but did not perform sensitivity-analyses due to an
13
14 insufficient number of included studies, the inclusion of high risk of bias studies only, or
15
16 unclear information regarding study quality. Formal assessments of potential publication
17
18 bias like funnel plots were undertaken or planned about twice as frequently among reviews
19
20 produced by Cochrane (RR 1.98; 95% CI 1.63 to 2.41) than in SRs published in high impact
21
22 journals. However, 47.3% (107/226) of Cochrane reviews and 1.7% (3/173) of reviews from
23
24 high-impact journals planned, but could not perform such assessments due to an insufficient
25
26 number of included studies (AMSTAR Item 10). The vast majority of SRs both in Cochrane
27
28 reviews and high-impact journals disclosed potential conflicts of interest of the systematic
29
30 review authors (RR 1.01; 95% CI 1.00 to 1.03). However, potential conflicts of interest of the
31
32 trials included in the SRs were reported more frequently by Cochrane reviews than by SRs in
33
34 high-impact journals; with Cochrane reviews being more than four times as likely to provide
35
36 this information (RR 4.30; 95% CI 2.56 to 7.20) (Item 11).
37
38

39 *Characteristics of included SRs*

40
41 With regards to geographical origin, the largest proportion of Cochrane reviews
42
43 originated from Europe (67.3%; 233/346) and relatively infrequently originated from North
44
45 America (7.5%; 26/346); meanwhile, high-impact journal SRs were as likely to come from
46
47 Europe (44.2%; 95/215) or North America (40.9%; 88/215; Table 1). Cochrane reviews were
48
49 much less likely to use individual patient data (IPD) (RR 0.03; 95% CI 0.01 to 0.09) compared
50
51 to aggregate study-level data. The majority of Cochrane reviews used the latter (95.7%;
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

331/346), with only three (0.9%; 3/346) including individual patient data exclusively, and 12 (3.5%; 12/346) using both types of data. SRs from high-impact journals were also primarily based on study level data (68.4%; 147/215), but a much larger proportion used IPD (31.2%; 67/216). Network meta-analyses were uncommon among both Cochrane reviews (0.6%; 2/346) and high-impact SRs (2.8%; 6/215).

Cochrane reviews predominantly investigated therapeutic (89%; 308/346) questions. Among SRs from high-impact journals, there were also a large number of prognostic reviews (37.2%; 80/215) in addition to therapeutic reviews (41.9%; 90/215; Figure 4). Overall, Cochrane reviews were less likely to include non-randomised controlled trials (RR 0.04; 95% CI 0.02 to 0.09). Therapeutic reviews published in the CDSR primarily included RCTs in 78.6% (242/308) or both RCTs and non-RCTs in 21.1% (65/308). High-impact journal reviews assessing therapeutic questions were primarily based on RCTs (58.9% (53/90)), with only 26.7% (24/90) based on non-RCTs.

Content of included SRs

91.9% (318/346) of the Cochrane reviews and 70.2% (151/215) high-impact journal SRs focused on adult study populations. Only 7.5% (26/346) of SRs from the CDSR and 2.8% (6/215) of reviews from high-impact journals focused solely on paediatric patients.

The largest group of Cochrane reviews addressed general cancer topics (for example: supportive measures for patients receiving cytotoxic chemotherapy) not limited to a specific type of disease (18.8 %; 65/346), followed by SRs concerning hematological malignancies (12.4%; 43/346), and breast cancer (8.4%; 29/346; Figure 5). Among SRs published in high-

1
2
3
4
5
6 impact journals, general cancer topics was also the main category followed by breast cancer
7
8 in 21.4% (47/215) and colorectal cancer in 7.9% (17/215).
9

10
11 SRs published in Cochrane most commonly examined supportive care interventions
12
13 (40.3%; 126/313), followed by chemotherapy (20.1%; 63/313), and surgery (16.7%; 49/313;
14
15 Figure 6). Reviews in high-impact journals, on the other hand, predominantly evaluated
16
17 specific chemotherapy regimens (25.3%; 23/91), new drugs (18.7%; 17/91), and supportive
18
19 care interventions (18.7%; 17/91).
20

21
22 Overall, Cochrane reviews included fewer studies per review than high-impact journal
23
24 SRs (median: 6 studies (IQR: 2-13) compared to 18 (18-38.8)) and fewer patients (1020
25
26 (194.5-2845) compared to 7730 (3288-29.423)). About 11.3% (39/346) of Cochrane SRs were
27
28 so-called “empty reviews”, meaning the authors could not identify eligible studies to include
29
30 in their review. Furthermore, 35 (10.1%) reviews retrieved from the CDSR included only one
31
32 study. In contrast, none of the SRs in high-impact journals were empty or contained only a
33
34 single study.
35

36 *Citations*

37
38 Cochrane reviews were cited considerably less frequently than SRs published in high-
39
40 impact medical journals. The mean number of citations for Cochrane reviews was 6.92,
41
42 ranging from 0 to 143. High-impact journal SRs had a mean of 74.45 citations with a range
43
44 from 0 to 652.
45
46
47
48
49
50
51
52
53
54

Discussion

Principal findings

This methodological assessment found that Cochrane reviews were conducted with greater methodological rigor than SRs published in high-impact journals but were cited less frequently. The largest gap in terms of methodological quality with regards to an individual AMSTAR criterion was the reporting of excluded studies, which was met by all Cochrane reviews and only 11.2% (24/215) of SRs published by high-impact journals. Other major differences relate to the reporting of possible conflicts of interest of included studies, the existence of an a priori design, the conduct of sensitivity analyses for study quality of included studies, and the inclusion of non-published studies. High-impact SRs were more likely to be based on IPD, include non-RCTs and address questions other than therapy, namely prognosis. SRs that included only one or no included studies were published exclusively in the Cochrane Library, and not in high-impact journals.

Strengths and weaknesses of this systematic review

We performed this study based on an a priori protocol, a comprehensive search strategy, and data abstraction in duplicate, which lends strength to the validity of our findings. In addition, we performed a clinical content analysis comparing the two groups of SR sources. The reliability of this work was ensured through adherence to the review methods proposed by PRISMA and Cochrane. Our quality assessment was based on AMSTAR, an instrument previously validated for the assessment of SRs from RCTs which represented the best available tool at the time when we planned and conducted this review.^{16 17} An updated version of AMSTAR has only recently become available.¹⁸

1
2
3
4
5
6 Given its focus on methodological quality, this study is unable to explain the missing link
7
8 between the high methodological quality of Cochrane reviews and relatively low citation
9
10 rates. Potential explanations may relate to the clinical topic areas, and too great a focus on
11
12 evidence from RCTs, which has long been a hallmark of Cochrane reviews. In addition,
13
14 Cochrane reviews that include none (“empty reviews”) or only one study are less likely to
15
16 provide newsworthy results and yield high citation rates.
17

18
19 The Cochrane Library permits co-publication of Cochrane reviews in other journals, which is
20
21 however subject to formal pre-approval. A large number of co-published reviews could have
22
23 potentially biased our results, though we identified only two reviews with this issue; this this
24
25 concern is only of minor relevance.^{19 20}
26

27 28 *Strengths and weaknesses in relation to other systematic reviews*

29
30 In 2016, an assessment of cross-sectional SRs was published which included a similar
31
32 comparison of Cochrane and non-Cochrane reviews.⁵ This assessment was cross-disciplinary
33
34 and not limited to cancer alone. It comprised of SRs published during a one month period in
35
36 2014, and only 3% (9/300) of the total assessed SRs came from journals with an impact
37
38 factor exceeding ten. Most of the randomly selected SRs and Cochrane reviews investigated
39
40 therapeutic questions. Similar to our study, Cochrane reviews were more likely to fulfil the
41
42 important methodological criteria such as protocol availability, the inclusion of unpublished
43
44 and grey literature, an electronic data-search in more than two databases, data extraction
45
46 and study selection performed in duplicate, or the assessment of study quality. Findings
47
48 were also similar with regards to the proportion of reviews that did not perform a sensitivity
49
50 analysis based on study quality.⁵ Another similar study by Moher et al. documented
51
52 improved reporting over a 10 year time frame.⁴ A variety of other reports, including
53
54

1
2
3
4
5
6 assessments in other medical research fields have identified similar deficiencies in the
7
8 quality of SRs but none of them have specifically focused on oncology-related reviews.^{6 16 21-}
9

10²⁶

11
12
13 *Meaning of this methodological systematic review: explanations, implications and further*
14
15 *research*

16
17 Our methodological assessment highlights the major differences that exist among
18
19 published SRs in oncology. Users of the medical literature should therefore not assume that
20
21 SRs are equivalent in their design, methodological rigor, or validity of their conclusions.

22
23 Quality criteria for SRs are well established; one key criterion is that of an a priori protocol
24
25 which governs all aspects of the review process to prevent selective or biased reporting and
26
27 avoid duplicate publication.²⁷⁻³⁰ Registration of protocols with platforms such as PROSPERO
28
29 can aid in holding SRs accountable in this regard; some journals have made this mandatory.³¹
30
31 Deficits in the disclosure of excluded studies, for example, narrow the transparency of study
32
33 selection, while absence of sensitivity analyses impede readers' accessibility of the findings
34
35 against the background of study quality. Conflicts of interest may also play a role in the
36
37 heterogeneity of published SRs.

38
39
40 A practical reason for differences in the reporting quality between Cochrane reviews
41
42 and high-impact medical journals may lie in the limited space for reporting provided in
43
44 printed medical journals. A recent assessment of meta-analyses of surgical interventions
45
46 supports the assumption of the negative association between limited publication space and
47
48 completeness of reporting.²⁵ Cochrane does not impose space restrictions and as such
49
50 Cochrane SR authors have more freedom to provide complete reporting. However, given
51
52 that most journals now offer the opportunity to provide additional e-content on the
53
54

1
2
3
4
5
6 internet, there should be fewer reasons for less than complete transparency. In this
7
8 assessment, we took care to include all available content, including online supplementary
9
10 tables and appendices in our assessment. Published Cochrane reviews typically also undergo
11
12 a more rigorous development process that includes the compulsory publication of a protocol
13
14 that has previously undergone internal editorial review and external peer review as specified
15
16 in the organization's MECIR policy. This may be the main reason why Cochrane reviews are
17
18 much more likely to meet more of the requirements of transparent reporting checklists.^{17 32}

19
20 ³³ Journal editors should similarly mandate strict adherence to PRISMA and other reporting
21
22 guidelines.
23

24
25 Given the considerable investment of resources that goes into development of high
26
27 quality Cochrane reviews, their relatively low impact is a concern. It appears critically
28
29 important that Cochrane editors take greater initiative at directing review authors to topics
30
31 where the greatest clinical interest lies.
32

33
34 This work demonstrates the need to critically assess SRs prior to using their evidence.
35
36 For clinicians, the *Users' Guide to the Medical Literature* by Murad, et al.³⁰ provides a
37
38 practical framework for assessing the validity, impact and applicability of SRs. For
39
40 researchers and policy-makers aside from AMSTAR, the recently introduced ROBIS tool
41
42 allows to comprehensively evaluate possible risk of bias in SRs at the review level.³⁴ At
43
44 present it covers SRs with interventional, diagnostic, prognostic, and etiologic review
45
46 questions and involves a three domain appraisal of the relevance of the respective review,
47
48 an evaluation of possible risks of bias during the review process, and a concluding judgment
49
50 of overall risk of bias of the review findings.³⁴
51
52
53
54
55
56
57
58
59
60

Conclusion

Cancer-related SRs that are published in the CDSR demonstrate higher adherence to methodological and reporting standards than cancer-related SRs published in high-impact medical journals but are cited less frequently. Our assessment underscores the importance of performing a critical appraisal of SRs before including their evidence into guideline development or making individual clinical decisions.

Acknowledgements

Contributors: MG designed the data collection tools and analysis, selected studies, analysed and extracted data, and drafted and revised the paper. VN designed the data collection tools and analysis, selected studies, analysed and extracted data, and drafted and revised the paper. AW extracted and analysed data and revised the paper. PD initiated the project, designed the data collection tools and analysis, selected studies, monitored data collection and analysis, and revised the paper. NS initiated the project, designed the data collection tools and analysis, selected studies, monitored data collection and analysis, and revised the paper. All authors approved the final version of the article. All authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Copyright: The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the BMJ Publishing Group Ltd and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above. We attest that we have obtained appropriate permissions and paid any required fees for use of copyright protected materials.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Funding: Two authors received travel grants by Cochrane to attend and present data at the 23rd Cochrane Colloquium in Seoul, 2016. This research received no other specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: MG, AW and NS are part of the Cochrane Haematological Malignancies Group, PD is part of the Cochrane Urology Group. Further they declare: No other support from any organisation for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethical approval: Not required

Data sharing: No additional data available

Transparency: We affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

1
2
3
4
5
6 **Figure legends**
7

8
9 Figure 1. PRISMA flow diagram of Cochrane reviews
10

11
12 Figure 2. PRISMA flow diagram of high-impact journal SRs
13

14
15 Figure 3. Forrest plot comparing to what extent Cochrane reviews and SRs published in high-
16 impact journals meet criteria for methodological quality
17

18
19 Figure 4. Distribution of Cochrane reviews and high-impact journal SRs by review question
20

21
22 Figure 5. Distribution of Cochrane reviews and high-impact journal SRs by disease
23

24
25 Figure 6. Distribution of Cochrane reviews and high-impact journal SRs by intervention
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

References

1. 2015 Journal Citation Reports®: Clarivate Analytics; 2017 [
2. Woolf S, Schunemann HJ, Eccles MP, et al. Developing clinical practice guidelines: types of evidence and outcomes; values and economics, synthesis, grading, and presentation and deriving recommendations. *Implementation science : IS* 2012;7:61. doi: 10.1186/1748-5908-7-61 [published Online First: 2012/07/06]
3. Mulrow CD. Rationale for systematic reviews. *BMJ (Clinical research ed)* 1994;309(6954):597-9. [published Online First: 1994/09/03]
4. Moher D, Tetzlaff J, Tricco AC, et al. Epidemiology and reporting characteristics of systematic reviews. *PLoS medicine* 2007;4(3):e78. doi: 10.1371/journal.pmed.0040078 [published Online First: 2007/03/29]
5. Page MJ, Shamseer L, Altman DG, et al. Epidemiology and Reporting Characteristics of Systematic Reviews of Biomedical Research: A Cross-Sectional Study. *PLoS medicine* 2016;13(5):e1002028. doi: 10.1371/journal.pmed.1002028 [published Online First: 2016/05/25]
6. Han JL, Gandhi S, Bockoven CG, et al. The landscape of systematic reviews in urology (1998 to 2015): an assessment of methodological quality. *BJU International* 2017;119(4):638-49. doi: 10.1111/bju.13653
7. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC medical research methodology* 2007;7:10. doi: 10.1186/1471-2288-7-10 [published Online First: 2007/02/17]
8. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ (Clinical research ed)* 2011;343:d4002. doi: 10.1136/bmj.d4002 [published Online First: 2011/07/26]
9. Flaherty KT, Hennig M, Lee SJ, et al. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. *The Lancet Oncology* 2014;15(3):297-304. doi: 10.1016/s1470-2045(14)70007-5 [published Online First: 2014/02/04]
10. Freund KM, Battaglia TA, Calhoun E, et al. Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. *Journal of the National Cancer Institute* 2014;106(6):dju115. doi: 10.1093/jnci/dju115 [published Online First: 2014/06/19]
11. Lemieux J, Goodwin PJ, Bordeleau LJ, et al. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). *Journal of the National Cancer Institute* 2011;103(3):178-231. doi: 10.1093/jnci/djq508 [published Online First: 2011/01/11]
12. Paoletti X, Oba K, Bang YJ, et al. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. *Journal of the National Cancer Institute* 2013;105(21):1667-70. doi: 10.1093/jnci/djt269 [published Online First: 2013/10/11]

13. Peron J, Pond GR, Gan HK, et al. Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. *Journal of the National Cancer Institute* 2012;104(13):982-9. doi: 10.1093/jnci/djs259 [published Online First: 2012/07/05]
14. Zikos E, Ghislain I, Coens C, et al. Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials. *The Lancet Oncology* 2014;15(2):e78-89. doi: 10.1016/s1470-2045(13)70493-5 [published Online First: 2014/02/01]
15. Henson L, Gao W, Higginson I, et al. Emergency department attendance by patients with cancer in the last month of life: a systematic review and meta-analysis. *Lancet (London, England)* 2015;385 Suppl 1:S41. doi: 10.1016/s0140-6736(15)60356-7 [published Online First: 2015/08/28]
16. Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. *Journal of clinical epidemiology* 2009;62(10):1013-20. doi: 10.1016/j.jclinepi.2008.10.009 [published Online First: 2009/02/24]
17. Shea BJ, Bouter LM, Peterson J, et al. External validation of a measurement tool to assess systematic reviews (AMSTAR). *PloS one* 2007;2(12):e1350. doi: 10.1371/journal.pone.0001350 [published Online First: 2007/12/27]
18. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ (Clinical research ed)* 2017;358 doi: 10.1136/bmj.j4008
19. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. *Journal of the National Cancer Institute* 2012;104(21):1625-34. doi: 10.1093/jnci/djs374 [published Online First: 2012/09/11]
20. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer. *The Cochrane database of systematic reviews* 2012(4):Cd003916. doi: 10.1002/14651858.CD003916.pub4 [published Online First: 2012/04/20]
21. Fleming PS, Koletsi D, Seehra J, et al. Systematic reviews published in higher impact clinical journals were of higher quality. *Journal of clinical epidemiology* 2014;67(7):754-9. doi: 10.1016/j.jclinepi.2014.01.002 [published Online First: 2014/04/09]
22. Bafeta A, Trinquart L, Seror R, et al. Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review. *BMJ (Clinical research ed)* 2013;347:f3675. doi: 10.1136/bmj.f3675 [published Online First: 2013/07/03]
23. Cullis PS, Gudlaugsdottir K, Andrews J. A systematic review of the quality of conduct and reporting of systematic reviews and meta-analyses in paediatric surgery. *PloS one* 2017;12(4):e0175213. doi: 10.1371/journal.pone.0175213 [published Online First: 2017/04/07]

24. Fleming PS, Seehra J, Polychronopoulou A, et al. Cochrane and non-Cochrane systematic reviews in leading orthodontic journals: a quality paradigm? *European journal of orthodontics* 2013;35(2):244-8. doi: 10.1093/ejo/cjs016 [published Online First: 2012/04/19]
25. Adie S, Ma D, Harris IA, et al. Quality of conduct and reporting of meta-analyses of surgical interventions. *Annals of surgery* 2015;261(4):685-94. doi: 10.1097/sla.0000000000000836 [published Online First: 2015/01/13]
26. Windsor B, Popovich I, Jordan V, et al. Methodological quality of systematic reviews in subfertility: a comparison of Cochrane and non-Cochrane systematic reviews in assisted reproductive technologies. *Human reproduction (Oxford, England)* 2012;27(12):3460-6. doi: 10.1093/humrep/des342 [published Online First: 2012/10/05]
27. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ : British Medical Journal* 2015;349 doi: 10.1136/bmj.g7647
28. Page MJ, McKenzie JE, Kirkham J, et al. Bias due to selective inclusion and reporting of outcomes and analyses in systematic reviews of randomised trials of healthcare interventions. *The Cochrane database of systematic reviews* 2014(10):Mr000035. doi: 10.1002/14651858.MR000035.pub2 [published Online First: 2014/10/02]
29. Stewart L, Moher D, Shekelle P. Why prospective registration of systematic reviews makes sense. *Systematic reviews* 2012;1:7. doi: 10.1186/2046-4053-1-7 [published Online First: 2012/05/17]
30. Murad M, Montori VM, Ioannidis JA, et al. How to read a systematic review and meta-analysis and apply the results to patient care: Users' guides to the medical literature. *JAMA* 2014;312(2):171-79. doi: 10.1001/jama.2014.5559
31. Dahm P. Raising the bar for systematic reviews with Assessment of Multiple Systematic Reviews (AMSTAR). *BJU International* 2017;119(2):193-93. doi: 10.1111/bju.13754
32. Higgins JG, S. (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. March 2011 ed: The Cochrane Collaboration, 2011.
33. Julian PT Higgins TL, Jackie Chandler, David Tovey, Rachel Churchill. *Methodological Expectations of Cochrane Intervention Reviews*. London: Cochrane 2016.
34. Whiting P, Savović J, Higgins JPT, et al. ROBIS: A new tool to assess risk of bias in systematic reviews was developed. *Journal of clinical epidemiology*;69:225-34. doi: 10.1016/j.jclinepi.2015.06.005

Table 1: Baseline characteristics of the included Cochrane reviews and high-impact journal SRs

	Cochrane	High-impact journals								
	Cochrane reviews (n=346)	Total high-impact journal SRs (n=215)	J Natl Cancer Inst (n=56)	J Clin Oncol (n=56)	Lancet Oncology (n=53)	The BMJ (n=22)	Lancet (n=14)	JAMA (n=12)	CA Cancer J Clin (n=1)	Cancer Research (n=1)
Year first published (Number of SR (%))										
2011	45 (13.1)	45 (20.9)	9 (16.1)	14 (25)	13 (24.5)	2 (9.1)	4 (28.6)	3 (25)		
2012	60 (17.3)	50 (23.2)	20 (35.7)	11 (19.6)	11 (20.8)	4 (18.2)	1 (7.1)	3 (25)		
2013	80 (23.1)	31 (14.4)	7 (12.5)	8 (14.3)	8 (15.1)	5 (22.7)	2 (14.3)	1 (8.3)		
2014	59 (17.1)	51 (23.7)	11 (19.6)	10 (17.9)	15 (28.3)	7 (31.8)	4 (28.6)	4 (33.3)		
2015	69 (19.9)	32 (14.9)	6 (10.7)	11 (19.6)	5 (9.4)	4 (18.2)	3 (21.4)	1 (8.3)	1 (100)	1 (100)
2016	33 (9.5)	6 (2.8)	3 (5.4)	2 (3.6)	1 (1.9)					
Region (Number of SR (%))										
Europe	233 (67.3)	95 (44.2)	14 (25)	20 (35.7)	34 (64.2)	12 (54.5)	13 (92.9)	1 (8.3)	1 (100)	
North America	26 (7.5)	88 (40.9)	33 (58.9)	27 (48.2)	10 (18.9)	6 (27.3)	1 (7.1)	10 (83.3)		1 (100)
Asia	49 (14.2)	16 (7.4)	6 (10.7)	3 (5.4)	3 (5.7)	3 (13.6)		1 (8.3)		
Australia/ New Zealand	19 (5.5)	14 (6.5)	2 (3.6)	6 (10.7)	6 (11.3)					
South America	13 (3.8)	1 (0.5)	1 (1.8)							
Africa	6 (1.7)	1 (0.5)				1 (4.5)				
Review type (Number of SR (%))										
Study-level	331 (95.7)	147 (68.4)	39 (69.6)	40 (71.4)	35 (66)	19 (86.4)	1 (7.1)	11 (91.7)	1 (100)	1 (100)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

	<u>Cochrane</u>	<u>High-impact journals</u>								
	<u>Cochrane reviews (n=346)</u>	<i>Total high-impact journal SRs (n=215)</i>	<u>J Natl Cancer Inst (n=56)</u>	<u>J Clin Oncol (n=56)</u>	<u>Lancet Oncology (n=53)</u>	<u>The BMJ (n=22)</u>	<u>Lancet (n=14)</u>	<u>JAMA (n=12)</u>	<u>CA Cancer J Clin (n=1)</u>	<u>Cancer Research (n=1)</u>
data										
IPD	3 (0.9)	67 (31.2)	17 (30.4)	15 (26.8)	18 (34)	3 (13.6)	13 (92.9)	1 (8.3)		
Both	12 (3.5)	1 (0.5)		1 (1.8)						
Network Meta-Analysis (Number of SR (%))	2 (0.6)	6 (2.8)	3 (5.4)		3 (5.7)					
Study type (Number of SR (%))										
RCT	264 (76.3)	75 (34.9)	15 (26.8)	21 (37.5)	14 (26.4)	7 (31.8)	12 (85.7)	5 (41.7)	1 (100)	
non-RCT	5 (1.4)	85 (39.5)	27 (48.2)	16 (28.6)	27 (50.9)	12 (54.5)	1 (7.1)	2 (16.7)		
Both	77 (22.3)	46 (21.4)	9 (16.1)	19 (33.9)	9 (17)	3 (13.6)	1 (7.1)	5 (41.7)		
Unclear		9 (4.2)	5 (8.9)		3 (5.7)					1 (100)
Population (Number of SR (%))										
Adult	318 (9.9)	151 (70.2)	39 (69.6)	43 (76.8)	32 (60.4)	14 (63.6)	13 (92.9)	9 (75)	1 (100)	
Paediatric	26 (7.5)	6 (2.8)	1 (1.8)	1 (1.8)	4 (7.5)					
Both	2 (0.6)	22 (10.2)	5 (8.9)	6 (10.7)	7 (13.2)	4 (18.2)				
Unclear		36 (16.7)	11 (19.6)	6 (10.7)	10 (18.9)	4 (18.2)	1 (7.1)	3 (25)		1 (100)
Included studies (Median (IQR))	6 (2-13)	18 (10-38,8)	20 (12-43.8)	16 (9-36.3)	24 (12.8-44.8)	16 (9.6-26.5)	16 (25-9.8)	16.5 (10.3-24.8)	14	37

	<u>Cochrane</u>	<u>High-impact journals</u>								
	<u>Cochrane reviews (n=346)</u>	<i>Total high-impact journal SRs (n=215)</i>	<u>J Natl Cancer Inst (n=56)</u>	<u>J Clin Oncol (n=56)</u>	<u>Lancet Oncology (n=53)</u>	<u>The BMJ (n=22)</u>	<u>Lancet (n=14)</u>	<u>JAMA (n=12)</u>	<u>CA Cancer J Clin (n=1)</u>	<u>Cancer Research (n=1)</u>
Included patients (Median (IQR))	1020 (194.5-2845)	7730 (3288-29423)	8216 (3288-35568)	4758,5 (184.5-11091.8)	4600 (3033-21137)	117597 (10903-890992.3)	21471.5 (13287.5-45195.8)	12813.5 (4075.5-48067.3)	3377	Not reported
Citations (Median (IQR))	3 (1-7)	46 (18,5-86,5)	30.5 (9.8-55.3)	48,5 (18-70.3)	40 (22-97)	40 (15-80.3)	157 (54-351.8)	101 (45.3-155.8)	8	15
SR= systematic review, IPD= Individual Patient Data, J Natl Cancer Inst= Journal of the National Cancer Institute, J Clin Oncol= Journal of Clinical Oncology, CA Cancer J Clin= A Cancer Journal for Clinicians, Cancer Res= Cancer Research, RCT=randomised controlled trial, IQR= interquartile range										

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix

Appendix table 1: Search strategy for high-impact journals SRs

Search
<p>#1 Search (((((((((((("Cancer Research"[Journal]) OR "Ca-A Cancer Journal for Clinicians"[Journal]) OR "Nature reviews. Clinical oncology"[Journal]) OR "Clinical cancer research : an official journal of the American Association for Cancer Research"[Journal]) OR)) OR (((("BMJ (Clinical research ed.)"[Journal]) OR "The Lancet. Oncology"[Journal]) OR "JAMA"[Journal]) OR "The New England journal of medicine"[Journal]) OR "Journal of clinical oncology : official journal of the American Society of Clinical Oncology"[Journal]) OR "Annals of oncology : official journal of the European Society for Medical Oncology / ESMO"[Journal]) OR "Journal of the National Cancer Institute"[Journal]) OR "Lancet (London, England)"[Journal])])))])</p>
<p>#2 Search (((((((((((((((((((((((((((((((((NEOPLASMS BY HISTOLOGIC TYPE[MeSH Terms]) OR NEOPLASMS BY SITE[MeSH Terms]) OR neoplas*) OR tumor*) OR tumour*) OR ((Krebs* or cancer*)) OR malignan*) OR ((carcino* or karzino* or karzinom*)) OR sarcom*) OR (leukem* or leukaem*)) OR lymphom*) OR melano*) OR metastas*) OR ((mesothelio* or mesotelio*)) OR carcinomatos*) OR ((gliom* or glioblastom*)) OR osteo*sarcom*) OR ((blastom* or neuroblastom*))])))])</p>
<p>#3 Search (((((systematic review[Title/Abstract]) OR (((((meta-</p>

1
2
3
4
5
6 analys*[Title/Abstract] OR metaanalys*[Title/Abstract])))

7
8
9 [#4](#) Search ((#1 and #2 and #3))

10
11
12 [#5](#) Search (#1 and #2) Filters: Meta-Analysis; Systematic Reviews

13
14
15 [#6](#) Search (#4 or #7) Filters: Publication date from 2011/01/01 to 2016/05/31
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Appendix table 2: Extracted items


Item	Extracted	Example
1.	Author	
2.	Title	
3.	Journal	Cochrane, A Cancer Journal for Clinicians, New England Journal of Medicine, The Lancet, JAMA, Lancet Oncology, Journal of Clinical Oncology, The BMJ, Nature Reviews Clinical Oncology, Journal of the National Cancer Institute, Cancer Research
4.	Year last updated	2011-2016
5.	Year first published	2011-2016
6.	Cochrane group	
7.	Region of corresponding author	Africa, Asia, Australia/ New Zealand, Europe, North America, South America
8.	Review type	SR based on trial-level data, Individual Patient Data SR, Both
9.	Network Meta-Analysis	Yes, No
10.	Included study type	RCTs, non-RCTs, Both
11.	Question type	Diagnosis, Epidemiology, Prevention, Prognosis, Screening, Therapy

Item	Extracted	Example
12.	Disease	Bladder, bones (incl. spine), brain (incl. CNS), breast, cancer in general, cervical, colorectal, endometrial, oesophagus, gastric, haematological (leukaemia, lymphoma, myeloma), head and neck, lung, melanoma, mixed (but not general, other (e.g. male breast cancer, liver metastases), ovarian, pancreas, prostate, renal, uterus
13.	Intervention	Behavioural (e.g. exercise, diet, smoking), chemotherapy, mixed interventions, "new drug" (targeted therapy and monoclonal antibodies), radiotherapy, supportive, surgery, thermal (e.g. hyperthermia, cryotherapy), not applicable (if diagnostic, prognostic, preventive, epidemiologic, screening)
14.	Population	Adult, paediatric, both
15.	Number of included studies	

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Item	Extracted	Example
16.	Number included patients	

For peer review only



Appendix table 3: Extracted quality indicators

Item	AMSTAR	This work
1.	Was an 'a priori' design provided	Was the review question established before the conduct of the review?
		Were the in- and exclusion criteria defined before the conduct of the review?
2.	Was there duplicate study selection and data extraction?	Was the study selection and data-extraction undertaken by two independently working authors?
		Was the consensus procedure described?
		Was the interobserver-agreement (quantitatively) assessed?
3.	Was a comprehensive literature search performed?	Were at least two electronic databases searched?
		Were the years included in the searches reported?
		Were the database searches supported by other sources?
4.	Was the status of publication	Were reviews irrespective of publication

Item	AMSTAR	This work
	(i.e. grey literature) used as an inclusion criterion?	status included? Were reviews in languages other than English included?
5.	Was a list of studies (included and excluded) provided?	Was a list of included studies provided? Was a list of excluded studies provided?
6.	Were the characteristics of the included studies provided?	Were study characteristic of every included study included?
7.	Was the scientific quality of the included studies assessed and documented?	Was the quality of included studies included by available tools (e.g. Cochrane's Risk of Bias, ROBINS, Newcastle-Ottawa scale)
8.	Was the scientific quality of the included studies used appropriately in formulating conclusions?	If a Meta-analysis was performed: Was the study quality included into the analysis via sensitivity- or subgroup analysis?
9.	Were the methods used to combine the findings of studies appropriate?	Was possible heterogeneity assessed?

Item	AMSTAR	This work
10.	Was the likelihood of publication bias assessed?	Was possible publication bias formally assessed?
11.	Was the conflict of interest included?	Were possible Conflicts of Interest regarding the review disclosed?
		Were possible Conflicts of Interest of the included studies reported?

References

References of assessed reviews

Cochrane reviews

1. Abdel-Rahman Omar M, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. *Cochrane Database of Systematic Reviews* 2016; (2).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011313.pub2/abstract>.
2. Abdul Razak Albiruni R, Li L, Bryant A, et al. Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease. *Cochrane Database of Systematic Reviews* 2011; (3).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007584.pub2/abstract>.
3. Aghoram R, Cai P, Dickinson James A. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. *Cochrane Database of Systematic Reviews* 2012; (9).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002799.pub2/abstract>.
4. Akl Elie A, Kahale L, Terrenato I, et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. *Cochrane Database of Systematic Reviews* 2014; (7).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006466.pub5/abstract>.
5. Akl Elie A, Kahale Lara A, Ballout Rami A, et al. Parenteral anticoagulation in ambulatory patients with cancer. *Cochrane Database of Systematic Reviews* 2014; (12).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006652.pub4/abstract>.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
6. Akl Elie A, Kahale Lara A, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database of Systematic Reviews 2014; (7).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006650.pub4/abstract>.
7. Akl Elie A, Kahale Lara A, Neumann I, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database of Systematic Reviews 2014; (6).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006649.pub6/abstract>.
8. Akl Elie A, Kahale Lara A, Sperati F, et al. Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer. Cochrane Database of Systematic Reviews 2014; (6).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009447.pub2/abstract>.
9. Akl Elie A, Ramly Elie P, Kahale Lara A, et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database of Systematic Reviews 2014; (10).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006468.pub5/abstract>.
10. Al Rawahi T, Lopes Alberto D, Bristow Robert E, et al. Surgical cytoreduction for recurrent epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2013; (2).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008765.pub3/abstract>.
11. Alazzam Mi, Tidy J, Osborne R, et al. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia. Cochrane Database of Systematic Reviews 2016; (1).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008891.pub3/abstract>.
12. Amarasena Isuru U, Chatterjee S, Walters Julia AE, et al. Platinum versus non-platinum chemotherapy regimens for small cell lung cancer. Cochrane Database of Systematic

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reviews 2015; (8).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006849.pub3/abstract>.

13. Ang C, Bryant A, Barton Desmond PJ, et al. Exenterative surgery for recurrent gynaecological malignancies. Cochrane Database of Systematic Reviews 2014; (2).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010449.pub2/abstract>.

14. Ang C, Chan Karen KL, Bryant A, et al. Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2011; (4).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007697.pub2/abstract>.

15. Anglemeyer A, Agrawal Anurag K, Rutherford George W. Treatment of Kaposi sarcoma in children with HIV-1 infection. Cochrane Database of Systematic Reviews 2014; (1).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009826.pub2/abstract>.

16. Arbyn M, Roelens J, Simoens C, et al. Human papillomavirus testing versus repeat cytology for triage of minor cytological cervical lesions. Cochrane Database of Systematic Reviews 2013; (3).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008054.pub2/abstract>.

17. Archampong D, Borowski D, Wille-Jørgensen P, et al. Workload and surgeon's specialty for outcome after colorectal cancer surgery. Cochrane Database of Systematic Reviews 2012; (3).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005391.pub3/abstract>.

18. Arcidiacono Paolo G, Calori G, Carrara S, et al. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database of Systematic Reviews 2011; (3).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007519.pub2/abstract>.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
19. Baalbergen A, Veenstra Y, Stalpers L. Primary surgery versus primary radiotherapy with or without chemotherapy for early adenocarcinoma of the uterine cervix. Cochrane Database of Systematic Reviews 2013; (1).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006248.pub3/abstract>.
20. Bala Malgorzata M, Riemsma Robert P, Wolff R, et al. Microwave coagulation for liver metastases. Cochrane Database of Systematic Reviews 2013; (10).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010163.pub2/abstract>.
21. Bala Malgorzata M, Riemsma Robert P, Wolff R, et al. Cryotherapy for liver metastases. Cochrane Database of Systematic Reviews 2013; (6).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009058.pub2/abstract>.
22. Balduzzi S, Mantarro S, Guarneri V, et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews 2014; (6).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006242.pub2/abstract>.
23. Barone Damiano G, Lawrie Theresa A, Hart Michael G. Image guided surgery for the resection of brain tumours. Cochrane Database of Systematic Reviews 2014; (1).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009685.pub2/abstract>.
24. Bath-Hextall Fiona J, Matin Rubeta N, Wilkinson D, et al. Interventions for cutaneous Bowen's disease. Cochrane Database of Systematic Reviews 2013; (6).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007281.pub2/abstract>.
25. Bauer K, Rancea M, Roloff V, et al. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews 2012; (11).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008079.pub2/abstract>.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

26. Bauer K, Skoetz N, Monsef I, et al. Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database of Systematic Reviews 2011; (5).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007941.pub3/abstract>.
27. Bell Rae F, Eccleston C, Kalso Eija A. Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database of Systematic Reviews 2012; (6).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003351.pub3/abstract>.
28. Bennett C, Green S, DeCaestecker J, et al. Surgery versus radical endotherapies for early cancer and high-grade dysplasia in Barrett's oesophagus. Cochrane Database of Systematic Reviews 2012; (11).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007334.pub4/abstract>.
29. Bennett Michael H, Feldmeier J, Smee R, et al. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database of Systematic Reviews 2012; (4).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005007.pub3/abstract>.
30. Bergenthal N, Will A, Streckmann F, et al. Aerobic physical exercise for adult patients with haematological malignancies. Cochrane Database of Systematic Reviews 2014; (11).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009075.pub2/abstract>.
31. Bergner N, Monsef I, Illerhaus G, et al. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL). Cochrane Database of Systematic Reviews 2012; (11).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009355.pub2/abstract>.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
32. Bessell A, Glennly A-M, Furness S, et al. Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment. Cochrane Database of Systematic Reviews 2011; (9).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006205.pub3/abstract>.
33. Best Lawrence MJ, Mughal M, Gurusamy Kurinchi S. Laparoscopic versus open gastrectomy for gastric cancer. Cochrane Database of Systematic Reviews 2016; (3).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011389.pub2/abstract>.
34. Best Lawrence MJ, Mughal M, Gurusamy Kurinchi S. Non-surgical versus surgical treatment for oesophageal cancer. Cochrane Database of Systematic Reviews 2016; (3). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011498.pub2/abstract>.
35. Billson Hazel A, Holland C, Curwell J, et al. Perioperative nutrition interventions for women with ovarian cancer. Cochrane Database of Systematic Reviews 2013; (9).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009884.pub2/abstract>.
36. Bjelakovic G, Gluud Lise L, Nikolova D, et al. Vitamin D supplementation for prevention of cancer in adults. Cochrane Database of Systematic Reviews 2014; (6).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007469.pub2/abstract>.
37. Bleeker G, Tytgat Godelieve AM, Adam Judit A, et al. 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database of Systematic Reviews 2015; (9).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009263.pub2/abstract>.
38. Bourke L, Homer Kate E, Thaha Mohamed A, et al. Interventions for promoting habitual exercise in people living with and beyond cancer. Cochrane Database of Systematic Reviews 2013; (9).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010192.pub2/abstract>.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

39. Braam Katja I, van der Torre P, Takken T, et al. Physical exercise training interventions for children and young adults during and after treatment for childhood cancer. Cochrane Database of Systematic Reviews 2016; (3).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008796.pub3/abstract>.
40. Bradt J, Shim M, Goodill Sherry W. Dance/movement therapy for improving psychological and physical outcomes in cancer patients. Cochrane Database of Systematic Reviews 2015; (1).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007103.pub3/abstract>.
41. Brockbank E, Kokka F, Bryant A, et al. Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer. Cochrane Database of Systematic Reviews 2013; (3).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008217.pub3/abstract>.
42. Brocklehurst P, Kujan O, O'Malley Lucy A, et al. Screening programmes for the early detection and prevention of oral cancer. Cochrane Database of Systematic Reviews 2013; (11).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004150.pub4/abstract>.
43. Burdett S, Pignon Jean P, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database of Systematic Reviews 2015; (3).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011430/abstract>.
44. Cakmakkaya Ozlem S, Kolodzie K, Apfel Christian C, et al. Anaesthetic techniques for risk of malignant tumour recurrence. Cochrane Database of Systematic Reviews 2014; (11).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008877.pub2/abstract>.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
45. Candy B, Jones L, Vickerstaff V, et al. Interventions for sexual dysfunction following treatments for cancer in women. Cochrane Database of Systematic Reviews 2016; (2). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005540.pub3/abstract>.
46. Carvalho Alan PV, Vital Flávia MR, Soares Bernardo GO. Exercise interventions for shoulder dysfunction in patients treated for head and neck cancer. Cochrane Database of Systematic Reviews 2012; (4). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008693.pub2/abstract>.
47. Cavalheri V, Tahirah F, Nonoyama Mika L, et al. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer. Cochrane Database of Systematic Reviews 2013; (7). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009955.pub2/abstract>.
48. Chan Benjamin KY, Wiseberg-Firtell Jill A, Jois Ramesh HS, et al. Localization techniques for guided surgical excision of non-palpable breast lesions. Cochrane Database of Systematic Reviews 2015; (12). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009206.pub2/abstract>.
49. Chan Kelvin KW, Glenny A-M, Weldon Jo C, et al. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy. Cochrane Database of Systematic Reviews 2015; (12). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010341.pub2/abstract>.
50. Charoenkwan K, Kietpeerakool C. Retroperitoneal drainage versus no drainage after pelvic lymphadenectomy for the prevention of lymphocyst formation in women with gynaecological malignancies. Cochrane Database of Systematic Reviews 2016; (6). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007387.pub4/abstract>.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

51. Chen H, Li J, Cui T, et al. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database of Systematic Reviews 2011; (11).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008018.pub2/abstract>.
52. Chen X, Deng L, Jiang X, et al. Chinese herbal medicine for oesophageal cancer. Cochrane Database of Systematic Reviews 2016; (1).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004520.pub7/abstract>.
53. Cheuk Daniel KL, Chiang Alan KS, Chan Godfrey CF, et al. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cochrane Database of Systematic Reviews 2014; (3).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006945.pub4/abstract>.
54. Cheuk Daniel KL, Chiang Alan KS, Lee Tsz L, et al. Vaccines for prophylaxis of viral infections in patients with hematological malignancies. Cochrane Database of Systematic Reviews 2011; (3).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006505.pub2/abstract>.
55. Cirocchi R, Trastulli S, Abraha I, et al. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable Stage IV colorectal cancer. Cochrane Database of Systematic Reviews 2012; (8).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008997.pub2/abstract>.
56. Cirocchi R, Trastulli S, Boselli C, et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database of Systematic Reviews 2012; (6). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006317.pub3/abstract>.
57. Clarke T, Galaal K, Bryant A, et al. Evaluation of follow-up strategies for patients with epithelial ovarian cancer following completion of primary treatment. Cochrane

Database of Systematic Reviews 2014; (9).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006119.pub3/abstract>.

58. Cortés-Jofré M, Rueda J-R, Corsini-Muñoz G, et al. Drugs for preventing lung cancer in healthy people. Cochrane Database of Systematic Reviews 2012; (10).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002141.pub2/abstract>.

59. Cousins Sarah E, Tempest E, Feuer David J. Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database of Systematic Reviews 2016; (1).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002764.pub2/abstract>.

60. Coyne I, O'Mathúna Dónal P, Gibson F, et al. Interventions for promoting participation in shared decision-making for children with cancer. Cochrane Database of Systematic Reviews 2016; (11).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008970.pub3/abstract>.

61. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database of Systematic Reviews 2012; (11).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006145.pub3/abstract>.

62. Crighton Gemma L, Estcourt Lise J, Wood Erica M, et al. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database of Systematic Reviews 2015; (9).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010981.pub2/abstract>.

63. Daly T, Hickey Brigid E, Lehman M, et al. Adjuvant radiotherapy following radical prostatectomy for prostate cancer. Cochrane Database of Systematic Reviews 2011;

- 1
2
3
4
5
6 (12).
7
8 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007234.pub2/abstract>.
9
- 10 64. Day J, Yust-Katz S, Cachia D, et al. Interventions for the management of fatigue in adults
11 with a primary brain tumour. Cochrane Database of Systematic Reviews 2016; (4).
12
13 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011376.pub2/abstract>.
14
15
- 16 65. Day J, Zienius K, Gehring K, et al. Interventions for preventing and ameliorating cognitive
17 deficits in adults treated with cranial irradiation. Cochrane Database of Systematic
18 Reviews 2014; (12).
19
20 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011335.pub2/abstract>.
21
22
23
- 24 66. de Boer Angela GEM, Taskila Tyna K, Tamminga Sietske J, et al. Interventions to enhance
25 return-to-work for cancer patients. Cochrane Database of Systematic Reviews 2015;
26 (9). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007569.pub3/abstract>.
27
28
29
- 30 67. De Caluwé L, Van Nieuwenhove Y, Ceelen Wim P. Preoperative chemoradiation versus
31 radiation alone for stage II and III resectable rectal cancer. Cochrane Database of
32 Systematic Reviews 2013; (2).
33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006041.pub3/abstract>.
35
36
37
- 38 68. de Castria Tiago B, da Silva Edina MK, Gois Aecio FT, et al. Cisplatin versus carboplatin in
39 combination with third-generation drugs for advanced non-small cell lung cancer.
40 Cochrane Database of Systematic Reviews 2013; (8).
41
42 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009256.pub2/abstract>.
43
44
45
- 46 69. de Zwart V, Gouw Samantha C, Meyer-Wentrup Friederike AG. Antibody therapies for
47 lymphoma in children. Cochrane Database of Systematic Reviews 2016; (1).
48
49 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011181.pub2/abstract>.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
70. Dear Rachel F, McGeechan K, Jenkins Marisa C, et al. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database of Systematic Reviews 2013; (12).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008792.pub2/abstract>.
71. Deng L, Zhang J, Wu T, et al. Combination chemotherapy for primary treatment of high-risk gestational trophoblastic tumour. Cochrane Database of Systematic Reviews 2013; (1).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005196.pub4/abstract>.
72. Deva S, Jameson M. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Cochrane Database of Systematic Reviews 2012; (8).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007814.pub2/abstract>.
73. Diaz-Nieto R, Orti-Rodríguez R, Winslet M. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database of Systematic Reviews 2013; (9). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008415.pub2/abstract>.
74. Dominick S, Hickey M, Chin J, et al. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Cochrane Database of Systematic Reviews 2015; (12).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007245.pub3/abstract>.
75. Dong Z, Xu J, Wang Z, et al. Stents for the prevention of pancreatic fistula following pancreaticoduodenectomy. Cochrane Database of Systematic Reviews 2016; (5).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008914.pub3/abstract>.
76. D'Souza N, Darmanin G, Fedorowicz Z. Immediate versus delayed reconstruction following surgery for breast cancer. Cochrane Database of Systematic Reviews 2011; (7). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008674.pub2/abstract>.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

77. Edey Katharine A, Allan E, Murdoch John B, et al. Interventions for the treatment of Paget's disease of the vulva. Cochrane Database of Systematic Reviews 2013; (10). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009245.pub2/abstract>.
78. Elattar A, Bryant A, Winter-Roach Brett A, et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2011; (8). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007565.pub2/abstract>.
79. Eleje George U, Eke Ahizechukwu C, Igberase Gabriel O, et al. Palliative interventions for controlling vaginal bleeding in advanced cervical cancer. Cochrane Database of Systematic Reviews 2015; (5). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011000.pub2/abstract>.
80. Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, et al. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database of Systematic Reviews 2013; (10). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008983.pub2/abstract>.
81. Eliyas S, Al-Khayatt A, Porter Richard WJ, et al. Dental extractions prior to radiotherapy to the jaws for reducing post-radiotherapy dental complications. Cochrane Database of Systematic Reviews 2013; (2). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008857.pub2/abstract>.
82. Estcourt L, Stanworth S, Doree C, et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews 2012; (5). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004269.pub3/abstract>.
83. Estcourt Lise J, Stanworth S, Doree C, et al. Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after

1
2
3
4
5
6 myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database of
7
8 Systematic Reviews 2015; (10).

9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010984.pub2/abstract>.

11
12 84. Estcourt Lise J, Stanworth Simon J, Doree C, et al. Granulocyte transfusions for
13
14 preventing infections in people with neutropenia or neutrophil dysfunction.

15
16 Cochrane Database of Systematic Reviews 2015; (6).

17
18 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005341.pub3/abstract>.

19
20 85. Everett T, Bryant A, Griffin Michelle F, et al. Interventions targeted at women to
21
22 encourage the uptake of cervical screening. Cochrane Database of Systematic
23
24 Reviews 2011; (5).

25
26 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002834.pub2/abstract>.

27
28 86. Ezzo J, Manheimer E, McNeely Margaret L, et al. Manual lymphatic drainage for
29
30 lymphedema following breast cancer treatment. Cochrane Database of Systematic
31
32 Reviews 2015; (5).

33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003475.pub2/abstract>.

35
36 87. Farquhar C, Marjoribanks J, Lethaby A, et al. High-dose chemotherapy and autologous
37
38 bone marrow or stem cell transplantation versus conventional chemotherapy for
39
40 women with early poor prognosis breast cancer. Cochrane Database of Systematic
41
42 Reviews 2016; (5).

43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003139.pub3/abstract>.

45
46 88. Felbel S, Meerpohl Joerg J, Monsef I, et al. Yoga in addition to standard care for patients
47
48 with haematological malignancies. Cochrane Database of Systematic Reviews 2014;
49
50 (6). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010146.pub2/abstract>.

- 1
2
3
4
5
6 89. Ford Alexander C, Forman D, Hunt R, et al. Helicobacter pylori eradication for the
7
8 prevention of gastric neoplasia. Cochrane Database of Systematic Reviews 2015; (7).
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005583.pub2/abstract>.
11
12 90. Frost Jonathan A, Webster Katie E, Bryant A, et al. Lymphadenectomy for the
13
14 management of endometrial cancer. Cochrane Database of Systematic Reviews 2015;
15
16 (9). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007585.pub3/abstract>.
17
18 91. Fu J, Fang F, Xie L, et al. Prophylactic chemotherapy for hydatidiform mole to prevent
19
20 gestational trophoblastic neoplasia. Cochrane Database of Systematic Reviews 2012;
21
22 (10).
23
24 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007289.pub2/abstract>.
25
26 92. Furness S, Glenny A-M, Worthington Helen V, et al. Interventions for the treatment of
27
28 oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database of
29
30 Systematic Reviews 2011; (4).
31
32 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006386.pub3/abstract>.
33
34 93. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in
35
36 afebrile neutropenic patients following chemotherapy. Cochrane Database of
37
38 Systematic Reviews 2012; (1).
39
40 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004386.pub3/abstract>.
41
42 94. Gaitskell K, Martinek I, Bryant A, et al. Angiogenesis inhibitors for the treatment of
43
44 ovarian cancer. Cochrane Database of Systematic Reviews 2011; (9).
45
46 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007930.pub2/abstract>.
47
48 95. Galaal K, Al Moundhri M, Bryant A, et al. Adjuvant chemotherapy for advanced
49
50 endometrial cancer. Cochrane Database of Systematic Reviews 2014; (5).
51
52 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010681.pub2/abstract>.
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
96. Galaal K, Bryant A, Deane Katherine HO, et al. Interventions for reducing anxiety in women undergoing colposcopy. Cochrane Database of Systematic Reviews 2011; (12).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006013.pub3/abstract>.
97. Galaal K, Bryant A, Fisher Ann D, et al. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database of Systematic Reviews 2012; (9).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006655.pub2/abstract>.
98. Galaal K, van der Heijden E, Godfrey K, et al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database of Systematic Reviews 2013; (2).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006812.pub3/abstract>.
99. Galway K, Black A, Cantwell M, et al. Psychosocial interventions to improve quality of life and emotional wellbeing for recently diagnosed cancer patients. Cochrane Database of Systematic Reviews 2012; (11).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007064.pub2/abstract>.
100. Gartlehner G, Thaler K, Chapman A, et al. Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk. Cochrane Database of Systematic Reviews 2013; (4).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009632.pub2/abstract>.
101. Gbabe Oluwatoyin F, Okwundu Charles I, Dediccoat M, et al. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults. Cochrane Database of Systematic Reviews 2014; (9).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003256.pub2/abstract>.

- 1
2
3
4
5
6
7 102. George R, Jeba J, Ramkumar G, et al. Interventions for the treatment of metastatic
8
9 extradural spinal cord compression in adults. Cochrane Database of Systematic
10
11 Reviews 2015; (9).
12 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006716.pub3/abstract>.
13
- 14 103. Ghersi D, Willson Melina L, Chan Matthew Ming K, et al. Taxane-containing regimens for
15
16 metastatic breast cancer. Cochrane Database of Systematic Reviews 2015; (6).
17
18 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003366.pub3/abstract>.
19
- 20 104. Goodwin A, Parker S, Ghersi D, et al. Post-operative radiotherapy for ductal carcinoma
21
22 in situ of the breast. Cochrane Database of Systematic Reviews 2013; (11).
23
24 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000563.pub7/abstract>.
25
- 26 105. Goossen Ginette M, Kremer Leontien CM, van de Wetering Marianne D. Influenza
27
28 vaccination in children being treated with chemotherapy for cancer. Cochrane
29
30 Database of Systematic Reviews 2013; (8).
31
32 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006484.pub3/abstract>.
33
- 34 106. Gordijn Maartje S, Rensen N, Gemke Reinoud JBJ, et al. Hypothalamic-pituitary-adrenal
35
36 (HPA) axis suppression after treatment with glucocorticoid therapy for childhood
37
38 acute lymphoblastic leukaemia. Cochrane Database of Systematic Reviews 2015; (8).
39
40 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008727.pub3/abstract>.
41
- 42 107. Gøtzsche Peter C, Johansen Helle K. Routine versus selective antifungal administration
43
44 for control of fungal infections in patients with cancer. Cochrane Database of
45
46 Systematic Reviews 2014; (9).
47
48 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000026.pub2/abstract>.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 108. Gøtzsche Peter C, Jørgensen Karsten J. Screening for breast cancer with mammography.
8
9 Cochrane Database of Systematic Reviews 2013; (6).
10
11 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001877.pub5/abstract>.
12
13 109. Grabosch Shannon M, Shariff Osman M, Wulff Judith L, et al. Non-steroidal anti-
14
15 inflammatory agents to induce regression and prevent the progression of cervical
16
17 intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2014; (4).
18
19 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004121.pub3/abstract>.
20
21 110. Grande Antonio J, Silva V, Riera R, et al. Exercise for cancer cachexia in adults. Cochrane
22
23 Database of Systematic Reviews 2014; (11).
24
25 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010804.pub2/abstract>.
26
27 111. Gupta Aditya K, Paquet M, Villanueva E, et al. Interventions for actinic keratoses.
28
29 Cochrane Database of Systematic Reviews 2012; (12).
30
31 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004415.pub2/abstract>.
32
33 112. Gurion R, Belnik-Plitman Y, Gafter-Gvili A, et al. Colony-stimulating factors for
34
35 prevention and treatment of infectious complications in patients with acute
36
37 myelogenous leukemia. Cochrane Database of Systematic Reviews 2012; (6).
38
39 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008238.pub3/abstract>.
40
41 113. Gurumurthy M, Bryant A, Shanbhag S. Effectiveness of different treatment modalities
42
43 for the management of adult-onset granulosa cell tumours of the ovary (primary and
44
45 recurrent). Cochrane Database of Systematic Reviews 2014; (4).
46
47 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006912.pub2/abstract>.
48
49 114. Gurusamy Kurinchi S, Kumar S, Davidson Brian R. Prophylactic gastrojejunostomy for
50
51 unresectable periampullary carcinoma. Cochrane Database of Systematic Reviews
52
53
54
55
56
57
58
59
60

2013; (2).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008533.pub3/abstract>.

115. Gurusamy Kurinchi S, Kumar S, Davidson Brian R, et al. Resection versus other treatments for locally advanced pancreatic cancer. Cochrane Database of Systematic Reviews 2014; (2).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010244.pub2/abstract>.

116. Gurusamy Kurinchi S, Pallari E, Midya S, et al. Laparoscopic versus open transhiatal oesophagectomy for oesophageal cancer. Cochrane Database of Systematic Reviews 2016; (3).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011390.pub2/abstract>.

117. Hadley G, Derry S, Moore RA, et al. Transdermal fentanyl for cancer pain. Cochrane Database of Systematic Reviews 2013; (10).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010270.pub2/abstract>.

118. Haldar K, Gaitskell K, Bryant A, et al. Epidermal growth factor receptor blockers for the treatment of ovarian cancer. Cochrane Database of Systematic Reviews 2011; (10).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007927.pub3/abstract>.

119. Hart Michael G, Garside R, Rogers G, et al. Chemotherapy wafers for high grade glioma. Cochrane Database of Systematic Reviews 2011; (3).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007294.pub2/abstract>.

120. Hart Michael G, Garside R, Rogers G, et al. Temozolomide for high grade glioma. Cochrane Database of Systematic Reviews 2013; (4).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007415.pub2/abstract>.

121. Hartmann T, Hübel K, Monsef I, et al. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous

Formatted: English (U.S.), Do not check spelling or grammar

Formatted: English (U.S.), Do not check spelling or grammar

- 1
2
3
4
5
6 transplantation in people with malignant lymphoma or multiple myeloma. Cochrane
7 Database of Systematic Reviews 2015; (10).
8
9 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010615.pub2/abstract>.
- 10
11
12 122. Helm CW, Lorenz Douglas J, Meyer Nicholas J, et al. Retinoids for preventing the
13 progression of cervical intra-epithelial neoplasia. Cochrane Database of Systematic
14 Reviews 2013; (6).
15
16 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003296.pub3/abstract>.
- 17
18
19 123. Henschke N, Maher Christopher G, Ostelo Raymond WJG, et al. Red flags to screen for
20 malignancy in patients with low-back pain. Cochrane Database of Systematic Reviews
21 2013; (2).
22
23 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008686.pub2/abstract>.
- 24
25
26 124. Henson Caroline C, Burden S, Davidson Susan E, et al. Nutritional interventions for
27 reducing gastrointestinal toxicity in adults undergoing radical pelvic radiotherapy.
28 Cochrane Database of Systematic Reviews 2013; (11).
29
30 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009896.pub2/abstract>.
- 31
32
33 125. Herbst C, Monsef I, Specht L, et al. Chemotherapy alone versus chemotherapy plus
34 radiotherapy for adults with early stage Hodgkin lymphoma. Cochrane Database of
35 Systematic Reviews 2011; (4).
36
37 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007110.pub3/abstract>.
- 38
39
40 126. Hickey Brigid E, Francis Daniel P, Lehman M. Sequencing of chemotherapy and
41 radiotherapy for early breast cancer. Cochrane Database of Systematic Reviews 2013;
42 (4). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005212.pub3/abstract>.
- 43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 127. Hilgart Jennifer S, Coles B, Iredale R. Cancer genetic risk assessment for individuals at
8 risk of familial breast cancer. Cochrane Database of Systematic Reviews 2012; (2).
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003721.pub3/abstract>.
11
12 128. Holme Ø, Bretthauer M, Fretheim A, et al. Flexible sigmoidoscopy versus faecal occult
13 blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane
14 Database of Systematic Reviews 2013; (9).
15
16 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009259.pub2/abstract>.
17
18 129. Holtick U, Albrecht M, Chemnitz Jens M, et al. Bone marrow versus peripheral blood
19 allogeneic haematopoietic stem cell transplantation for haematological malignancies
20 in adults. Cochrane Database of Systematic Reviews 2014; (4).
21
22 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010189.pub2/abstract>.
23
24 130. Hurlow A, Bennett Michael I, Robb Karen A, et al. Transcutaneous electric nerve
25 stimulation (TENS) for cancer pain in adults. Cochrane Database of Systematic
26 Reviews 2012; (3).
27
28 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006276.pub3/abstract>.
29
30 131. Hüttner Felix J, Fitzmaurice C, Schwarzer G, et al. Pylorus-preserving
31 pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic
32 Whipple) for surgical treatment of periampullary and pancreatic carcinoma.
33
34 Cochrane Database of Systematic Reviews 2016; (2).
35
36 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006053.pub6/abstract>.
37
38 132. Hutzschenreuter F, Monsef I, Kreuzer K-A, et al. Granulocyte and granulocyte-
39 macrophage colony stimulating factors for newly diagnosed patients with
40 myelodysplastic syndromes. Cochrane Database of Systematic Reviews 2016; (2).
41
42 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009310.pub2/abstract>.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 133. Ilic D, Forbes Kristian M, Hased C. Lycopene for the prevention of prostate cancer.
8
9 Cochrane Database of Systematic Reviews 2011; (11).
10
11 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008007.pub2/abstract>.
12
13 134. Ilic D, Misso Marie L. Screening for testicular cancer. Cochrane Database of Systematic
14
15 Reviews 2011; (2).
16
17 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007853.pub2/abstract>.
18
19 135. Ilic D, Neuberger Molly M, Djulbegovic M, et al. Screening for prostate cancer. Cochrane
20
21 Database of Systematic Reviews 2013; (1).
22
23 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004720.pub3/abstract>.
24
25 136. Itchaki G, Gafter-Gvili A, Lahav M, et al. Anthracycline-containing regimens for
26
27 treatment of follicular lymphoma in adults. Cochrane Database of Systematic
28
29 Reviews 2013; (7).
30
31 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008909.pub2/abstract>.
32
33 137. Jaaback K, Johnson N, Lawrie Theresa A. Intraperitoneal chemotherapy for the initial
34
35 management of primary epithelial ovarian cancer. Cochrane Database of Systematic
36
37 Reviews 2016; (1).
38
39 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005340.pub4/abstract>.
40
41 138. Jassim Ghufuran A, Whitford David L, Hickey A, et al. Psychological interventions for
42
43 women with non-metastatic breast cancer. Cochrane Database of Systematic
44
45 Reviews 2015; (5).
46
47 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008729.pub2/abstract>.
48
49 139. Jin H, Leng Q, Li C. Dietary flavonoid for preventing colorectal neoplasms. Cochrane
50
51 Database of Systematic Reviews 2012; (8).
52
53 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009350.pub2/abstract>.
54
55
56
57
58
59
60

- 1
2
3
4
5
6 140. Jin X, Ruiz Beguerie J, Sze Daniel M-y, et al. Ganoderma lucidum (Reishi mushroom) for
7
8 cancer treatment. Cochrane Database of Systematic Reviews 2016; (4).
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007731.pub3/abstract>.
11
12 141. Johansen Helle K, Gøtzsche Peter C. Amphotericin B versus fluconazole for controlling
13
14 fungal infections in neutropenic cancer patients. Cochrane Database of Systematic
15
16 Reviews 2014; (9).
17
18 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000239.pub2/abstract>.
19
20 142. Johansen Helle K, Gøtzsche Peter C. Amphotericin B lipid soluble formulations versus
21
22 amphotericin B in cancer patients with neutropenia. Cochrane Database of
23
24 Systematic Reviews 2014; (9).
25
26 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000969.pub2/abstract>.
27
28 143. Johnson N, Bryant A, Miles T, et al. Adjuvant chemotherapy for endometrial cancer
29
30 after hysterectomy. Cochrane Database of Systematic Reviews 2011; (10).
31
32 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003175.pub2/abstract>.
33
34 144. Jones Daniel J, Bunn F, Bell-Syer Sophie V. Prophylactic antibiotics to prevent surgical
35
36 site infection after breast cancer surgery. Cochrane Database of Systematic Reviews
37
38 2014; (3).
39
40 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005360.pub4/abstract>.
41
42 145. Jones G, Cleves A, Wilt Timothy J, et al. Intravesical gemcitabine for non-muscle invasive
43
44 bladder cancer. Cochrane Database of Systematic Reviews 2012; (1).
45
46 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009294.pub2/abstract>.
47
48 146. Jørgensen Karsten J, Gøtzsche Peter C, Dalbøge Christina S, et al. Voriconazole versus
49
50 amphotericin B or fluconazole in cancer patients with neutropenia. Cochrane
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 Database of Systematic Reviews 2014; (2).
7
8 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004707.pub3/abstract>.
9
- 10 147. Kaushik S, Pepas L, Nordin A, et al. Surgical interventions for high-grade vulval
11 intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2014; (3).
12
13 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007928.pub3/abstract>.
14
15
- 16 148. Kerrigan S, Grant R. Antiepileptic drugs for treating seizures in adults with brain
17 tumours. Cochrane Database of Systematic Reviews 2011; (8).
18
19 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008586.pub2/abstract>.
20
21
- 22 149. Khan F, Amatya B, Ng L, et al. Multidisciplinary rehabilitation for follow-up of women
23 treated for breast cancer. Cochrane Database of Systematic Reviews 2012; (12).
24
25 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009553.pub2/abstract>.
26
27
- 28 150. Khan F, Amatya B, Ng L, et al. Multidisciplinary rehabilitation after primary brain tumour
29 treatment. Cochrane Database of Systematic Reviews 2015; (8).
30
31 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009509.pub3/abstract>.
32
33
- 34 151. Kharfan-Dabaja M, Mhaskar R, Reljic T, et al. Mycophenolate mofetil versus
35 methotrexate for prevention of graft-versus-host disease in people receiving
36 allogeneic hematopoietic stem cell transplantation. Cochrane Database of Systematic
37
38 Reviews 2014; (7).
39
40 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010280.pub2/abstract>.
41
42
43
- 44 152. Khasraw M, Ameratunga Malaka S, Grant R, et al. Antiangiogenic therapy for high-grade
45 glioma. Cochrane Database of Systematic Reviews 2014; (9).
46
47 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008218.pub3/abstract>.
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

153. Kidane B, Coughlin S, Vogt K, et al. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database of Systematic Reviews 2015; (5).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001556.pub3/abstract>.
154. Kietpeerakool C, Supoken A, Laopaiboon M, et al. Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer. Cochrane Database of Systematic Reviews 2016; (1).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011732.pub2/abstract>.
155. Knijnenburg Sebastiaan L, Mulder Renée L, Schouten-Van Meeteren Antoinette YN, et al. Early and late renal adverse effects after potentially nephrotoxic treatment for childhood cancer. Cochrane Database of Systematic Reviews 2013; (10).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008944.pub2/abstract>.
156. Kokka F, Bryant A, Brockbank E, et al. Surgical treatment of stage IA2 cervical cancer. Cochrane Database of Systematic Reviews 2014; (5).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010870.pub2/abstract>.
157. Kokka F, Bryant A, Brockbank E, et al. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer. Cochrane Database of Systematic Reviews 2015; (4).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010260.pub2/abstract>.
158. Kong A, Johnson N, Kitchener Henry C, et al. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database of Systematic Reviews 2012; (4).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003916.pub4/abstract>.
159. Kucukmetin A, Biliatis I, Naik R, et al. Laparoscopically assisted radical vaginal hysterectomy versus radical abdominal hysterectomy for the treatment of early

1
2
3
4
5
6 cervical cancer. Cochrane Database of Systematic Reviews 2013; (10).

7
8 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006651.pub3/abstract>.

9
10 160. Kunath F, Grobe Henrik R, Rücker G, et al. Non-steroidal antiandrogen monotherapy
11 compared with luteinising hormone-releasing hormone agonists or surgical
12 castration monotherapy for advanced prostate cancer. Cochrane Database of
13 Systematic Reviews 2014; (6).

14
15
16 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009266.pub2/abstract>.

17
18 161. Kyrgidis A, Tzellos T, Mocellin S, et al. Sentinel lymph node biopsy followed by lymph
19 node dissection for localised primary cutaneous melanoma. Cochrane Database of
20 Systematic Reviews 2015; (5).

21
22 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010307.pub2/abstract>.

23
24 162. Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after
25 conservative treatment for cervical intraepithelial neoplasia. Cochrane Database of
26 Systematic Reviews 2015; (9).

27
28 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008478.pub2/abstract>.

29
30 163. Lanceley A, Fiander A, McCormack M, et al. Follow-up protocols for women with
31 cervical cancer after primary treatment. Cochrane Database of Systematic Reviews
32 2013; (11).

33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008767.pub2/abstract>.

35
36 164. Lawal Aramide O, Musekiwa A, Grobler L. Interferon after surgery for women with
37 advanced (Stage II-IV) epithelial ovarian cancer. Cochrane Database of Systematic
38 Reviews 2013; (6).

39
40
41 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009620.pub2/abstract>.

- 1
2
3
4
5
6
7 165. Lawrie Theresa A, Bryant A, Cameron A, et al. Pegylated liposomal doxorubicin for
8 relapsed epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2013;
9
10 (7). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006910.pub2/abstract>.
11
12 166. Lawrie Theresa A, Nordin A, Chakrabarti M, et al. Medical and surgical interventions for
13 the treatment of usual-type vulval intraepithelial neoplasia. Cochrane Database of
14 Systematic Reviews 2016; (1).
15
16 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011837.pub2/abstract>.
17
18 167. Lawrie Theresa A, Patel A, Martin-Hirsch Pierre PL, et al. Sentinel node assessment for
19 diagnosis of groin lymph node involvement in vulval cancer. Cochrane Database of
20 Systematic Reviews 2014; (6).
21
22 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010409.pub2/abstract>.
23
24 168. Lawrie Theresa A, Rabbie R, Thoma C, et al. Pegylated liposomal doxorubicin for first-
25 line treatment of epithelial ovarian cancer. Cochrane Database of Systematic Reviews
26 2013; (10).
27
28 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010482.pub2/abstract>.
29
30 169. Lawrie Theresa A, Winter-Roach Brett A, Heus P, et al. Adjuvant (post-surgery)
31 chemotherapy for early stage epithelial ovarian cancer. Cochrane Database of
32 Systematic Reviews 2015; (12).
33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004706.pub5/abstract>.
35
36 170. Lecavalier-Barsoum M, Quon H, Abdulkarim B. Adjuvant treatment of anaplastic
37 oligodendrogliomas and oligoastrocytomas. Cochrane Database of Systematic
38 Reviews 2014; (5).
39
40 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007104.pub2/abstract>.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 171. Lee Siew H, Grant R, Kennedy C, et al. Positioning and spinal bracing for pain relief in
8 metastatic spinal cord compression in adults. Cochrane Database of Systematic
9 Reviews 2015; (9).
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007609.pub3/abstract>.
11
12
13
14 172. Leffers N, Daemen T, Helfrich W, et al. Antigen-specific active immunotherapy for
15 ovarian cancer. Cochrane Database of Systematic Reviews 2014; (9).
16 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007287.pub3/abstract>.
17
18
19
20 173. Li X, Xu S, Tan Y, et al. The effects of idarubicin versus other anthracyclines for induction
21 therapy of patients with newly diagnosed leukaemia. Cochrane Database of
22 Systematic Reviews 2015; (6).
23 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010432.pub2/abstract>.
24
25
26
27
28 174. Liu R, Wang X, Tian Jin H, et al. High dose rate versus low dose rate intracavity
29 brachytherapy for locally advanced uterine cervix cancer. Cochrane Database of
30 Systematic Reviews 2014; (10).
31 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007563.pub3/abstract>.
32
33
34
35
36 175. Loeffen Erik AH, te Poele Esther M, Tissing Wim JE, et al. Very early discharge versus
37 early discharge versus non-early discharge in children with cancer and febrile
38 neutropenia. Cochrane Database of Systematic Reviews 2016; (2).
39 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008382.pub2/abstract>.
40
41
42
43
44 176. Lu D, Wang X, Shi G. Perioperative enhanced recovery programmes for gynaecological
45 cancer patients. Cochrane Database of Systematic Reviews 2015; (3).
46 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008239.pub4/abstract>.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

177. Macaya A, Muñoz-Santos C, Balaguer A, et al. Interventions for anal canal intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2012; (12).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009244.pub2/abstract>.
178. Macey R, Walsh T, Brocklehurst P, et al. Diagnostic tests for oral cancer and potentially malignant disorders in patients presenting with clinically evident lesions. Cochrane Database of Systematic Reviews 2015; (5).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010276.pub2/abstract>.
179. Manser R, Lethaby A, Irving Louis B, et al. Screening for lung cancer. Cochrane Database of Systematic Reviews 2013; (6).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001991.pub3/abstract>.
180. Mao C, Fu X-H, Yuan J-Q, et al. Interleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remission. Cochrane Database of Systematic Reviews 2015; (11).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010248.pub2/abstract>.
181. Mao C, Yang Z-Y, He B-F, et al. Toremifene versus tamoxifen for advanced breast cancer. Cochrane Database of Systematic Reviews 2012; (7).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008926.pub2/abstract>.
182. Martí-Carvajal Arturo J, Anand V, Solà I. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database of Systematic Reviews 2015; (6).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008562.pub3/abstract>.
183. Martin-Hirsch Pierre PL, Bryant A. Interventions for preventing blood loss during the treatment of cervical intraepithelial neoplasia. Cochrane Database of Systematic

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reviews 2013; (12).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001421.pub3/abstract>.

184. Martin-Hirsch Pierre PL, Bryant A, Keep Sarah L, et al. Adjuvant progestagens for endometrial cancer. Cochrane Database of Systematic Reviews 2011; (6).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001040.pub2/abstract>.

185. Martin-Hirsch Pierre PL, Paraskeva E, Bryant A, et al. Surgery for cervical intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2013; (12).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001318.pub3/abstract>.

186. Masterson L, Moualed D, Masood A, et al. De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cochrane Database of Systematic Reviews 2014; (2).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010271.pub2/abstract>.

187. McCarthy K, Pearson K, Fulton R, et al. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database of Systematic Reviews 2012; (12).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008368.pub2/abstract>.

188. Mei L, Chen H, Wei Dong M, et al. Maintenance chemotherapy for ovarian cancer. Cochrane Database of Systematic Reviews 2013; (6).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007414.pub3/abstract>.

189. Mhaskar R, Clark Otavio Augusto C, Lyman G, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia. Cochrane Database of Systematic Reviews 2014; (10).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003039.pub2/abstract>.

- 1
2
3
4
5
6 190. Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma: a
7
8 network meta-analysis. Cochrane Database of Systematic Reviews 2012; (5).
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003188.pub3/abstract>.
11
12 191. Mhaskar R, Wao H, Miladinovic B, et al. The role of iron in the management of
13
14 chemotherapy-induced anemia in cancer patients receiving erythropoiesis-
15
16 stimulating agents. Cochrane Database of Systematic Reviews 2016; (2).
17
18 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009624.pub2/abstract>.
19
20 192. Mical P, Borok S, Vidal L, et al. Empirical antibiotics targeting gram-positive bacteria for
21
22 the treatment of febrile neutropenic patients with cancer. Cochrane Database of
23
24 Systematic Reviews 2014; (6).
25
26 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003914.pub4/abstract>.
27
28 193. Michiels Erna MC, Schouten-Van Meeteren Antoinette YN, Doz F, et al. Chemotherapy
29
30 for children with medulloblastoma. Cochrane Database of Systematic Reviews 2015;
31
32 (1). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006678.pub2/abstract>.
33
34 194. Milazzo S, Horneber M. Laetrile treatment for cancer. Cochrane Database of Systematic
35
36 Reviews 2015; (4).
37
38 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005476.pub4/abstract>.
39
40 195. Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy.
41
42 Cochrane Database of Systematic Reviews 2014; (9).
43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007291.pub3/abstract>.
45
46 196. Mishra Shiraz I, Scherer Roberta W, Geigle Paula M, et al. Exercise interventions on
47
48 health-related quality of life for cancer survivors. Cochrane Database of Systematic
49
50 Reviews 2012; (8).
51
52 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007566.pub2/abstract>.
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 197. Mishra Shiraz I, Scherer Roberta W, Snyder C, et al. Exercise interventions on health-
7
8 related quality of life for people with cancer during active treatment. Cochrane
9
10 Database of Systematic Reviews 2012; (8).
11
12 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008465.pub2/abstract>.
13
- 14 198. Mocellin S, Lens Marko B, Pasquali S, et al. Interferon alpha for the adjuvant treatment
15
16 of cutaneous melanoma. Cochrane Database of Systematic Reviews 2013; (6).
17
18 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008955.pub2/abstract>.
19
- 20 199. Mocellin S, McCulloch P, Kazi H, et al. Extent of lymph node dissection for
21
22 adenocarcinoma of the stomach. Cochrane Database of Systematic Reviews 2015;
23
24 (8). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001964.pub4/abstract>.
25
- 26 200. Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the
27
28 preoperative locoregional staging of primary gastric cancer. Cochrane Database of
29
30 Systematic Reviews 2015; (2).
31
32 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009944.pub2/abstract>.
33
- 34 201. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast
35
36 cancer. Cochrane Database of Systematic Reviews 2012; (4).
37
38 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006243.pub2/abstract>.
39
- 40 202. Molassiotis A, Bailey C, Caress A, et al. Interventions for cough in cancer. Cochrane
41
42 Database of Systematic Reviews 2015; (5).
43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007881.pub3/abstract>.
45
- 46 203. Moore Philippa M, Rivera Mercado S, Grez Artigues M, et al. Communication skills
47
48 training for healthcare professionals working with people who have cancer. Cochrane
49
50 Database of Systematic Reviews 2013; (3).
51
52 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003751.pub3/abstract>.
53
54

- 1
2
3
4
5
6 204. Morrison J, Haldar K, Kehoe S, et al. Chemotherapy versus surgery for initial treatment
7
8 in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews
9
10 2012; (8).
11
12 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005343.pub3/abstract>.
13
- 14 205. Moschetti I, Cinquini M, Lambertini M, et al. Follow-up strategies for women treated for
15
16 early breast cancer. Cochrane Database of Systematic Reviews 2016; (5).
17
18 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001768.pub3/abstract>.
19
- 20 206. Muchtar E, Vidal L, Ram R, et al. The role of maintenance therapy in acute
21
22 promyelocytic leukemia in the first complete remission. Cochrane Database of
23
24 Systematic Reviews 2013; (3).
25
26 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009594.pub2/abstract>.
27
- 28 207. Mulder Renée L, Paulides M, Langer T, et al. Cyclophosphamide versus ifosfamide for
29
30 paediatric and young adult bone and soft tissue sarcoma patients. Cochrane
31
32 Database of Systematic Reviews 2015; (9).
33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006300.pub4/abstract>.
35
- 36 208. Mulder Renée L, van Dalen Elvira C, Van den Hof M, et al. Hepatic late adverse effects
37
38 after antineoplastic treatment for childhood cancer. Cochrane Database of
39
40 Systematic Reviews 2011; (7).
41
42 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008205.pub2/abstract>.
43
- 44 209. Mustafa M, Carson-Stevens A, Gillespie D, et al. Psychological interventions for women
45
46 with metastatic breast cancer. Cochrane Database of Systematic Reviews 2013; (6).
47
48 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004253.pub4/abstract>.
49
- 50 210. Nagorni A, Bjelakovic G, Petrovic B. Narrow band imaging versus conventional white
51
52 light colonoscopy for the detection of colorectal polyps. Cochrane Database of
53
54

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Systematic Reviews 2012; (1).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008361.pub2/abstract>.

211. Nama V, Nordin A, Bryant A. Patient-reported outcome measures for follow-up after gynaecological cancer treatment. Cochrane Database of Systematic Reviews 2013; (11).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010299.pub2/abstract>.

212. Narayanan K, Hadid Omar H, Barnes Eric A. Mohs micrographic surgery versus surgical excision for periocular basal cell carcinoma. Cochrane Database of Systematic Reviews 2014; (12).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007041.pub4/abstract>.

213. Naumann-Winter F, Greb A, Borchmann P, et al. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database of Systematic Reviews 2012; (10).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004626.pub3/abstract>.

214. Nicholson Brian D, Shinkins B, Pathiraja I, et al. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database of Systematic Reviews 2015; (12).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011134.pub2/abstract>.

215. Nugent B, Lewis S, O'Sullivan Joe M. Enteral feeding methods for nutritional management in patients with head and neck cancers being treated with radiotherapy and/or chemotherapy. Cochrane Database of Systematic Reviews 2013; (1).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007904.pub3/abstract>.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

216. O'Connor A, McNamara D, O'Moráin Colm A. Surveillance of gastric intestinal metaplasia for the prevention of gastric cancer. Cochrane Database of Systematic Reviews 2013; (9).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009322.pub2/abstract>.
217. Okebe Joseph U, Skoetz N, Meremikwu Martin M, et al. Therapeutic interventions for Burkitt lymphoma in children. Cochrane Database of Systematic Reviews 2011; (7).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005198.pub3/abstract>.
218. Oliveri Roberto S, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2011; (3).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004787.pub2/abstract>.
219. Ostuzzi G, Matcham F, Dauchy S, et al. Antidepressants for the treatment of depression in people with cancer. Cochrane Database of Systematic Reviews 2015; (6).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011006.pub2/abstract>.
220. Pachler J, Wille-Jørgensen P. Quality of life after rectal resection for cancer, with or without permanent colostomy. Cochrane Database of Systematic Reviews 2012; (12).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004323.pub4/abstract>.
221. Paley Carole A, Johnson Mark I, Tashani Osama A, et al. Acupuncture for cancer pain in adults. Cochrane Database of Systematic Reviews 2015; (10).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007753.pub3/abstract>.
222. Parahoo K, McDonough S, McCaughan E, et al. Psychosocial interventions for men with prostate cancer. Cochrane Database of Systematic Reviews 2013; (12).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008529.pub3/abstract>.

- 1
2
3
4
5
6 223. Patil Chirag G, Pricola K, Sarmiento JM, et al. Whole brain radiation therapy (WBRT)
7
8 alone versus WBRT and radiosurgery for the treatment of brain metastases.
9
10 Cochrane Database of Systematic Reviews 2012; (9).
11
12 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006121.pub3/abstract>.
13
- 14 224. Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-aminoglycoside
15
16 combination therapy in cancer patients with neutropenia. Cochrane Database of
17
18 Systematic Reviews 2013; (6).
19
20 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003038.pub2/abstract>.
21
- 22 225. Peinemann F, Bartel C, Grouven U. First-line allogeneic hematopoietic stem cell
23
24 transplantation of HLA-matched sibling donors compared with first-line ciclosporin
25
26 and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic
27
28 anemia. Cochrane Database of Systematic Reviews 2013; (7).
29
30 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006407.pub2/abstract>.
31
- 32 226. Peinemann F, Enk H, Smith Lesley A. Autologous hematopoietic stem cell
33
34 transplantation following high-dose chemotherapy for nonrhabdomyosarcoma soft
35
36 tissue sarcomas. Cochrane Database of Systematic Reviews 2013; (4).
37
38 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008216.pub5/abstract>.
39
- 40 227. Peinemann F, Grouven U, Hemkens Lars G, et al. Low-dose rate brachytherapy for men
41
42 with localized prostate cancer. Cochrane Database of Systematic Reviews 2011; (7).
43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008871.pub2/abstract>.
45
- 46 228. Peinemann F, Kahangire Doreen A, van Dalen Elvira C, et al. Rapid COJEC versus
47
48 standard induction therapies for high-risk neuroblastoma. Cochrane Database of
49
50 Systematic Reviews 2015; (5).
51
52 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010774.pub2/abstract>.
53
54

- 1
2
3
4
5
6 229. Peinemann F, van Dalen Elvira C, Kahangire Doreen A, et al. Retinoic acid post
7
8 consolidation therapy for high-risk neuroblastoma patients treated with autologous
9
10 hematopoietic stem cell transplantation. Cochrane Database of Systematic Reviews
11
12 2015; (1).
13
14 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010685.pub2/abstract>.
15
- 16 230. Pelayo Alvarez M, Westeel V, Cortés-Jofré M, et al. Chemotherapy versus best
17
18 supportive care for extensive small cell lung cancer. Cochrane Database of Systematic
19
20 Reviews 2013; (11).
21
22 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001990.pub3/abstract>.
23
- 24 231. Peng L, Min S, Zejun Z, et al. Spinal cord stimulation for cancer-related pain in adults.
25
26 Cochrane Database of Systematic Reviews 2015; (6).
27
28 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009389.pub3/abstract>.
29
- 30 232. Pepas L, Kaushik S, Nordin A, et al. Medical interventions for high-grade vulval
31
32 intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2015; (8).
33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007924.pub3/abstract>.
35
- 36 233. Petersen Sune H, Harling H, Kirkeby Lene T, et al. Postoperative adjuvant chemotherapy
37
38 in rectal cancer operated for cure. Cochrane Database of Systematic Reviews 2012;
39
40 (3). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004078.pub2/abstract>.
41
- 42 234. Phillips Robert S, Friend Amanda J, Gibson F, et al. Antiemetic medication for
43
44 prevention and treatment of chemotherapy-induced nausea and vomiting in
45
46 childhood. Cochrane Database of Systematic Reviews 2016; (2).
47
48 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007786.pub3/abstract>.
49
- 50 235. Pidala J, Djulbegovic B, Anasetti C, et al. Allogeneic hematopoietic cell transplantation
51
52 for adult acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane
53
54

- 1
2
3
4
5
6 Database of Systematic Reviews 2011; (10).
7
8 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008818.pub2/abstract>.
9
- 10 236. Preston Nancy J, Hurlow A, Brine J, et al. Blood transfusions for anaemia in patients
11 with advanced cancer. Cochrane Database of Systematic Reviews 2012; (2).
12
13 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009007.pub2/abstract>.
14
15
- 16 237. Rai Bhavan P, Shelley M, Coles B, et al. Surgical management for upper urinary tract
17 transitional cell carcinoma. Cochrane Database of Systematic Reviews 2011; (4).
18
19 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007349.pub2/abstract>.
20
21
- 22 238. Rancea M, Monsef I, von Tresckow B, et al. High-dose chemotherapy followed by
23 autologous stem cell transplantation for patients with relapsed/refractory Hodgkin
24 lymphoma. Cochrane Database of Systematic Reviews 2013; (6).
25
26 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009411.pub2/abstract>.
27
28
- 29 239. Rao Ahsan M, Ahmed I. Laparoscopic versus open liver resection for benign and
30 malignant hepatic lesions in adults. Cochrane Database of Systematic Reviews 2013;
31 (5). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010162.pub2/abstract>.
32
33
- 34 240. Ratnavelu Nithya DG, Brown Andrew P, Mallett S, et al. Intraoperative frozen section
35 analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.
36
37 Cochrane Database of Systematic Reviews 2016; (3).
38
39 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010360.pub2/abstract>.
40
41
- 42 241. Reid J, Mills M, Cantwell M, et al. Thalidomide for managing cancer cachexia. Cochrane
43 Database of Systematic Reviews 2012; (4).
44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008664.pub2/abstract>.
46
47
- 48 242. Renner P, Milazzo S, Liu Jian P, et al. Primary prophylactic colony-stimulating factors for
49 the prevention of chemotherapy-induced febrile neutropenia in breast cancer
50
51
52
53
54

- 1
2
3
4
5
6 patients. Cochrane Database of Systematic Reviews 2012; (10).
7
8 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007913.pub2/abstract>.
9
- 10 243. Resende Heloisa M, Jacob Luiz Felipe P, Quinellato Luciano V, et al. Combination
11 chemotherapy versus single-agent chemotherapy during preoperative
12 chemoradiation for resectable rectal cancer. Cochrane Database of Systematic
13 Reviews 2015; (10).
14
15 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008531.pub2/abstract>.
16
17
- 18 244. Reveiz L, Rueda J-R, Cardona Andrés F. Palliative endobronchial brachytherapy for non-
19 small cell lung cancer. Cochrane Database of Systematic Reviews 2012; (12).
20
21 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004284.pub3/abstract>.
22
23
- 24 245. Reveiz L, Rueda J-R, Cardona Andrés F. Chemotherapy for brain metastases from small
25 cell lung cancer. Cochrane Database of Systematic Reviews 2012; (6).
26
27 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007464.pub2/abstract>.
28
29
- 30 246. Riemsma Robert P, Bala Malgorzata M, Wolff R, et al. Percutaneous ethanol injection
31 for liver metastases. Cochrane Database of Systematic Reviews 2013; (5).
32
33 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008717.pub2/abstract>.
34
35
- 36 247. Riemsma Robert P, Bala Malgorzata M, Wolff R, et al. Electro-coagulation for liver
37 metastases. Cochrane Database of Systematic Reviews 2013; (5).
38
39 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009497.pub2/abstract>.
40
41
- 42 248. Riemsma Robert P, Bala Malgorzata M, Wolff R, et al. Transarterial
43 (chemo)embolisation versus no intervention or placebo intervention for liver
44 metastases. Cochrane Database of Systematic Reviews 2013; (4).
45
46 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009498.pub3/abstract>.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 249. Riviere D, Gurusamy Kurinchi S, Kooby David A, et al. Laparoscopic versus open distal
7
8 pancreatotomy for pancreatic cancer. Cochrane Database of Systematic Reviews
9
10 2016; (4).
11
12 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011391.pub2/abstract>.
13
- 14 250. Rizzuto I, Behrens Renee F, Smith Lesley A. Risk of ovarian cancer in women treated
15
16 with ovarian stimulating drugs for infertility. Cochrane Database of Systematic
17
18 Reviews 2013; (8).
19
20 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008215.pub2/abstract>.
21
- 22 251. Robertson L, Yeoh Su E, Stansby G, et al. Effect of testing for cancer on cancer- and
23
24 venous thromboembolism (VTE)-related mortality and morbidity in patients with
25
26 unprovoked VTE. Cochrane Database of Systematic Reviews 2015; (3).
27
28 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010837.pub2/abstract>.
29
- 30 252. Rogers L, Siu Shing Shun N, Luesley D, et al. Radiotherapy and chemoradiation after
31
32 surgery for early cervical cancer. Cochrane Database of Systematic Reviews 2012; (5).
33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007583.pub3/abstract>.
35
- 36 253. Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Perioperative chemo(radio)therapy
37
38 versus primary surgery for resectable adenocarcinoma of the stomach,
39
40 gastroesophageal junction, and lower esophagus. Cochrane Database of Systematic
41
42 Reviews 2013; (5).
43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008107.pub2/abstract>.
45
- 46 254. Rooney Alasdair G, Grant R. Pharmacological treatment of depression in patients with a
47
48 primary brain tumour. Cochrane Database of Systematic Reviews 2013; (5).
49
50 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006932.pub3/abstract>.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

255. Roqué i Figuls M, Martinez-Zapata Maria J, Scott-Brown M, et al. Radioisotopes for metastatic bone pain. Cochrane Database of Systematic Reviews 2011; (3).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003347.pub3/abstract>.
256. Rosa D, Medeiros L, Edelweiss MI, et al. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database of Systematic Reviews 2012; (11).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005342.pub4/abstract>.
257. Rueda J-R, Solà I, Pascual A, et al. Non-invasive interventions for improving well-being and quality of life in patients with lung cancer. Cochrane Database of Systematic Reviews 2011; (9).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004282.pub3/abstract>.
258. Rutten Marianne J, Leeflang Mariska MG, Kenter Gemma G, et al. Laparoscopy for diagnosing resectability of disease in patients with advanced ovarian cancer. Cochrane Database of Systematic Reviews 2014; (2).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009786.pub2/abstract>.
259. Ryzewska L, Tierney J, Vale Claire L, et al. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database of Systematic Reviews 2012; (12).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007406.pub3/abstract>.
260. Salhofer I, Will A, Monsef I, et al. Meditation for adults with haematological malignancies. Cochrane Database of Systematic Reviews 2016; (2).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011157.pub2/abstract>.
261. Samuel M, Khin Lay W, Brennan Victoria K, et al. Timing of breast surgery in premenopausal breast cancer patients. Cochrane Database of Systematic Reviews

2011; (5).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003720.pub2/abstract>.

262. Santos Fábio N, de Castria Tiago B, Cruz Marcelo RS, et al. Chemotherapy for advanced non-small cell lung cancer in the elderly population. Cochrane Database of Systematic Reviews 2015; (10).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010463.pub2/abstract>.

263. Sarmiento JM, Venteicher Andrew S, Patil Chirag G. Early versus delayed postoperative radiotherapy for treatment of low-grade gliomas. Cochrane Database of Systematic Reviews 2015; (6).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009229.pub2/abstract>.

264. Scatchard K, Forrest Jennifer L, Flubacher M, et al. Chemotherapy for metastatic and recurrent cervical cancer. Cochrane Database of Systematic Reviews 2012; (10).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006469.pub2/abstract>.

265. Schaaf M, Reiser M, Borchmann P, et al. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults. Cochrane Database of Systematic Reviews 2012; (1).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007678.pub2/abstract>.

266. Schlaak M, Pickenhain J, Theurich S, et al. Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma. Cochrane Database of Systematic Reviews 2013; (8).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008908.pub3/abstract>.

267. Schmidt-Hansen M, Baldwin David R, Hasler E, et al. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung

- 1
2
3
4
5
6 cancer. Cochrane Database of Systematic Reviews 2014; (11).
7
8 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009519.pub2/abstract>.
9
- 10 268. Schmidt-Hansen M, Bennett Michael I, Arnold S, et al. Oxycodone for cancer-related
11 pain. Cochrane Database of Systematic Reviews 2015; (2).
12
13 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003870.pub5/abstract>.
14
15
- 16 269. Schmidt-Hansen M, Bromham N, Taubert M, et al. Buprenorphine for treating cancer
17 pain. Cochrane Database of Systematic Reviews 2015; (3).
18
19 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009596.pub4/abstract>.
20
21
- 22 270. Schoot Reineke A, Kremer Leontien CM, van de Wetering Marianne D, et al. Systemic
23 treatments for the prevention of venous thrombo-embolic events in paediatric
24 cancer patients with tunnelled central venous catheters. Cochrane Database of
25 Systematic Reviews 2013; (9).
26
27 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009160.pub2/abstract>.
28
29
- 30 271. Schoot Reineke A, van Dalen Elvira C, van Ommen Cornelia H, et al. Antibiotic and other
31 lock treatments for tunnelled central venous catheter-related infections in children
32 with cancer. Cochrane Database of Systematic Reviews 2013; (6).
33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008975.pub2/abstract>.
35
36
- 37 272. Scott David A, Mills M, Black A, et al. Multidimensional rehabilitation programmes for
38 adult cancer survivors. Cochrane Database of Systematic Reviews 2013; (3).
39
40 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007730.pub2/abstract>.
41
42
- 43 273. Scott K, Hayden Patrick J, Will A, et al. Bortezomib for the treatment of multiple
44 myeloma. Cochrane Database of Systematic Reviews 2016; (4).
45
46 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010816.pub2/abstract>.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 274. Semple C, Parahoo K, Norman A, et al. Psychosocial interventions for patients with head
7 and neck cancer. Cochrane Database of Systematic Reviews 2013; (7).
8
9 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009441.pub2/abstract>.
10
11
12 275. Shang Pan F, Kwong J, Wang Zhi P, et al. Intravesical Bacillus Calmette-Guérin versus
13 epirubicin for Ta and T1 bladder cancer. Cochrane Database of Systematic Reviews
14 2011; (5).
15
16 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006885.pub2/abstract>.
17
18
19 276. Sharif Fyeza NJ, Oliver R, Sweet C, et al. Interventions for the treatment of keratocystic
20 odontogenic tumours. Cochrane Database of Systematic Reviews 2015; (11).
21
22 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008464.pub3/abstract>.
23
24
25 277. Shelley M, Cleves A, Wilt Timothy J, et al. Gemcitabine for unresectable, locally
26 advanced or metastatic bladder cancer. Cochrane Database of Systematic Reviews
27 2011; (4).
28
29 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008976.pub2/abstract>.
30
31
32 278. Shepherd Jonathan P, Frampton Geoff K, Harris P. Interventions for encouraging sexual
33 behaviours intended to prevent cervical cancer. Cochrane Database of Systematic
34 Reviews 2011; (4).
35
36 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001035.pub2/abstract>.
37
38
39 279. Shylasree TS, Bryant A, Athavale R. Chemotherapy and/or radiotherapy in combination
40 with surgery for ovarian carcinosarcoma. Cochrane Database of Systematic Reviews
41 2013; (2).
42
43 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006246.pub2/abstract>.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 280. Shylasree TS, Bryant A, Howells Robert EJ. Chemoradiation for advanced primary vulval
7 cancer. Cochrane Database of Systematic Reviews 2011; (4).

8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003752.pub3/abstract>.

11
12 281. Sickinger M-T, von Tresckow B, Kobe C, et al. Positron emission tomography-adapted
13 therapy for first-line treatment in individuals with Hodgkin lymphoma. Cochrane
14 Database of Systematic Reviews 2015; (1).

15
16
17 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010533.pub2/abstract>.

18
19
20 282. Skoetz N, Bauer K, Elter T, et al. Alemtuzumab for patients with chronic lymphocytic
21 leukaemia. Cochrane Database of Systematic Reviews 2012; (2).

22
23 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008078.pub2/abstract>.

24
25 283. Skoetz N, Bohlius J, Engert A, et al. Prophylactic antibiotics or G(M)-CSF for the
26 prevention of infections and improvement of survival in cancer patients receiving
27 myelotoxic chemotherapy. Cochrane Database of Systematic Reviews 2015; (12).

28
29
30 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007107.pub3/abstract>.

31
32
33 284. Smith Lesley A, Azariah F, Lavender Verna TC, et al. Cannabinoids for nausea and
34 vomiting in adults with cancer receiving chemotherapy. Cochrane Database of
35 Systematic Reviews 2015; (11).

36
37
38 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009464.pub2/abstract>.

39
40
41 285. Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the development of
42 gastric pre-malignant lesions. Cochrane Database of Systematic Reviews 2014; (12).

43
44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010623.pub2/abstract>.

46
47
48 286. Soon Yu Y, Tham Ivan Weng K, Lim Keith H, et al. Surgery or radiosurgery plus whole
49 brain radiotherapy versus surgery or radiosurgery alone for brain metastases.

Formatted: English (U.S.), Do not check spelling or grammar

Formatted: English (U.S.), Do not check spelling or grammar

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- Cochrane Database of Systematic Reviews 2014; (3).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009454.pub2/abstract>.
287. Spanjersberg Willem R, Reurings J, Keus F, et al. Fast track surgery versus conventional recovery strategies for colorectal surgery. Cochrane Database of Systematic Reviews 2011; (2).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007635.pub2/abstract>.
288. Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ. Cochrane Database of Systematic Reviews 2012; (10).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007847.pub2/abstract>.
289. Stevens R, Macbeth F, Toy E, et al. Palliative radiotherapy regimens for patients with thoracic symptoms from non-small cell lung cancer. Cochrane Database of Systematic Reviews 2015; (1).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002143.pub4/abstract>.
290. Straube C, Derry S, Jackson Kenneth C, et al. Codeine, alone and with paracetamol (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews 2014; (9). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006601.pub4/abstract>.
291. Stuver Martijn M, ten Tusscher Marieke R, Agasi-Idenburg Carla S, et al. Conservative interventions for preventing clinically detectable upper-limb lymphoedema in patients who are at risk of developing lymphoedema after breast cancer therapy. Cochrane Database of Systematic Reviews 2015; (2).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009765.pub2/abstract>.
292. Taefi A, Abrishami A, Nasseri-Moghaddam S, et al. Surgical resection versus liver transplant for patients with hepatocellular carcinoma. Cochrane Database of

- 1
2
3
4
5
6 Systematic Reviews 2013; (6).
7
8 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006935.pub2/abstract>.
9
- 10 293. Tangjitgamol S, Katanyoo K, Laopaiboon M, et al. Adjuvant chemotherapy after
11 concurrent chemoradiation for locally advanced cervical cancer. Cochrane Database
12 of Systematic Reviews 2014; (12).
13
14 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010401.pub2/abstract>.
15
16 294. Theurich S, Fischmann H, Shimabukuro-Vornhagen A, et al. Polyclonal anti-thymocyte
17 globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or
18 bone marrow transplantation in adults. Cochrane Database of Systematic Reviews
19 2012; (9).
20
21 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009159.pub2/abstract>.
22
23 295. Thomson David R, Sadideen H, Furniss D. Wound drainage after axillary dissection for
24 carcinoma of the breast. Cochrane Database of Systematic Reviews 2013; (10).
25
26 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006823.pub2/abstract>.
27
28 296. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with
29 cancer. Cochrane Database of Systematic Reviews 2012; (12).
30
31 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003407.pub5/abstract>.
32
33 297. Torres Maria FS, Porfirio Gustavo JM, Carvalho Alan PV, et al. Non-invasive positive
34 pressure ventilation for prevention of complications after pulmonary resection in
35 lung cancer patients. Cochrane Database of Systematic Reviews 2015; (9).
36
37 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010355.pub2/abstract>.
38
39 298. Tou S, Malik Ali I, Wexner Steven D, et al. Energy source instruments for laparoscopic
40 colectomy. Cochrane Database of Systematic Reviews 2011; (5).
41
42 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007886.pub2/abstract>.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 299. Tsao May N, Lloyd N, Wong Rebecca KS, et al. Whole brain radiotherapy for the
8 treatment of newly diagnosed multiple brain metastases. Cochrane Database of
9 Systematic Reviews 2012; (4).
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003869.pub3/abstract>.
11
12
13
14 300. Tzellos T, Kyrgidis A, Mocellin S, et al. Interventions for melanoma in situ, including
15 lentigo maligna. Cochrane Database of Systematic Reviews 2014; (12).
16 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010308.pub2/abstract>.
17
18
19
20 301. Vale Claire L, Tierney J, Bull Sarah J, et al. Chemotherapy for advanced, recurrent or
21 metastatic endometrial carcinoma. Cochrane Database of Systematic Reviews 2012;
22 (8). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003915.pub4/abstract>.
23
24
25
26 302. van Dalen Elvira C, Caron Huib N, Dickinson Heather O, et al. Cardioprotective
27 interventions for cancer patients receiving anthracyclines. Cochrane Database of
28 Systematic Reviews 2011; (6).
29 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003917.pub4/abstract>.
30
31
32
33 303. van Dalen Elvira C, de Lijster Manou S, Leijssen Lieve GJ, et al. Minimally invasive
34 surgery versus open surgery for the treatment of solid abdominal and thoracic
35 neoplasms in children. Cochrane Database of Systematic Reviews 2015; (1).
36 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008403.pub3/abstract>.
37
38
39
40 304. van Dalen Elvira C, Mank A, Leclercq E, et al. Low bacterial diet versus control diet to
41 prevent infection in cancer patients treated with chemotherapy causing episodes of
42 neutropenia. Cochrane Database of Systematic Reviews 2016; (4).
43 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006247.pub3/abstract>.
44
45
46
47 305. van Dalen Elvira C, Raphaël Martine F, Caron Huib N, et al. Treatment including
48 anthracyclines versus treatment not including anthracyclines for childhood cancer.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Cochrane Database of Systematic Reviews 2014; (9).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006647.pub4/abstract>.

306. van Dalen Elvira C, van As Jorrit W, de Camargo B. Methotrexate for high-grade osteosarcoma in children and young adults. Cochrane Database of Systematic Reviews 2011; (5).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006325.pub3/abstract>.

307. van Dalen Elvira C, van der Pal Helena JH, Kremer Leontien CM. Different dosage schedules for reducing cardiotoxicity in people with cancer receiving anthracycline chemotherapy. Cochrane Database of Systematic Reviews 2016; (3).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005008.pub4/abstract>.

308. van de Wetering Fleur T, Verleye L, Andreyev HJN, et al. Non-surgical interventions for late rectal problems (proctopathy) of radiotherapy in people who have received radiotherapy to the pelvis. Cochrane Database of Systematic Reviews 2016; (4).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003455.pub2/abstract>.

309. van de Wetering Marianne D, van Woensel Job BM, Lawrie Theresa A. Prophylactic antibiotics for preventing Gram positive infections associated with long-term central venous catheters in oncology patients. Cochrane Database of Systematic Reviews 2013; (11).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003295.pub3/abstract>.

310. van der Heijden E, Lopes Alberto D, Bryant A, et al. Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test. Cochrane Database of Systematic Reviews 2015; (1).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010757.pub2/abstract>.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
311. van der Velden J, Fons G, Lawrie Theresa A. Primary groin irradiation versus primary groin surgery for early vulvar cancer. Cochrane Database of Systematic Reviews 2011; (5). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002224.pub2/abstract>.
312. Veeravagu A, Chang Steven D, Black Keith L, et al. Biopsy versus resection for the management of low-grade gliomas. Cochrane Database of Systematic Reviews 2013; (4). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009319.pub3/abstract>.
313. Vennix S, Pelzers L, Bouvy N, et al. Laparoscopic versus open total mesorectal excision for rectal cancer. Cochrane Database of Systematic Reviews 2014; (4). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005200.pub3/abstract>.
314. Vidal L, Ben dor I, Paul M, et al. Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients. Cochrane Database of Systematic Reviews 2013; (10). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003992.pub3/abstract>.
315. Vidal L, Gafter-Gvili A, Gurion R, et al. Bendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews 2012; (9). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009045.pub2/abstract>.
316. Vinceti M, Dennert G, Crespi Catherine M, et al. Selenium for preventing cancer. Cochrane Database of Systematic Reviews 2014; (3). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005195.pub3/abstract>.
317. Wagner Anna D, Thomssen C, Haerting J, et al. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer. Cochrane Database of Systematic Reviews 2012; (7). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008941.pub2/abstract>.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

318. Walsh T, Liu Joseph LY, Brocklehurst P, et al. Clinical assessment to screen for the detection of oral cavity cancer and potentially malignant disorders in apparently healthy adults. Cochrane Database of Systematic Reviews 2013; (11).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010173.pub2/abstract>.
319. Wang Z, Chen J, Su K, et al. Abdominal drainage versus no drainage post-gastrectomy for gastric cancer. Cochrane Database of Systematic Reviews 2015; (5).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008788.pub3/abstract>.
320. Ward Evelyn J, Henry Lisa M, Friend Amanda J, et al. Nutritional support in children and young people with cancer undergoing chemotherapy. Cochrane Database of Systematic Reviews 2015; (8).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003298.pub3/abstract>.
321. Warner L, Chudasama J, Kelly Charles G, et al. Radiotherapy versus open surgery versus endolaryngeal surgery (with or without laser) for early laryngeal squamous cell cancer. Cochrane Database of Systematic Reviews 2014; (12).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002027.pub2/abstract>.
322. Weberschock T, Strametz R, Lorenz M, et al. Interventions for mycosis fungoides. Cochrane Database of Systematic Reviews 2012; (9).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008946.pub2/abstract>.
323. Wei Mao L, Kang D, Gu L, et al. Chemotherapy for thymic carcinoma and advanced thymoma in adults. Cochrane Database of Systematic Reviews 2013; (8).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008588.pub2/abstract>.
324. Weis S, Franke A, Berg T, et al. Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma. Cochrane Database of Systematic

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Reviews 2015; (1).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006745.pub3/abstract>.

325. Weis S, Franke A, Mössner J, et al. Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2013; (12).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003046.pub3/abstract>.

326. Weitz M, Strahm B, Meerpohl Joerg J, et al. Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. Cochrane Database of Systematic Reviews 2015; (12).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009898.pub3/abstract>.

327. Weitz M, Strahm B, Meerpohl Joerg J, et al. Extracorporeal photopheresis versus standard treatment for acute graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patients. Cochrane Database of Systematic Reviews 2015; (12).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009759.pub3/abstract>.

328. Wiffen Philip J, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database of Systematic Reviews 2014; (5).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011056.pub2/abstract>.

329. Wiffen Philip J, Derry S, Naessens K, et al. Oral tapentadol for cancer pain. Cochrane Database of Systematic Reviews 2015; (9).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011460.pub2/abstract>.

Formatted: English (U.S.), Do not check spelling or grammar

Formatted: English (U.S.), Do not check spelling or grammar

- 1
2
3
4
5
6
7 330. Wiffen Philip J, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane Database of
8
9 Systematic Reviews 2016; (4).
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003868.pub4/abstract>.
11
12 331. Wiggans Alison J, Cass Gemma KS, Bryant A, et al. Poly(ADP-ribose) polymerase (PARP)
13
14 inhibitors for the treatment of ovarian cancer. Cochrane Database of Systematic
15
16 Reviews 2015; (5).
17
18 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007929.pub3/abstract>.
19
20 332. Williams C, Bryant A. Short versus long duration infusions of paclitaxel for any advanced
21
22 adenocarcinoma. Cochrane Database of Systematic Reviews 2011; (5).
23
24 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003911.pub2/abstract>.
25
26 333. Wolf E, Milazzo S, Boehm K, et al. Thymic peptides for treatment of cancer patients.
27
28 Cochrane Database of Systematic Reviews 2011; (2).
29
30 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003993.pub3/abstract>.
31
32 334. Wong Matthew HF, Stockler Martin R, Pavlakis N. Bisphosphonates and other bone
33
34 agents for breast cancer. Cochrane Database of Systematic Reviews 2012; (2).
35
36 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003474.pub3/abstract>.
37
38 335. Woo Yin L, Kyrgiou M, Bryant A, et al. Centralisation of services for gynaecological
39
40 cancer. Cochrane Database of Systematic Reviews 2012; (3).
41
42 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007945.pub2/abstract>.
43
44 336. Worthington Helen V, Clarkson Jan E, Bryan G, et al. Interventions for preventing oral
45
46 mucositis for patients with cancer receiving treatment. Cochrane Database of
47
48 Systematic Reviews 2011; (4).
49
50 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000978.pub5/abstract>.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 337. Wulaningsih W, Wardhana A, Watkins J, et al. Irinotecan chemotherapy combined with
7
8 fluoropyrimidines versus irinotecan alone for overall survival and progression-free
9
10 survival in patients with advanced and/or metastatic colorectal cancer. Cochrane
11
12 Database of Systematic Reviews 2016; (2).
13
14 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008593.pub3/abstract>.
15
- 16 338. Yalçın B, Kremer Leontien CM, van Dalen Elvira C. High-dose chemotherapy and
17
18 autologous haematopoietic stem cell rescue for children with high-risk
19
20 neuroblastoma. Cochrane Database of Systematic Reviews 2015; (10).
21
22 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006301.pub4/abstract>.
23
- 24 339. Yang J, Zhu L, Wu Z, et al. Chinese herbal medicines for induction of remission in
25
26 advanced or late gastric cancer. Cochrane Database of Systematic Reviews 2013; (4).
27
28 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005096.pub4/abstract>.
29
- 30 340. Yang S, Wu S, Huang Y, et al. Screening for oesophageal cancer. Cochrane Database of
31
32 Systematic Reviews 2012; (12).
33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007883.pub2/abstract>.
35
- 36 341. Yang S, Wu S, Zhou J, et al. Screening for nasopharyngeal cancer. Cochrane Database of
37
38 Systematic Reviews 2015; (11).
39
40 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008423.pub2/abstract>.
41
- 42 342. Yang Z-Y, Liu L, Mao C, et al. Chemotherapy with cetuximab versus chemotherapy alone
43
44 for chemotherapy-naïve advanced non-small cell lung cancer. Cochrane Database of
45
46 Systematic Reviews 2014; (11).
47
48 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009948.pub2/abstract>.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7 343. Yuan Y, Zeng X, Hu Y, et al. Omentoplasty for oesophagostomy after
8 oesophagectomy. Cochrane Database of Systematic Reviews 2014; (10).
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008446.pub3/abstract>.
11
12 344. Zacher J, Kasenda B, Engert A, et al. The role of additional radiotherapy for primary
13 central nervous system lymphoma. Cochrane Database of Systematic Reviews 2014;
14
15 (6). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009211.pub2/abstract>.
16
17 345. Zani Emerson L, Clark Otavio Augusto C, Rodrigues Netto Jr N. Antibiotic prophylaxis for
18 transrectal prostate biopsy. Cochrane Database of Systematic Reviews 2011; (5).
19
20
21 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006576.pub2/abstract>.
22
23 346. Zhong Jian H, Li Le Q, Wu Liu C. Lamivudine with or without adefovir
24 dipivoxil for postoperative hepatocellular carcinoma. Cochrane Database of
25 Systematic Reviews 2011; (12).
26
27 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008713.pub2/abstract>.
28
29

30
31 *High impact journal SRs*

- 32
33 1. Menarche, menopause, and breast cancer risk: individual participant meta-analysis,
34 including 118 964 women with breast cancer from 117 epidemiological studies. The Lancet
35 Oncology 2012;13(11):1141-51.
36
37 2. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-
38 analysis of individual participant data. Lancet (London, England) 2014;383(9928):1561-71.
39
40 3. Endometrial cancer and oral contraceptives: an individual participant meta-analysis of 27
41 276 women with endometrial cancer from 36 epidemiological studies. The Lancet Oncology
42
43 2015;16(9):1061-70.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
4. Ahmed M, Purushotham AD, Douek M. Novel techniques for sentinel lymph node biopsy in breast cancer: a systematic review. *The Lancet Oncology* 2014;15(8):e351-62.
5. Al Khabori M, de Almeida JR, Guyatt GH, et al. Autologous stem cell transplantation in follicular lymphoma: a systematic review and meta-analysis. *Journal of the National Cancer Institute* 2012;104(1):18-28.
6. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. *The Lancet Oncology* 2012;13(5):518-27.
7. Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. *Journal of the National Cancer Institute* 2011;103(17):1299-309.
8. Arbyn M, Verdoodt F, Snijders PJ, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. *The Lancet Oncology* 2014;15(2):172-83.
9. Aune D, Chan DS, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer: systematic review and dose-response meta-analysis of prospective studies. *BMJ (Clinical research ed)* 2011;343:d6617.
10. Bach, Smith-Bindman R, Wood DE, et al. Benefits and harms of CT screening for lung cancer: a systematic review. *Jama* 2012;307(22):2418-29.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

11. Baldwin C, Spiro A, Ahern R, et al. Oral nutritional interventions in malnourished patients with cancer: a systematic review and meta-analysis. *Journal of the National Cancer Institute* 2012;104(5):371-85.

12. Ballard-Barbash R, Friedenreich CM, Courneya KS, et al. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. *Journal of the National Cancer Institute* 2012;104(11):815-40.

13. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. *The Lancet Oncology* 2011;12(1):65-82.

14. Bao Y, Michaud DS, Spiegelman D, et al. Folate intake and risk of pancreatic cancer: pooled analysis of prospective cohort studies. *Journal of the National Cancer Institute* 2011;103(24):1840-50.

15. Beral V, Gaitskell K, Hermon C, et al. Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies. *The Lancet Oncology* 2012;13(9):946-56.

16. Beral V, Gaitskell K, Hermon C, et al. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. *Lancet (London, England)* 2015;385(9980):1835-42.

17. Biagi JJ, Raphael MJ, Mackillop WJ, et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. *Jama* 2011;305(22):2335-42.

- 1
2
3
4
5
6 18. Blanchard P, Bourhis J, Lacas B, et al. Taxane-cisplatin-fluorouracil as induction
7
8 chemotherapy in locally advanced head and neck cancers: an individual patient data meta-
9
10 analysis of the meta-analysis of chemotherapy in head and neck cancer group. *Journal of*
11
12 *clinical oncology : official journal of the American Society of Clinical Oncology*
13
14 2013;31(23):2854-60.
15
16
17 19. Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in nasopharyngeal
18
19 carcinoma: an update of the MAC-NPC meta-analysis. *The Lancet Oncology* 2015;16(6):645-
20
21 55.
22
23
24 20. Blanke CD, Bot BM, Thomas DM, et al. Impact of young age on treatment efficacy and
25
26 safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase
27
28 III chemotherapy trials. *Journal of clinical oncology : official journal of the American Society*
29
30 *of Clinical Oncology* 2011;29(20):2781-6.
31
32
33 21. Blumenthal GM, Karuri SW, Zhang H, et al. Overall response rate, progression-free
34
35 survival, and overall survival with targeted and standard therapies in advanced non-small-
36
37 cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.
38
39 *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
40
41 2015;33(9):1008-14.
42
43
44 22. Boehmer U, Cooley TP, Clark MA. Cancer and men who have sex with men: a systematic
45
46 review. *The Lancet Oncology* 2012;13(12):e545-53.
47
48
49 23. Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2
50
51 mutations and survival in women with invasive epithelial ovarian cancer. *Jama*
52
53 2012;307(4):382-90.
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

24. Boniol M, Autier P, Boyle P, et al. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. *BMJ (Clinical research ed)* 2012;345:e4757.

25. Bourhis J, Blanchard P, Maillard E, et al. Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29(18):2590-7.

26. Bowers DC, Nathan PC, Constine L, et al. Subsequent neoplasms of the CNS among survivors of childhood cancer: a systematic review. *The Lancet Oncology* 2013;14(8):e321-8.

27. Boyle T, Keegel T, Bull F, et al. Physical activity and risks of proximal and distal colon cancers: a systematic review and meta-analysis. *Journal of the National Cancer Institute* 2012;104(20):1548-61.

28. Brasme JF, Morfouace M, Grill J, et al. Delays in diagnosis of paediatric cancers: a systematic review and comparison with expert testimony in lawsuits. *The Lancet Oncology* 2012;13(10):e445-59.

29. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. *BMJ (Clinical research ed)* 2014;348:g2467.

30. Breugom AJ, Swets M, Bosset JF, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. *The Lancet Oncology* 2015;16(2):200-7.

1
2
3
4
5
6 31. Brinton LA, Cook MB, McCormack V, et al. Anthropometric and hormonal risk factors for
7 male breast cancer: male breast cancer pooling project results. Journal of the National
8 Cancer Institute 2014;106(3):djt465.
9

10
11
12
13 32. Castellsague X, Diaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with
14 human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological
15 studies. The Lancet Oncology 2011;12(11):1023-31.
16
17

18
19
20 33. Castillo JJ, Dalia S, Shum H. Meta-analysis of the association between cigarette smoking
21 and incidence of Hodgkin's Lymphoma. Journal of clinical oncology : official journal of the
22 American Society of Clinical Oncology 2011;29(29):3900-6.
23
24

25
26 34. Chatzinasiou F, Lill CM, Kypreou K, et al. Comprehensive field synopsis and systematic
27 meta-analyses of genetic association studies in cutaneous melanoma. Journal of the National
28 Cancer Institute 2011;103(16):1227-35.
29
30

31
32
33 35. Chellapandian D, Lehrnbecher T, Phillips B, et al. Bronchoalveolar lavage and lung biopsy
34 in patients with cancer and hematopoietic stem-cell transplantation recipients: a systematic
35 review and meta-analysis. Journal of clinical oncology : official journal of the American
36 Society of Clinical Oncology 2015;33(5):501-9.
37
38
39

40
41
42 36. Chen LS, Hung RJ, Baker T, et al. CHRNA5 risk variant predicts delayed smoking cessation
43 and earlier lung cancer diagnosis--a meta-analysis. Journal of the National Cancer Institute
44 2015;107(5).
45
46
47
48
49
50
51
52
53
54

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

37. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast cancer treated with bevacizumab. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29(6):632-8.

38. Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. *BMJ (Clinical research ed)* 2014;348:g1903.

39. Church DN, Stelloo E, Nout RA, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. *Journal of the National Cancer Institute* 2015;107(1):402.

40. Coleman R, Powles T, Paterson A, et al. Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. *Lancet (London, England)* 2015;386(10001):1353-61.

41. Collins M, Wilhelm M, Conyers R, et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31(18):2303-12.

42. Coory M, White VM, Johnson KS, et al. Systematic review of quality improvement interventions directed at cancer specialists. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31(12):1583-91.

43. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet (London, England)* 2014;384(9938):164-72.

- 1
2
3
4
5
6 44. Crowe FL, Appleby PN, Travis RC, et al. Circulating fatty acids and prostate cancer risk:
7 individual participant meta-analysis of prospective studies. *Journal of the National Cancer*
8 *Institute* 2014;106(9).
9
10
11
12
13 45. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention
14 of breast cancer: an updated meta-analysis of individual participant data. *Lancet (London,*
15 *England)* 2013;381(9880):1827-34.
16
17
18
19
20 46. Dabestani S, Marconi L, Hofmann F, et al. Local treatments for metastases of renal cell
21 carcinoma: a systematic review. *The Lancet Oncology* 2014;15(12):e549-61.
22
23
24
25 47. D'Amico AV, Chen MH, de Castro M, et al. Surrogate endpoints for prostate cancer-
26 specific mortality after radiotherapy and androgen suppression therapy in men with
27 localised or locally advanced prostate cancer: an analysis of two randomised trials. *The*
28 *Lancet Oncology* 2012;13(2):189-95.
29
30
31
32
33 48. Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving surgery
34 on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient
35 data for 10,801 women in 17 randomised trials. *Lancet (London, England)*
36 2011;378(9804):1707-16.
37
38
39
40
41
42 49. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and
43 other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of
44 randomised trials. *Lancet (London, England)* 2011;378(9793):771-84.
45
46
47
48
49 50. de Jong MC, Kors WA, de Graaf P, et al. Trilateral retinoblastoma: a systematic review
50 and meta-analysis. *The Lancet Oncology* 2014;15(10):1157-67.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

51. De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30(20):2559-65.

52. Deppen SA, Blume JD, Kensinger CD, et al. Accuracy of FDG-PET to diagnose lung cancer in areas with infectious lung disease: a meta-analysis. *Jama* 2014;312(12):1227-36.

53. Di Leo A, Desmedt C, Bartlett JM, et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. *The Lancet Oncology* 2011;12(12):1134-42.

54. DiSipio T, Rye S, Newman B, et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. *The Lancet Oncology* 2013;14(6):500-15.

55. dos Santos LV, Souza FH, Brunetto AT, et al. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. *Journal of the National Cancer Institute* 2012;104(17):1280-92.

56. Dowsett M, Forbes JF, Bradley R, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet (London, England)* 2015;386(10001):1341-52.

57. Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma: review of adverse event management strategies. *Journal of the National Cancer Institute* 2012;104(2):93-113.

- 1
2
3
4
5
6 58. Eliassen AH, Hendrickson SJ, Brinton LA, et al. Circulating carotenoids and risk of breast
7 cancer: pooled analysis of eight prospective studies. *Journal of the National Cancer Institute*
8 2012;104(24):1905-16.
9
10
11
12
13 59. Engelhardt EG, Garvelink MM, de Haes JH, et al. Predicting and communicating the risk of
14 recurrence and death in women with early-stage breast cancer: a systematic review of risk
15 prediction models. *Journal of clinical oncology : official journal of the American Society of*
16 *Clinical Oncology* 2014;32(3):238-50. doi: 10.1200/jco.2013.50.3417
17
18
19
20
21
22 60. Faller H, Schuler M, Richard M, et al. Effects of psycho-oncologic interventions on
23 emotional distress and quality of life in adult patients with cancer: systematic review and
24 meta-analysis. *Journal of clinical oncology : official journal of the American Society of Clinical*
25 *Oncology* 2013;31(6):782-93.
26
27
28
29
30
31 61. Fokom-Domgue J, Combescure C, Fokom-Defo V, et al. Performance of alternative
32 strategies for primary cervical cancer screening in sub-Saharan Africa: systematic review and
33 meta-analysis of diagnostic test accuracy studies. *BMJ (Clinical research ed)* 2015;351:h3084.
34
35
36
37
38 62. Fong DY, Ho JW, Hui BP, et al. Physical activity for cancer survivors: meta-analysis of
39 randomised controlled trials. *BMJ (Clinical research ed)* 2012;344:e70.
40
41
42
43 63. Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent
44 gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-
45 analysis of randomised controlled trials. *BMJ (Clinical research ed)* 2014;348:g3174.
46
47
48
49
50
51
52
53
54

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

64. Freese KE, Kokai L, Edwards RP, et al. Adipose-derived stems cells and their role in human cancer development, growth, progression, and metastasis: a systematic review. *Cancer research* 2015;75(7):1161-8.

65. Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. *Journal of the National Cancer Institute* 2014;106(6):dju091.

66. Garcia MK, McQuade J, Haddad R, et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31(7):952-60.

67. Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2014;32(4):335-46.

68. Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29(16):2144-9.

69. Ghesquieres H, Slager SL, Jardin F, et al. Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2015;33(33):3930-7.

1
2
3
4
5
6 70. Greco MT, Roberto A, Corli O, et al. Quality of cancer pain management: an update of a
7
8 systematic review of undertreatment of patients with cancer. *Journal of clinical oncology* :
9
10 official journal of the American Society of Clinical Oncology 2014;32(36):4149-54.
11

12
13 71. Green J, Cairns BJ, Casabonne D, et al. Height and cancer incidence in the Million Women
14
15 Study: prospective cohort, and meta-analysis of prospective studies of height and total
16
17 cancer risk. *The Lancet Oncology* 2011;12(8):785-94.
18

19
20 72. Gupta S, Hunsberger S, Boerner SA, et al. Meta-analysis of the relationship between dose
21
22 and benefit in phase I targeted agent trials. *Journal of the National Cancer Institute*
23
24 2012;104(24):1860-6.
25

26
27 73. Hamaker ME, Jonker JM, de Rooij SE, et al. Frailty screening methods for predicting
28
29 outcome of a comprehensive geriatric assessment in elderly patients with cancer: a
30
31 systematic review. *The Lancet Oncology* 2012;13(10):e437-44.
32

33
34 74. Hart SL, Hoyt MA, Diefenbach M, et al. Meta-analysis of efficacy of interventions for
35
36 elevated depressive symptoms in adults diagnosed with cancer. *Journal of the National*
37
38 *Cancer Institute* 2012;104(13):990-1004.
39

40
41 75. Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen test:
42
43 a review of current evidence. *Jama* 2014;311(11):1143-9.
44

45
46 76. Heikkila K, Nyberg ST, Theorell T, et al. Work stress and risk of cancer: meta-analysis of
47
48 5700 incident cancer events in 116,000 European men and women. *BMJ (Clinical research*
49
50 *ed)* 2013;346:f165.
51

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

77. Heine JJ, Scott CG, Sellers TA, et al. A novel automated mammographic density measure and breast cancer risk. *Journal of the National Cancer Institute* 2012;104(13):1028-37.

78. Heleno B, Thomsen MF, Rodrigues DS, et al. Quantification of harms in cancer screening trials: literature review. *BMJ (Clinical research ed)* 2013;347:f5334.

79. Henson KE, Jaggi R, Cutter D, et al. Inferring the Effects of Cancer Treatment: Divergent Results From Early Breast Cancer Trialists' Collaborative Group Meta-Analyses of Randomized Trials and Observational Data From SEER Registries. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2016.

80. Henson LA, Gao W, Higginson IJ, et al. Emergency department attendance by patients with cancer in their last month of life: a systematic review and meta-analysis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2015;33(4):370-6.

81. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. *The Lancet Oncology* 2014;15(9):986-96.

82. Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30(13):1541-9.

- 1
2
3
4
5
6 83. Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract
7
8 cancer: a systematic review and meta-analysis. *Journal of clinical oncology : official journal of*
9
10 the American Society of Clinical Oncology 2012;30(16):1934-40.
11
12
13 84. Hornberger J, Alvarado MD, Rebecca C, et al. Clinical validity/utility, change in practice
14
15 patterns, and economic implications of risk stratifiers to predict outcomes for early-stage
16
17 breast cancer: a systematic review. *Journal of the National Cancer Institute*
18
19 2012;104(14):1068-79.
20
21
22 85. Horowitz NA, Benyamini N, Wohlfart K, et al. Reproductive organ involvement in non-
23
24 Hodgkin lymphoma during pregnancy: a systematic review. *The Lancet Oncology*
25
26 2013;14(7):e275-82.
27
28
29 86. Houssami N, Turner R, Macaskill P, et al. An individual person data meta-analysis of
30
31 preoperative magnetic resonance imaging and breast cancer recurrence. *Journal of clinical*
32
33 *oncology : official journal of the American Society of Clinical Oncology* 2014;32(5):392-401.
34
35
36 87. Howard-Anderson J, Ganz PA, Bower JE, et al. Quality of life, fertility concerns, and
37
38 behavioral health outcomes in younger breast cancer survivors: a systematic review. *Journal*
39
40 *of the National Cancer Institute* 2012;104(5):386-405.
41
42
43 88. Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with
44
45 chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III
46
47 studies. *Journal of clinical oncology : official journal of the American Society of Clinical*
48
49 *Oncology* 2011;29(13):1757-64.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

89. Jenkins MA, Dowty JG, Ait Ouakrim D, et al. Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2015;33(4):326-31.

90. Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30(29):3578-87.

91. Joensuu H, Vehtari A, Riihimaki J, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. *The Lancet Oncology* 2012;13(3):265-74.

92. Jung S, Spiegelman D, Baglietto L, et al. Fruit and vegetable intake and risk of breast cancer by hormone receptor status. *Journal of the National Cancer Institute* 2013;105(3):219-36.

93. Kamangar F, Shakeri R, Malekzadeh R, et al. Opium use: an emerging risk factor for cancer? *The Lancet Oncology* 2014;15(2):e69-77.

94. Keum N, Greenwood DC, Lee DH, et al. Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. *Journal of the National Cancer Institute* 2015;107(2).

95. Kiely BE, Soon YY, Tattersall MH, et al. How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29(4):456-63.

- 1
2
3
4
5
6 96. Knoll GA, Kokolo MB, Mallick R, et al. Effect of sirolimus on malignancy and survival after
7 kidney transplantation: systematic review and meta-analysis of individual patient data. BMJ
8 (Clinical research ed) 2014;349:g6679.
9
10
11
12 97. Kolahdooz F, Jang SL, Corriveau A, et al. Knowledge, attitudes, and behaviours towards
13 cancer screening in indigenous populations: a systematic review. The Lancet Oncology
14 2014;15(11):e504-16.
15
16
17 98. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial
18 cancer: an updated Cochrane systematic review and meta-analysis. Journal of the National
19 Cancer Institute 2012;104(21):1625-34.
20
21
22 99. Kotecha RS, Pascoe EM, Rushing EJ, et al. Meningiomas in children and adolescents: a
23 meta-analysis of individual patient data. The Lancet Oncology 2011;12(13):1229-39.
24
25
26 100. Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of
27 patient-reported outcome measures toward improvement of patient outcomes, processes of
28 care, and health service outcomes in cancer care? A systematic review of controlled trials.
29 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
30 2014;32(14):1480-501.
31
32
33 101. Kubben PL, ter Meulen KJ, Schijns OE, et al. Intraoperative MRI-guided resection of
34 glioblastoma multiforme: a systematic review. The Lancet Oncology 2011;12(11):1062-70.
35
36
37 102. Kumar N, Chen Y, Zaw AS, et al. Use of intraoperative cell-salvage for autologous blood
38 transfusions in metastatic spine tumour surgery: a systematic review. The Lancet Oncology
39 2014;15(1):e33-41.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

103. Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis. *BMJ (Clinical research ed)* 2014;349:g6192.

104. Lallas A, Kyrgidis A, Ferrara G, et al. Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review. *The Lancet Oncology* 2014;15(4):e178-83.

105. Lansbury L, Bath-Hextall F, Perkins W, et al. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. *BMJ (Clinical research ed)* 2013;347:f6153.

106. Laurie SA, Ho AL, Fury MG, et al. Systemic therapy in the management of metastatic or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review. *The Lancet Oncology* 2011;12(8):815-24.

107. Lavigne E, Holowaty EJ, Pan SY, et al. Breast cancer detection and survival among women with cosmetic breast implants: systematic review and meta-analysis of observational studies. *BMJ (Clinical research ed)* 2013;346:f2399.

108. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. *Journal of the National Cancer Institute* 2013;105(9):595-605.

109. Lee CK, Wu YL, Ding PN, et al. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-

1
2
3
4
5
6 Analysis. *Journal of clinical oncology : official journal of the American Society of Clinical*
7
8 *Oncology* 2015;33(17):1958-65.
9

10
11 110. Lee JK, Hahn S, Kim DW, et al. Epidermal growth factor receptor tyrosine kinase
12
13 inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type
14
15 epidermal growth factor receptor: a meta-analysis. *Jama* 2014;311(14):1430-7.
16

17
18 111. Lee L, Cheung WY, Atkinson E, et al. Impact of comorbidity on chemotherapy use and
19
20 outcomes in solid tumors: a systematic review. *Journal of clinical oncology : official journal of*
21
22 *the American Society of Clinical Oncology* 2011;29(1):106-17.
23

24
25 112. Lee SJ, Boscardin WJ, Stijacic-Cenzer I, et al. Time lag to benefit after screening for
26
27 breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden,
28
29 United Kingdom, and Denmark. *BMJ (Clinical research ed)* 2013;346:e8441.
30

31
32 113. Liao WC, Chien KL, Lin YL, et al. Adjuvant treatments for resected pancreatic
33
34 adenocarcinoma: a systematic review and network meta-analysis. *The Lancet Oncology*
35
36 2013;14(11):1095-103.
37

38
39 114. Liao WC, Tu YK, Wu MS, et al. Blood glucose concentration and risk of pancreatic
40
41 cancer: systematic review and dose-response meta-analysis. *BMJ (Clinical research ed)*
42
43 2015;349:g7371.
44

45
46 115. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. *The Lancet*
47
48 *Oncology* 2013;14(6):e218-28.
49

- 1
2
3
4
5
6 116. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with
7
8 rheumatoid arthritis treated with biologic therapy: a meta-analysis. *Jama* 2012;308(9):898-
9
10 908.
11
12
13 117. Lockett T, Goldstein D, Butow PN, et al. Psychological morbidity and quality of life of
14
15 ethnic minority patients with cancer: a systematic review and meta-analysis. *The Lancet*
16
17 *Oncology* 2011;12(13):1240-8.
18
19
20 118. Ma Y, Zhang P, Wang F, et al. Association between vitamin D and risk of colorectal
21
22 cancer: a systematic review of prospective studies. *Journal of clinical oncology : official*
23
24 *journal of the American Society of Clinical Oncology* 2011;29(28):3775-82.
25
26
27 119. Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and
28
29 associated neoplastic lesions in men who have sex with men: a systematic review and meta-
30
31 analysis. *The Lancet Oncology* 2012;13(5):487-500.
32
33
34 120. Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-
35
36 invasive bladder cancer after selective bladder-preserving combined-modality therapy: a
37
38 pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706,
39
40 9906, and 0233. *Journal of clinical oncology : official journal of the American Society of*
41
42 *Clinical Oncology* 2014;32(34):3801-9.
43
44
45 121. Maltoni M, Scarpi E, Rosati M, et al. Palliative sedation in end-of-life care and survival: a
46
47 systematic review. *Journal of clinical oncology : official journal of the American Society of*
48
49 *Clinical Oncology* 2012;30(12):1378-83.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 122. Manceau G, Karoui M, Werner A, et al. Comparative outcomes of rectal cancer surgery
7
8 between elderly and non-elderly patients: a systematic review. *The Lancet Oncology*
9
10 2012;13(12):e525-36.
11

12
13 123. Marinovich ML, Houssami N, Macaskill P, et al. Meta-analysis of magnetic resonance
14
15 imaging in detecting residual breast cancer after neoadjuvant therapy. *Journal of the*
16
17 *National Cancer Institute* 2013;105(5):321-33.
18

19
20 124. Markar SR, Wiggins T, Ni M, et al. Assessment of the quality of surgery within
21
22 randomised controlled trials for the treatment of gastro-oesophageal cancer: a systematic
23
24 review. *The Lancet Oncology* 2015;16(1):e23-31.
25

26
27 125. Martin-Doyle W, Leow JJ, Orsola A, et al. Improving selection criteria for early
28
29 cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. *Journal of*
30
31 *clinical oncology : official journal of the American Society of Clinical Oncology*
32
33 2015;33(6):643-50.
34

35
36 126. Manguen A, Le Pechoux C, Saunders MI, et al. Hyperfractionated or accelerated
37
38 radiotherapy in lung cancer: an individual patient data meta-analysis. *Journal of clinical*
39
40 *oncology : official journal of the American Society of Clinical Oncology* 2012;30(22):2788-97.
41

42
43 127. McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and axillary
44
45 surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of
46
47 individual patient data for 8135 women in 22 randomised trials. *Lancet (London, England)*
48
49 2014;383(9935):2127-35.
50

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

128. Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. *The Lancet Oncology* 2015;16(16):1639-50.

129. Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. *The Lancet Oncology* 2011;12(2):160-74.

130. Mitchell AJ, Ferguson DW, Gill J, et al. Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis. *The Lancet Oncology* 2013;14(8):721-32.

131. Mocellin S, Pilati P, Briarava M, et al. Breast Cancer Chemoprevention: A Network Meta-Analysis of Randomized Controlled Trials. *Journal of the National Cancer Institute* 2016;108(2).

132. Mocellin S, Verdi D, Pooley KA, et al. Telomerase reverse transcriptase locus polymorphisms and cancer risk: a field synopsis and meta-analysis. *Journal of the National Cancer Institute* 2012;104(11):840-54.

133. Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31(33):4188-98.

- 1
2
3
4
5
6
7 134. Myers ER, Moorman P, Gierisch JM, et al. Benefits and Harms of Breast Cancer
8 Screening: A Systematic Review. *Jama* 2015;314(15):1615-34.
9
10
11 135. Nagayama A, Hayashida T, Jinno H, et al. Comparative effectiveness of neoadjuvant
12 therapy for HER2-positive breast cancer: a network meta-analysis. *Journal of the National*
13 *Cancer Institute* 2014;106(9).
14
15
16
17 136. Nair VS, Maeda LS, Ioannidis JP. Clinical outcome prediction by microRNAs in human
18 cancer: a systematic review. *Journal of the National Cancer Institute* 2012;104(7):528-40.
19
20
21
22 137. Ndiaye C, Mena M, Alemany L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in
23 head and neck cancers: a systematic review and meta-analysis. *The Lancet Oncology*
24 *2014;15(12):1319-31.*
25
26
27
28
29 138. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with
30 cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.
31 *Jama* 2011;306(21):2359-66.
32
33
34
35
36 139. Niraula S, Amir E, Vera-Badillo F, et al. Risk of incremental toxicities and associated
37 costs of new anticancer drugs: a meta-analysis. *Journal of clinical oncology : official journal*
38 *of the American Society of Clinical Oncology* 2014;32(32):3634-42.
39
40
41
42 140. Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent versus
43 continuous androgen deprivation: a systematic review of randomized trials. *Journal of*
44 *clinical oncology : official journal of the American Society of Clinical Oncology*
45 *2013;31(16):2029-36.*
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 141. Niraula S, Seruga B, Ocana A, et al. The price we pay for progress: a meta-analysis of
7 harms of newly approved anticancer drugs. *Journal of clinical oncology : official journal of*
8
9 the American Society of Clinical Oncology 2012;30(24):3012-9.
10
11
12
13 142. Oba K, Paoletti X, Alberts S, et al. Disease-free survival as a surrogate for overall survival
14 in adjuvant trials of gastric cancer: a meta-analysis. *Journal of the National Cancer Institute*
15
16 2013;105(21):1600-7.
17
18
19
20 143. Ocana A, Vera-Badillo F, Seruga B, et al. HER3 overexpression and survival in solid
21 tumors: a meta-analysis. *Journal of the National Cancer Institute* 2013;105(4):266-73.
22
23
24
25 144. Ohri N, Shen X, Dicker AP, et al. Radiotherapy protocol deviations and clinical outcomes:
26 a meta-analysis of cooperative group clinical trials. *Journal of the National Cancer Institute*
27
28 2013;105(6):387-93.
29
30
31 145. Oostendorp LJ, Stalmeier PF, Donders AR, et al. Efficacy and safety of palliative
32 chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and
33 taxanes: a systematic review. *The Lancet Oncology* 2011;12(11):1053-61.
34
35
36
37
38 146. O'Sullivan CC, Bradbury I, Campbell C, et al. Efficacy of Adjuvant Trastuzumab for
39 Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and
40 Tumors \leq 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. *Journal of clinical*
41
42 oncology : official journal of the American Society of Clinical Oncology 2015;33(24):2600-8.
43
44
45
46
47 147. Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast
48 cancer screening decisions. *Jama* 2014;311(13):1327-35.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6 148. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide
7 therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. The Lancet
8 Oncology 2014;15(3):333-42.
9
10

11
12
13 149. Patel SH, Wang Z, Wong WW, et al. Charged particle therapy versus photon therapy for
14 paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-analysis.
15 The Lancet Oncology 2014;15(9):1027-38.
16
17

18
19
20 150. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer outcomes: a
21 systematic review and meta-analysis. Journal of clinical oncology : official journal of the
22 American Society of Clinical Oncology 2011;29(1):40-6.
23
24

25
26
27 151. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and
28 risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. The
29 Lancet Oncology 2012;13(4):385-94.
30
31

32
33
34 152. Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy
35 regimens for early breast cancer: meta-analyses of long-term outcome among 100,000
36 women in 123 randomised trials. Lancet (London, England) 2012;379(9814):432-44.
37
38

39
40
41 153. Pettersson A, Graff RE, Ursin G, et al. Mammographic density phenotypes and risk of
42 breast cancer: a meta-analysis. Journal of the National Cancer Institute 2014;106(5).
43
44

45
46
47 154. Phi XA, Houssami N, Obdeijn IM, et al. Magnetic resonance imaging improves breast
48 screening sensitivity in BRCA mutation carriers age \geq 50 years: evidence from an individual
49 patient data meta-analysis. Journal of clinical oncology : official journal of the American
50 Society of Clinical Oncology 2015;33(4):349-56.
51
52

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

155. Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma tumor syndrome: systematic review and revised diagnostic criteria. *Journal of the National Cancer Institute* 2013;105(21):1607-16.

156. Playdon MC, Bracken MB, Sanft TB, et al. Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis. *Journal of the National Cancer Institute* 2015;107(12):djv275.

157. Potter S, Brigid A, Whiting PF, et al. Reporting clinical outcomes of breast reconstruction: a systematic review. *Journal of the National Cancer Institute* 2011;103(1):31-46.

158. Proverbs-Singh T, Chiu SK, Liu Z, et al. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. *Journal of the National Cancer Institute* 2012;104(23):1837-40.

159. Puts MT, Hardt J, Monette J, et al. Use of geriatric assessment for older adults in the oncology setting: a systematic review. *Journal of the National Cancer Institute* 2012;104(15):1133-63.

160. Raaschou-Nielsen O, Andersen ZJ, Beelen R, et al. Air pollution and lung cancer incidence in 17 European cohorts: prospective analyses from the European Study of Cohorts for Air Pollution Effects (ESCAPE). *The Lancet Oncology* 2013;14(9):813-22.

161. Rahbari NN, Bork U, Motschall E, et al. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative

1
2
3
4
5
6 colorectal cancer: a systematic review and meta-analysis. Journal of clinical oncology :
7 official journal of the American Society of Clinical Oncology 2012;30(1):60-70.

10
11 162. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer
12 patients: a meta-analysis. Jama 2011;305(5):487-94.

15
16 163. Rao R, Euhus D, Mayo HG, et al. Axillary node interventions in breast cancer: a
17 systematic review. Jama 2013;310(13):1385-94.

20
21 164. Rebolj M, Bonde J, Njor SH, et al. Human papillomavirus testing in primary cervical
22 screening and the cut-off level for hybrid capture 2 tests: systematic review. BMJ (Clinical
23 research ed) 2011;342:d2757.

26
27 165. Richards CJ, Je Y, Schutz FA, et al. Incidence and risk of congestive heart failure in
28 patients with renal and nonrenal cell carcinoma treated with sunitinib. Journal of clinical
29 oncology : official journal of the American Society of Clinical Oncology 2011;29(25):3450-6.

32
33 166. Riester M, Wei W, Waldron L, et al. Risk prediction for late-stage ovarian cancer by
34 meta-analysis of 1525 patient samples. Journal of the National Cancer Institute 2014;106(5).

37
38 167. Rooney AG, Carson A, Grant R. Depression in cerebral glioma patients: a systematic
39 review of observational studies. Journal of the National Cancer Institute 2011;103(1):61-76.

42
43 168. Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and
44 other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review,
45 and meta-analysis. Journal of clinical oncology : official journal of the American Society of
46 Clinical Oncology 2014;32(10):1031-9.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

169. Rossi A, Chiodini P, Sun JM, et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. *The Lancet Oncology* 2014;15(11):1254-62.

170. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30(14):1692-8.

171. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. *Lancet (London, England)* 2011;377(9759):31-41.

172. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. *Lancet (London, England)* 2012;379(9826):1602-12.

173. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. *Lancet (London, England)* 2012;379(9826):1591-601.

174. Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2015;33(17):1889-94.

1
2
3
4
5
6 175. Schmid D, Leitzmann MF. Television viewing and time spent sedentary in relation to
7 cancer risk: a meta-analysis. *Journal of the National Cancer Institute* 2014;106(7).

10 176. Schmoll HJ, Twelves C, Sun W, et al. Effect of adjuvant capecitabine or fluorouracil, with
11 or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of
12 oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four
13 randomised controlled trials. *The Lancet Oncology* 2014;15(13):1481-92.

16 177. Schottker B, Jorde R, Peasey A, et al. Vitamin D and mortality: meta-analysis of
17 individual participant data from a large consortium of cohort studies from Europe and the
18 United States. *BMJ (Clinical research ed)* 2014;348:g3656.

21 178. Schutz FA, Je Y, Richards CJ, et al. Meta-analysis of randomized controlled trials for the
22 incidence and risk of treatment-related mortality in patients with cancer treated with
23 vascular endothelial growth factor tyrosine kinase inhibitors. *Journal of clinical oncology :*
24 official journal of the American Society of Clinical Oncology 2012;30(8):871-7.

27 179. Seng S, Liu Z, Chiu SK, et al. Risk of venous thromboembolism in patients with cancer
28 treated with Cisplatin: a systematic review and meta-analysis. *Journal of clinical oncology :*
29 official journal of the American Society of Clinical Oncology 2012;30(35):4416-26.

32 180. Shaikh F, Dupuis LL, Alexander S, et al. Cardioprotection and Second Malignant
33 Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline
34 Chemotherapy: A Systematic Review and Meta-Analysis. *Journal of the National Cancer*
35 Institute 2016;108(4).

1
2
3
4
5
6 181. Sheinfeld Gorin S, Krebs P, Badr H, et al. Meta-analysis of psychosocial interventions to
7 reduce pain in patients with cancer. *Journal of clinical oncology : official journal of the*
8
9
10 *American Society of Clinical Oncology* 2012;30(5):539-47.

11
12
13 182. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant
14 chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated
15
16 meta-analysis. *The Lancet Oncology* 2011;12(7):681-92.

17
18
19
20 183. Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of
21 patients with advanced-stage Hodgkin's lymphoma: a systematic review and network meta-
22
23 analysis. *The Lancet Oncology* 2013;14(10):943-52.

24
25
26 184. Sonneveld P, Goldschmidt H, Rosinol L, et al. Bortezomib-based versus nonbortezomib-
27 based induction treatment before autologous stem-cell transplantation in patients with
28
29 previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled
30
31 trials. *Journal of clinical oncology : official journal of the American Society of Clinical*
32
33 *Oncology* 2013;31(26):3279-87.

34
35
36
37 185. Spratt DE, Gordon Spratt EA, Wu S, et al. Efficacy of skin-directed therapy for cutaneous
38 metastases from advanced cancer: a meta-analysis. *Journal of clinical oncology : official*
39
40 *journal of the American Society of Clinical Oncology* 2014;32(28):3144-55.

41
42
43
44 186. Tang V, Boscardin WJ, Stijacic-Cenzer I, et al. Time to benefit for colorectal cancer
45 screening: survival meta-analysis of flexible sigmoidoscopy trials. *BMJ (Clinical research ed)*
46
47
48 2015;350:h1662.

- 1
2
3
4
5
6 187. Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-
7 lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Journal of the
8 National Cancer Institute 2014;106(6):dju124.
9
10
11
12
13 188. Teulings HE, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with
14 stage III-IV melanoma receiving immunotherapy and its association with survival: a
15 systematic review and meta-analysis. Journal of clinical oncology : official journal of the
16 American Society of Clinical Oncology 2015;33(7):773-81.
17
18
19
20
21
22 189. Theodoratou E, Montazeri Z, Hawken S, et al. Systematic meta-analyses and field
23 synopsis of genetic association studies in colorectal cancer. Journal of the National Cancer
24 Institute 2012;104(19):1433-57.
25
26
27
28
29 190. Thosani N, Thosani SN, Kumar S, et al. Reduced risk of colorectal cancer with use of oral
30 bisphosphonates: a systematic review and meta-analysis. Journal of clinical oncology :
31 official journal of the American Society of Clinical Oncology 2013;31(5):623-30.
32
33
34
35
36 191. Trabert B, Ness RB, Lo-Ciganic WH, et al. Aspirin, nonaspirin nonsteroidal anti-
37 inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian cancer: a
38 pooled analysis in the Ovarian Cancer Association Consortium. Journal of the National
39 Cancer Institute 2014;106(2):djt431.
40
41
42
43
44 192. Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review of
45 meta-analyses of observational studies. BMJ (Clinical research ed) 2015;350:g7607.
46
47
48
49 193. Vale CL, Burdett S, Ryzewska LH, et al. Addition of docetaxel or bisphosphonates to
50 standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 systematic review and meta-analyses of aggregate data. *The Lancet Oncology*
7
8 2016;17(2):243-56.
9
10
11 194. Valery PC, Moore SP, Meiklejohn J, et al. International variations in childhood cancer in
12 indigenous populations: a systematic review. *The Lancet Oncology* 2014;15(2):e90-e103.
13
14
15 195. Valsecchi ME, Silbermins D, de Rosa N, et al. Lymphatic mapping and sentinel lymph
16 node biopsy in patients with melanoma: a meta-analysis. *Journal of clinical oncology : official*
17 *journal of the American Society of Clinical Oncology* 2011;29(11):1479-87.
18
19
20
21
22 196. van der Pas MH, Meijer S, Hoekstra OS, et al. Sentinel-lymph-node procedure in colon
23 and rectal cancer: a systematic review and meta-analysis. *The Lancet Oncology*
24
25 2011;12(6):540-50.
26
27
28
29 197. Vera-Badillo FE, Templeton AJ, de Gouveia P, et al. Androgen receptor expression and
30 outcomes in early breast cancer: a systematic review and meta-analysis. *Journal of the*
31 *National Cancer Institute* 2014;106(1):djt319.
32
33
34
35
36 198. Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of
37 patients with follicular lymphoma: an updated systematic review and meta-analysis of
38 randomized trials. *Journal of the National Cancer Institute* 2011;103(23):1799-806.
39
40
41
42
43 199. Violette PD, Agoritsas T, Alexander P, et al. Decision aids for localized prostate cancer
44 treatment choice: Systematic review and meta-analysis. *CA: a cancer journal for clinicians*
45 2015;65(3):239-51.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


- 1
2
3
4
5
6 200. Vollset SE, Clarke R, Lewington S, et al. Effects of folic acid supplementation on overall
7 and site-specific cancer incidence during the randomised trials: meta-analyses of data on
8 50,000 individuals. *Lancet (London, England)* 2013;381(9871):1029-36.
9
10
11
12
13 201. Vora A, Andreano A, Pui CH, et al. Influence of Cranial Radiotherapy on Outcome in
14 Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy. *Journal*
15 *of clinical oncology : official journal of the American Society of Clinical Oncology* 2016.
16
17
18
19
20 202. Waldron L, Haibe-Kains B, Culhane AC, et al. Comparative meta-analysis of prognostic
21 gene signatures for late-stage ovarian cancer. *Journal of the National Cancer Institute*
22 2014;106(5).
23
24
25
26 203. Wang HT, Yao YH, Li BG, et al. Neuroendocrine Prostate Cancer (NEPC) progressing from
27 conventional prostatic adenocarcinoma: factors associated with time to development of
28 NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis. *Journal of*
29 *clinical oncology : official journal of the American Society of Clinical Oncology*
30 2014;32(30):3383-90.
31
32
33
34
35
36
37 204. Wang SY, Chu H, Shamliyan T, et al. Network meta-analysis of margin threshold for
38 women with ductal carcinoma in situ. *Journal of the National Cancer Institute*
39 2012;104(7):507-16.
40
41
42
43
44 205. Wang X, Ouyang Y, Liu J, et al. Fruit and vegetable consumption and mortality from all
45 causes, cardiovascular disease, and cancer: systematic review and dose-response meta-
46 analysis of prospective cohort studies. *BMJ (Clinical research ed)* 2014;349:g4490.
47
48
49
50
51
52
53
54
55
56
57
58
59
60


- 1
2
3
4
5
6 206. Wang Y, Yang F, Shen Y, et al. Maintenance Therapy With Immunomodulatory Drugs in
7
8 Multiple Myeloma: A Meta-Analysis and Systematic Review. *Journal of the National Cancer*
9
10 *Institute* 2016;108(3).
11
12
13 207. Wehner MR, Shive ML, Chren MM, et al. Indoor tanning and non-melanoma skin
14
15 cancer: systematic review and meta-analysis. *BMJ (Clinical research ed)* 2012;345:e5909.
16
17
18 208. Winter AC, Rice MS, Fortner RT, et al. Migraine and breast cancer risk: a prospective
19
20 cohort study and meta-analysis. *Journal of the National Cancer Institute* 2015;107(1):381.
21
22
23 209. Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the
24
25 staging and surveillance of melanoma patients: a meta-analysis. *Journal of the National*
26
27 *Cancer Institute* 2011;103(2):129-42.
28
29
30 210. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors with
31
32 tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.
33
34 *Journal of the National Cancer Institute* 2011;103(3):250-63.
35
36
37 211. Yothers G, Sargent DJ, Wolmark N, et al. Outcomes among black patients with stage II
38
39 and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. *Journal*
40
41 *of the National Cancer Institute* 2011;103(20):1498-506.
42
43
44 212. Zhang B, Beeghly-Fadiel A, Long J, et al. Genetic variants associated with breast-cancer
45
46 risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. *The*
47
48 *Lancet Oncology* 2011;12(5):477-88.
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6 213. Zhang B, Shu XO, Delahanty RJ, et al. Height and Breast Cancer Risk: Evidence From
7
8 Prospective Studies and Mendelian Randomization. Journal of the National Cancer Institute
9
10 2015;107(11).
11
12
13 214. Zhao FH, Lewkowitz AK, Chen F, et al. Pooled analysis of a self-sampling HPV DNA Test
14
15 as a cervical cancer primary screening method. Journal of the National Cancer Institute
16
17 2012;104(3):178-88.
18
19
20 215. Zheng JS, Hu XJ, Zhao YM, et al. Intake of fish and marine n-3 polyunsaturated fatty
21
22 acids and risk of breast cancer: meta-analysis of data from 21 independent prospective
23
24 cohort studies. BMJ (Clinical research ed) 2013;346:f3706.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only






189x134mm (72 x 72 DPI)


view only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



143x182mm (72 x 72 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



374x135mm (72 x 72 DPI)

peer review only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



262x210mm (72 x 72 DPI)

View only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



291x232mm (72 x 72 DPI)

View only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



276x221mm (72 x 72 DPI)

View only



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6 and Appendix
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7-8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8



PRISMA 2009 Checklist

Page 1 of 2

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	NA
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	NA
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9 and flow diagrams
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	NA
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	NA
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9-12 and forest plot
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	NA
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	NA
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	NA
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	13-16
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	13-14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	15-16
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	18

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>
For more information, visit: www.prisma-statement.org



PRISMA 2009 Checklist

For peer review only

- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47

BMJ Open

A Systematic Assessment of Cochrane Reviews and Systematic Reviews Published in High-Impact Medical Journals Related to Cancer

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-020869.R1
Article Type:	Research
Date Submitted by the Author:	01-Feb-2018
Complete List of Authors:	Goldkuhle, Marius; Uniklinik Koln, Department I of Internal Medicine Narayan, Vikram; Minneapolis Veterans Administration Health Care System, Urology Section; University of Minnesota, Department of Urology Weigl, Aaron; Uniklinik Koln Klinik I fur Innere Medizin Dahm, , Philipp ; Minneapolis Veterans Administration Health Care System, Urology Section; University of Minnesota, Department of Urology Skoetz, Nicole; University Hospital of Cologne , Cochrane Haematological Malignancies Group; Department I of Internal Medicine
Primary Subject Heading:	Research methods
Secondary Subject Heading:	Oncology
Keywords:	methodological systematic review, AMSTAR, quality assessment

SCHOLARONE™
Manuscripts

Only

1
2
3 **A Systematic Assessment of Cochrane Reviews and Systematic Reviews Published in High-**
4 **Impact Medical Journals Related to Cancer**
5
6
7
8
9
10
11
12
13

14 Marius Goldkuhle, Masters Student;¹ Vikram M. Narayan, House Officer;² Aaron Weigl,
15 Research Associate;¹ Philipp Dahm, Professor;² and Nicole Skoetz, MD Senior Lecturer¹
16
17
18

19
20 ¹Department of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937
21 Cologne, Germany
22

23 ²Minneapolis Veterans Administration Health Care System and Department of Urology,
24 University of Minnesota, Mayo Memorial Building, 420 Delaware St SE, MMC 394,
25 Minneapolis, MN 55455, US
26
27
28

29 **Correspondence to:**
30

31 Marius Goldkuhle, B.Sc.
32

33 Kerpener Str. 62
34

35 50937 Cologne, Germany
36

37 Email: marius.goldkuhle@uk-koeln.de
38

39 Phone: +49 221 478-96648
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Objective: To compare cancer-related systematic reviews (SRs) published in the Cochrane Database of SRs (CDSR) and high-impact journals, with respect to type, content, quality, and citation rates.

Design: Methodological SR with assessment and comparison of SRs and meta-analyses. Two authors independently assessed methodological quality using an Assessment of Multiple Systematic Reviews (AMSTAR)-based extraction form. Both authors independently screened search results, extracted content-relevant characteristics, and retrieved citation numbers of the included reviews using the Clarivate Analytics Web of Science database.

Data sources: Cancer-related SRs were retrieved from the CDSR, as well as from the ten journals which publish oncologic SRs and had the highest impact factors, using a comprehensive search in both the CDSR and MEDLINE.

Eligibility criteria for selecting studies: We included all cancer-related SRs and meta-analyses published from January 2011 to May 2016. Methodological SRs were excluded.

Results: We included 346 applicable Cochrane reviews and 215 SRs from high-impact journals. Cochrane reviews consistently met more individual AMSTAR criteria, notably with regards to an a-priori design (RR 3.89; 95% CI 3.10 to 4.88), inclusion of the grey literature and trial registries (RR 3.52; 95% CI 2.84 to 4.37) in their searches, and the reporting of excluded studies (RR 8.80; 95% CI 6.06 to 12.78). Cochrane reviews were less likely to address questions of prognosis (RR 0.04; 95% CI 0.02 to 0.09), use individual patient data (RR 0.03; 95% CI 0.01 to 0.09), or be based on non-randomised controlled trials (RR 0.04; 95% CI 0.02 to 0.09). Citation rates of Cochrane reviews were notably lower than those for high-

1
2
3 impact journals (Cochrane reviews: mean number of citations 6.52 (range 0 to 143); High-
4
5 impact journal SRs: 74.45 (0 to 652)).
6
7

8 **Conclusions:** When comparing cancer-related SRs published in the CDSR versus those
9
10 published in high-impact medical journals, Cochrane reviews were consistently of higher
11
12 methodological quality, but cited less frequently.
13
14
15

16 17 18 19 20 **Strengths and limitations of this study**

21
22 -Unique cross-disciplinary comparison of systematic reviews in oncology including over 550
23
24 SRs.
25
26

27
28 -Methodological assessment using AMSTAR, a validated and widely used tool to evaluate the
29
30 quality of systematic reviews.
31
32

33
34 -It was not feasible to blind the authors of this study to the source journal of a given review,
35
36 which may have potentially biased the assessments.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

The care of patients with cancer continues to be a clinical research priority as documented by an increasing number of publications of different types including systematic reviews (SRs). In fact, in recent years, oncology has been the medical discipline with the highest number of publications and the numbers continue to rise.¹ The large number of oncology-related research studies poses a tremendous challenge for patients, healthcare providers, and health policymakers alike when seeking to stay abreast of a particular oncologic topic. SRs follow reproducible methods to identify relevant studies for a given question, apply pre-defined and explicit eligibility criteria, perform assessments of the validity of findings, and systematically present the results. In this context, SRs can be helpful in summarizing the current best evidence for a particular clinical question to support both individual decision-making and in serving as the basis for clinical practice guidelines.^{2 3} Cochrane is widely known for having developed many of the methodological standards based on which SRs should be conducted. These standards are specified in the 2016 updated Methodological Expectations of Cochrane Intervention Reviews (MECIR). However, a large number of oncology-related SRs are currently published by clinical journals, high-impact medical journals, oncology focused journals, as well as subspecialty journals. As the number of SRs has steadily increased over the past two decades, their methodological rigor has been drawn into scrutiny.⁴⁻⁶ To date, no study has formally assessed the methodological quality of oncology-related SRs which assume such a prominent place in the medical literature.

In this study, we therefore sought to formally assess the methodological quality, type, content, and citation rates of oncology related SRs, comparing SRs published in high-impact medical journals with those published in the Cochrane Database of SRs (CDSR).

Methods

The design and eligibility criteria of this project were based on an a priori written protocol. Study reporting is provided in accordance with the PRISMA statement. However, as a methodology-focused review, it was not eligible for a registration in the International Prospective Register Of Systematic Reviews (PROSPERO).

Patient involvement:

Given its methodological focus, we did not evaluate patient-related outcomes. Therefore, we also chose not to involve patients' input in its design. However, the clear intent of this study is to indirectly benefit the welfare of patients by promoting the development and dissemination of high quality systematic reviews.

Eligibility criteria:

We selected all Cochrane reviews that examined questions related to oncology. We furthermore identified all cancer related SRs published in the highest impact medical journals, as defined by the InCites™ Journal Citation Report® 2014, from the same time period via an electronic database search. To reflect contemporary reviews, we chose the five-year period between January 2011 and May 2016 as the study timeframe. We did not apply restrictions with regards to study design or meta-analytic methods, and also included SRs without a meta-analysis. We broadly included studies related to all types of cancer.

The ten journals with the highest impact factors that published SRs on cancer topics were: *A Cancer Journal for Clinicians*, *New England Journal of Medicine*, *The Lancet*, *JAMA*, *Lancet Oncology*, *Journal of Clinical Oncology*, *The BMJ*, *Nature Reviews Clinical Oncology*,

1
2
3 *Journal of the National Cancer Institute, and Cancer Research.* We did not apply any
4
5 language restrictions, however all selected journals published exclusively in English. We
6
7 excluded SRs with a methodological focus. For our examination, we used the original English
8
9 version of each Cochrane review (given that foreign language translation exists for many
10
11 Cochrane reviews). In cases where one or more updates of previously published Cochrane
12
13 reviews existed, we based our assessment on the most recently published version within the
14
15 defined timeframe.
16
17

18 19 20 *Study identification and selection*

21
22 We identified all cancer-related Cochrane reviews in the CDSR from January 2011 to
23
24 May 2016 using the built in “Browse by topic” database function with the options “Cancer”
25
26 and “Stage: Review.” In a parallel step, we conducted a comprehensive literature search of
27
28 SRs published in the ten highest-impact journals from the same time-period on June 1st,
29
30 2016. An information specialist developed the search strategy for MEDLINE using the
31
32 following search terms: Cancer, leukaemia, tumor, tumour, leukemia, lymphoma, myeloma,
33
34 solid, neoplasm, meta-analysis, systematic review, publication dates: 2011 to 2016. We used
35
36 the following MeSH terms: Neoplasm by Histologic Type and Neoplasms by Site. The full
37
38 search strategy is provided in the *appendix*. Two authors independently (MG, VN) and in
39
40 duplicate performed title and abstract screening, full text screening, and ultimately,
41
42 selection of reviews to be included. We resolved discrepancies by discussion with one of two
43
44 other authors (NS, PD).
45
46
47
48

49 50 *Quality assessment*

51
52 We evaluated methodological quality with the Assessment of Multiple Systematic
53
54 Reviews (AMSTAR) checklist, by Shea, et al.⁷ The checklist consists of 11 items and was
55
56
57
58
59

1
2
3 specially developed to assess the methodological quality of SRs and meta-analyses. In cases
4
5 where AMSTAR combined several items into one criterion, we separated these out into 20
6
7 individual items for the sake of transparency but readjusted them into single items for the
8
9 AMSTAR scoring. A complete list of items can be found in the *appendix*; answer options were
10
11 “yes,” “no,” and “not applicable.” Methods like sensitivity- and subgroup-analyses, or funnel
12
13 plots for the assessment of publication bias require a minimum quantity of studies. For
14
15 example, meaningful interpretations of funnel plots require a threshold of at least ten
16
17 studies.⁸ In SRs where there was evidence that these secondary analyses were planned, but
18
19 could not be meaningfully conducted, this criterion was rated as fulfilled. Two authors (MG,
20
21 VN) performed the quality assessments independently and in duplicate. We resolved
22
23 disagreements by discussion and with a third author (NS, PD).
24
25
26
27
28

29 *Data extraction and extracted items*

30
31 The included studies were then reviewed in detail as part of a clinical content
32
33 analysis. We extracted the review type, the study design of the included studies, and review
34
35 question (e.g. therapeutic, diagnostic, or prognostic) of included studies. We chose the
36
37 following items to reflect the review content: Cancer type (e.g. breast, lung, colorectal, but
38
39 also “cancer in general”, “mixed” (but not in general) and “other” (e.g. liver metastases or
40
41 male breast cancer), intervention (e.g. chemotherapy, “new drug” (targeted therapies, such
42
43 as monoclonal antibodies and small molecules)), radiotherapy, surgery, supportive (e.g.
44
45 interventions for cancer-related pain, rehabilitation after cancer treatment, interventions for
46
47 depression in cancer patients, or adjuvant bisphosphonate treatment for cancer patients), or
48
49 not applicable (if prognostic, diagnostic or epidemiological review question), population
50
51 (adults, children or both), the number of included studies, and the number of included
52
53
54
55
56
57
58
59
60

1
2
3 patients. A complete list of the 17 criteria can be found in the *appendix*. To ensure the
4
5 completeness of our assessment we obtained and formally considered any additional
6
7 information from all (online) supplements and appendices. Two authors (MG, VN)
8
9 independently extracted this data using a previously piloted form. The data extraction form
10
11 was designed a priori with consensus of four authors (MG, VN, NS, PD). Discrepancies were
12
13 once again resolved through discussion and third author arbitration if necessary (NS, PD).
14
15

16 17 *Citations*

18
19 We gathered the citation counts for both Cochrane reviews and high-impact journal
20
21 reviews using the Clarivate Analytics Web of Science database. Citations counts were
22
23 assessed on February 15th, 2017 by two authors independently (AW, MG). For updates of
24
25 Cochrane reviews, we considered the citations of the respective update(s) and added
26
27 citations from the original review, as long as the original review and any updates were
28
29 published within the predefined timeframe of our study.
30
31
32

33 34 *Data synthesis and analysis*

35
36 For dichotomous variables, we determined rates, and for continuous variables, we
37
38 calculated median and interquartile range (IQR), or mean and range. To compare the quality
39
40 of both groups, we used risk ratios and the corresponding 95% confidence intervals. We
41
42 defined an event as fulfilling a given quality indicator and have presented this data in forest
43
44 plots. All statistical analyses were undertaken using Review Manager Version 5.3.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Search results

As shown in the study flowchart (Figure 1), our search for oncology-related Cochrane reviews identified 412 records, of which 346 were determined to be cancer related and appropriate according to our selection criteria. Our electronic database search for high-impact SRs identified 738 records, of which 215 were ultimately included, excluding seven reviews at the full-text stage which focused on methodological issues (Figure 2).⁹⁻¹⁵ The references of the included articles are provided in the *online appendix*.

Quality

In general, reviews published by Cochrane met each quality criterion to a greater extent than reviews published in high-impact journals (Figure 3). Cochrane reviews were more likely to report an a priori design, including the definition of the review question and a planned inclusion and exclusion criteria before conducting the review (both with a risk ratio of 3.89; 95% confidence interval (CI) 3.10 to 4.88) (AMSTAR Item 1). Differences also existed in the inclusion of unpublished and non-English literature; Cochrane reviews were more likely to include unpublished (risk ratios (RR) 3.52 (95% CI 2.84 to 4.37) and non-English studies) (RR 3.23 (95% CI 2.64 to 3.95)) (Item 4). Included studies were listed relatively equally between the two (RR 1.10; 95% CI 1.05 to 1.14) comparators, whereas a list of excluded studies, at least those rejected in the course of full-text screening, were provided almost nine times more often by Cochrane reviews (RR 8.80; 95% CI 6.06 to 12.78) (Item 5). Further, a quality assessment of the included studies (using tools such as Cochrane's Risk of Bias, the Jadad scale, or the Newcastle-Ottawa scale) was undertaken over twice as frequently in Cochrane reviews (RR 2.17; 95% CI 1.88 to 2.50) (Item 7). A meta-analysis was

1
2
3 conducted in 67% (227/346) of Cochrane reviews and in 80% (173/215) of high-impact
4
5 journal SRs. A sensitivity analysis based on study quality or risk of bias was more commonly
6
7 reported in Cochrane reviews (RR 4.17; 95% CI 3.07 to 5.67). Almost 23% (53/227) of
8
9 Cochrane reviews planned to undertake but did not perform sensitivity-analyses due to an
10
11 insufficient number of included studies, the inclusion of high risk of bias studies only, or
12
13 unclear information regarding study quality. Formal assessments of potential publication
14
15 bias like funnel plots were undertaken or planned about twice as frequently among reviews
16
17 produced by Cochrane (RR 1.98; 95% CI 1.63 to 2.41) than in SRs published in high impact
18
19 journals. However, 47.3% (107/226) of Cochrane reviews and 1.7% (3/173) of reviews from
20
21 high-impact journals planned but could not perform such assessments due to an insufficient
22
23 number of included studies (AMSTAR Item 10). The vast majority of SRs both in Cochrane
24
25 reviews and high-impact journals disclosed potential conflicts of interest of the SR authors
26
27 (RR 1.01; 95% CI 1.00 to 1.03). However, potential conflicts of interest of the trials included
28
29 in the SRs were reported more frequently by Cochrane reviews than by SRs in high-impact
30
31 journals; with Cochrane reviews being more than four times as likely to provide this
32
33 information (RR 4.30; 95% CI 2.56 to 7.20) (Item 11).
34
35
36
37
38
39

40 *Characteristics of included SRs*

41
42 With regards to geographical origin, the largest proportion of Cochrane reviews
43
44 originated from Europe (67.3%; 233/346) and relatively infrequently originated from North
45
46 America (7.5%; 26/346); meanwhile, high-impact journal SRs were as likely to come from
47
48 Europe (44.2%; 95/215) or North America (40.9%; 88/215; Table 1). Cochrane reviews were
49
50 much less likely to use individual patient data (IPD) (RR 0.03; 95% CI 0.01 to 0.09) compared
51
52 to aggregate study-level data. The majority of Cochrane reviews used the latter (95.7%;
53
54
55
56
57
58
59
60

1
2
3 331/346), with only three (0.9%; 3/346) including individual patient data exclusively, and 12
4
5 (3.5%; 12/346) using both types of data. SRs from high-impact journals were also primarily
6
7 based on study level data (68.4%; 147/215), but a much larger proportion used IPD (31.2%;
8
9 67/216). Network meta-analyses were uncommon among both Cochrane reviews (0.6%;
10
11 2/346) and high-impact SRs (2.8%; 6/215).

12
13
14
15 Cochrane reviews predominantly investigated therapeutic (89%; 308/346) questions.
16
17 Among SRs from high-impact journals, there was also a large number of prognostic reviews
18
19 (37.2%; 80/215) in addition to therapeutic reviews (41.9%; 90/215; Figure 4). Overall,
20
21 Cochrane reviews were less likely to include non-randomised controlled trials (RR 0.04; 95%
22
23 CI 0.02 to 0.09). Therapeutic reviews published in the CDSR primarily included RCTs in 78.6%
24
25 (242/308) or both RCTs and non-RCTs in 21.1% (65/308). High-impact journal reviews
26
27 assessing therapeutic questions were primarily based on RCTs (58.9% (53/90)), with only
28
29 26.7% (24/90) based on non-RCTs.
30
31
32
33

34 *Content of included SRs*

35
36 91.9% (318/346) of the Cochrane reviews and 70.2% (151/215) high-impact journal SRs
37
38 focused on adult study populations. Only 7.5% (26/346) of SRs from the CDSR and 2.8%
39
40 (6/215) of reviews from high-impact journals focused solely on paediatric patients.
41
42
43

44
45 The largest group of Cochrane reviews addressed general cancer topics (for example:
46
47 supportive measures for patients receiving cytotoxic chemotherapy) not limited to a specific
48
49 type of disease (18.8 %; 65/346), followed by SRs concerning hematological malignancies
50
51 (12.4%; 43/346), and breast cancer (8.4%; 29/346; Figure 5). Among SRs published in high-
52
53
54
55
56
57
58
59
60

1
2
3 impact journals, general cancer topics was also the main category followed by breast cancer
4
5 in 21.4% (47/215) and colorectal cancer in 7.9% (17/215).
6
7

8 SRs published in Cochrane most commonly examined supportive care interventions
9
10 (40.3%; 126/313), followed by chemotherapy (20.1%; 63/313), and surgery (16.7%; 49/313;
11
12 Figure 6). Reviews in high-impact journals, on the other hand, predominantly evaluated
13
14 specific chemotherapy regimens (25.3%; 23/91), new drugs (18.7%; 17/91), and supportive
15
16 care interventions (18.7%; 17/91).
17
18
19

20
21 Overall, Cochrane reviews included fewer studies per review than high-impact journal
22
23 SRs (median: 6 studies (IQR: 2-13) compared to 18 (18-38.8)) and fewer patients (1020
24
25 (194.5-2845) compared to 7730 (3288-29.423)). About 11.3% (39/346) of Cochrane SRs were
26
27 so-called “empty reviews”, meaning the authors could not identify eligible studies to include
28
29 in their review. Furthermore, 35 (10.1%) reviews retrieved from the CDSR included only one
30
31 study. In contrast, none of the SRs in high-impact journals were empty or contained only a
32
33 single study.
34
35
36

37 38 *Citations*

39
40 Cochrane reviews were cited considerably less frequently than SRs published in high-
41
42 impact medical journals. The mean number of citations for Cochrane reviews was 6.92,
43
44 ranging from 0 to 143. High-impact journal SRs had a mean of 74.45 citations with a range
45
46 from 0 to 652.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Principal findings

This methodological assessment found that Cochrane reviews were conducted with greater methodological rigor than SRs published in high-impact journals but were cited less frequently. The largest gap in terms of methodological quality with regards to an individual AMSTAR criterion was the reporting of excluded studies, which was met by all Cochrane reviews and only 11.2% (24/215) of SRs published by high-impact journals. Other major differences relate to the reporting of possible conflicts of interest of included studies, the existence of an a priori design, the conduct of sensitivity analyses for study quality of included studies, and the inclusion of non-published studies. High-impact SRs were more likely to be based on IPD, include non-RCTs and address questions other than therapy, namely prognosis. SRs that included only one or no included studies were published exclusively in the Cochrane Library, and not in high-impact journals.

Strengths and weaknesses of this systematic review

We performed this study based on an a priori protocol, a comprehensive search strategy, and data abstraction in duplicate, which lends strength to the validity of our findings. In addition, we performed a clinical content analysis comparing the two groups of SR sources. The reliability of this work was ensured through adherence to the review methods proposed by PRISMA and Cochrane. Our quality assessment was based on AMSTAR, an instrument previously validated for the assessment of SRs from RCTs which represented the best available tool at the time when we planned and conducted this review.^{16 17} An updated version of AMSTAR has only recently become available.¹⁸

1
2
3 Given its focus on methodological quality, this study is unable to explain the missing link
4
5 between the high methodological quality of Cochrane reviews and relatively low citation
6
7 rates. Potential explanations may relate to the clinical topic areas, and too great a focus on
8
9 evidence from RCTs, which has long been a hallmark of Cochrane reviews. In addition,
10
11 Cochrane reviews that include none (“empty reviews”) or only one study are less likely to
12
13 provide newsworthy results and yield high citation rates.
14
15

16
17 The Cochrane Library permits co-publication of Cochrane reviews in other journals, which is
18
19 however subject to formal pre-approval. A large number of co-published reviews could have
20
21 potentially biased our results, though we identified only two reviews with this issue; thus
22
23 this concern is only of minor relevance.^{19 20}
24
25

26 27 *Strengths and weaknesses in relation to other systematic reviews*

28
29 In 2016, a cross-sectional assessment of SRs was published which included a similar
30
31 comparison of Cochrane and non-Cochrane reviews.⁵ This assessment was cross-disciplinary
32
33 and not limited to cancer alone. It consisted of SRs published during a one-month period in
34
35 2014, and only 3% (9/300) of the total assessed SRs came from journals with an impact
36
37 factor exceeding ten. Most of the randomly selected SRs and Cochrane reviews investigated
38
39 therapeutic questions. Similar to our study, Cochrane reviews were more likely to fulfil the
40
41 important methodological criteria such as protocol availability, the inclusion of unpublished
42
43 and grey literature, an electronic data-search in more than two databases, data extraction
44
45 and study selection performed in duplicate, or the assessment of study quality. Findings
46
47 were also similar with regards to the proportion of reviews that did not perform a sensitivity
48
49 analysis based on study quality.⁵ Another similar study by Moher et al. documented
50
51 improved reporting over a 10 year time frame.⁴ A variety of other reports, including
52
53
54
55
56
57
58
59
60

1
2
3 assessments in other medical research fields have identified similar deficiencies in the
4
5 quality of SRs but none of them have specifically focused on oncology-related reviews.^{6 16 21-}

6
7 26

8
9
10 *Meaning of this methodological systematic review: explanations, implications and further*
11
12 *research*

13
14
15 Our methodological assessment highlights the major differences that exist among
16
17 published SRs in oncology. Users of the medical literature should therefore not assume that
18
19 SRs are equivalent in their design, methodological rigor, or validity of their conclusions.
20
21 Quality criteria for SRs are well established; one key criterion is that of an a priori protocol
22
23 which governs all aspects of the review process to prevent selective or biased reporting and
24
25 avoid duplicate publication.²⁷⁻³⁰ Registration of protocols with platforms such as PROSPERO
26
27 can aid in holding SRs accountable in this regard; some journals have made this mandatory.³¹
28
29 Deficits in the disclosure of excluded studies, for example, narrow the transparency of study
30
31 selection, while absence of sensitivity analyses impede the possibility of readers to assess
32
33 the findings against the background of study quality. Conflicts of interest may also play a role
34
35 in the heterogeneity of published SRs.
36
37
38
39
40

41 A practical reason for differences in the reporting quality between Cochrane reviews
42
43 and high-impact medical journals may lie in the limited space for reporting provided in
44
45 printed medical journals. A recent assessment of meta-analyses of surgical interventions
46
47 supports the assumption of the negative association between limited publication space and
48
49 completeness of reporting.²⁵ Cochrane does not impose space restrictions and as such
50
51 Cochrane SR authors have more freedom to provide complete reporting. However, given
52
53 that most journals now offer the opportunity to provide additional e-content on the
54
55
56
57
58
59
60

1
2
3 internet, there should be fewer reasons for less than complete transparency. In this
4
5 assessment, we took care to include all available content, including online supplementary
6
7 tables and appendices in our assessment. Published Cochrane reviews typically also undergo
8
9 a more rigorous development process that includes the compulsory publication of a protocol
10
11 that has previously undergone internal editorial review and external peer review as specified
12
13 in the organization's MECIR policy. This may be the main reason why Cochrane reviews are
14
15 much more likely to meet more of the requirements of transparent reporting checklists.^{17 32}
16
17
18 ³³ Journal editors should similarly mandate strict adherence to PRISMA and other reporting
19
20 guidelines.
21
22

23
24 Given the considerable investment of resources that goes into development of high
25
26 quality Cochrane reviews, their relatively low impact is a concern. It appears critically
27
28 important that Cochrane editors take greater initiative at directing review authors to topics
29
30 where the greatest clinical interest lies.
31
32

33
34 This work demonstrates the need to critically assess SRs prior to using their evidence.
35
36 For clinicians, the *Users' Guide to the Medical Literature* by Murad, et al.³⁰ provides a
37
38 practical framework for assessing the validity, impact and applicability of SRs. For
39
40 researchers and policy-makers aside from AMSTAR, the recently introduced ROBIS tool
41
42 allows to comprehensively evaluate possible risk of bias in SRs at the review level.³⁴ At
43
44 present it covers SRs with interventional, diagnostic, prognostic, and etiologic review
45
46 questions and involves a three domain appraisal of the relevance of the respective review,
47
48 an evaluation of possible risks of bias during the review process, and a concluding judgment
49
50 of overall risk of bias of the review findings.³⁴
51
52
53
54
55
56
57
58
59
60

Conclusion

Cancer-related SRs that are published in the CDSR demonstrate higher adherence to methodological and reporting standards than cancer-related SRs published in high-impact medical journals but are cited less frequently. Our assessment underscores the importance of performing a critical appraisal of SRs before including their evidence into guideline development or making individual clinical decisions.

For peer review only

Acknowledgements

Contributors: MG designed the data collection tools and analysis, selected studies, analysed and extracted data, and drafted and revised the paper. VN designed the data collection tools and analysis, selected studies, analysed and extracted data, and drafted and revised the paper. AW extracted and analysed data and revised the paper. PD initiated the project, designed the data collection tools and analysis, selected studies, monitored data collection and analysis, and revised the paper. NS initiated the project, designed the data collection tools and analysis, selected studies, monitored data collection and analysis, and revised the paper. All authors approved the final version of the article. All authors, external and internal, had full access to all of the data (including statistical reports and tables) in the study and can take responsibility for the integrity of the data and the accuracy of the data analysis.

Copyright: The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the BMJ Publishing Group Ltd and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above. We attest that we have obtained appropriate permissions and paid any required fees for use of copyright protected materials.

1
2
3 **Funding:** Two authors received travel grants by Cochrane to attend and present data at the
4
5 23rd Cochrane Colloquium in Seoul, 2016. This research received no other specific grant
6
7 from any funding agency in the public, commercial or not-for-profit sectors.
8
9

10 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at
11
12 www.icmje.org/coi_disclosure.pdf and declare: MG, AW and NS are part of the Cochrane
13
14 Haematological Malignancies Group, PD is part of the Cochrane Urology Group. Further they
15
16 declare: No other support from any organisation for the submitted work; no financial
17
18 relationships with any organisations that might have an interest in the submitted work in the
19
20 previous three years; no other relationships or activities that could appear to have
21
22 influenced the submitted work.
23
24
25

26
27 **Ethical approval:** Not required
28
29

30 **Data sharing:** No additional data available
31
32

33
34 **Transparency:** We affirm that the manuscript is an honest, accurate, and transparent
35
36 account of the study being reported; that no important aspects of the study have been
37
38 omitted; and that any discrepancies from the study as planned have been explained.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. PRISMA flow diagram of Cochrane reviews

Figure 2. PRISMA flow diagram of high-impact journal SRs

Figure 3. Forrest plot comparing to what extent Cochrane reviews and SRs published in high-impact journals meet criteria for methodological quality

Figure 4. Distribution of Cochrane reviews and high-impact journal SRs by review question

Figure 5. Distribution of Cochrane reviews and high-impact journal SRs by disease

Figure 6. Distribution of Cochrane reviews and high-impact journal SRs by intervention

References

1. 2015 Journal Citation Reports®: Clarivate Analytics; 2017 [
2. Woolf S, Schunemann HJ, Eccles MP, et al. Developing clinical practice guidelines: types of evidence and outcomes; values and economics, synthesis, grading, and presentation and deriving recommendations. *Implementation science : IS* 2012;7:61. doi: 10.1186/1748-5908-7-61 [published Online First: 2012/07/06]
3. Mulrow CD. Rationale for systematic reviews. *BMJ (Clinical research ed)* 1994;309(6954):597-9. [published Online First: 1994/09/03]
4. Moher D, Tetzlaff J, Tricco AC, et al. Epidemiology and reporting characteristics of systematic reviews. *PLoS medicine* 2007;4(3):e78. doi: 10.1371/journal.pmed.0040078 [published Online First: 2007/03/29]
5. Page MJ, Shamseer L, Altman DG, et al. Epidemiology and Reporting Characteristics of Systematic Reviews of Biomedical Research: A Cross-Sectional Study. *PLoS medicine* 2016;13(5):e1002028. doi: 10.1371/journal.pmed.1002028 [published Online First: 2016/05/25]
6. Han JL, Gandhi S, Bockoven CG, et al. The landscape of systematic reviews in urology (1998 to 2015): an assessment of methodological quality. *BJU International* 2017;119(4):638-49. doi: 10.1111/bju.13653
7. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. *BMC medical research methodology* 2007;7:10. doi: 10.1186/1471-2288-7-10 [published Online First: 2007/02/17]
8. Sterne JA, Sutton AJ, Ioannidis JP, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ (Clinical research ed)* 2011;343:d4002. doi: 10.1136/bmj.d4002 [published Online First: 2011/07/26]
9. Flaherty KT, Hennig M, Lee SJ, et al. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. *The Lancet Oncology* 2014;15(3):297-304. doi: 10.1016/s1470-2045(14)70007-5 [published Online First: 2014/02/04]
10. Freund KM, Battaglia TA, Calhoun E, et al. Impact of patient navigation on timely cancer care: the Patient Navigation Research Program. *Journal of the National Cancer Institute* 2014;106(6):dju115. doi: 10.1093/jnci/dju115 [published Online First: 2014/06/19]
11. Lemieux J, Goodwin PJ, Bordeleau LJ, et al. Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009). *Journal of the National Cancer Institute* 2011;103(3):178-231. doi: 10.1093/jnci/djq508 [published Online First: 2011/01/11]
12. Paoletti X, Oba K, Bang YJ, et al. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. *Journal of the National Cancer Institute* 2013;105(21):1667-70. doi: 10.1093/jnci/djt269 [published Online First: 2013/10/11]

13. Peron J, Pond GR, Gan HK, et al. Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. *Journal of the National Cancer Institute* 2012;104(13):982-9. doi: 10.1093/jnci/djs259 [published Online First: 2012/07/05]
14. Zikos E, Ghislain I, Coens C, et al. Health-related quality of life in small-cell lung cancer: a systematic review on reporting of methods and clinical issues in randomised controlled trials. *The Lancet Oncology* 2014;15(2):e78-89. doi: 10.1016/s1470-2045(13)70493-5 [published Online First: 2014/02/01]
15. Henson L, Gao W, Higginson I, et al. Emergency department attendance by patients with cancer in the last month of life: a systematic review and meta-analysis. *Lancet (London, England)* 2015;385 Suppl 1:S41. doi: 10.1016/s0140-6736(15)60356-7 [published Online First: 2015/08/28]
16. Shea BJ, Hamel C, Wells GA, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. *Journal of clinical epidemiology* 2009;62(10):1013-20. doi: 10.1016/j.jclinepi.2008.10.009 [published Online First: 2009/02/24]
17. Shea BJ, Bouter LM, Peterson J, et al. External validation of a measurement tool to assess systematic reviews (AMSTAR). *PloS one* 2007;2(12):e1350. doi: 10.1371/journal.pone.0001350 [published Online First: 2007/12/27]
18. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ (Clinical research ed)* 2017;358 doi: 10.1136/bmj.j4008
19. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. *Journal of the National Cancer Institute* 2012;104(21):1625-34. doi: 10.1093/jnci/djs374 [published Online First: 2012/09/11]
20. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial cancer. *The Cochrane database of systematic reviews* 2012(4):Cd003916. doi: 10.1002/14651858.CD003916.pub4 [published Online First: 2012/04/20]
21. Fleming PS, Koletsis D, Seehra J, et al. Systematic reviews published in higher impact clinical journals were of higher quality. *Journal of clinical epidemiology* 2014;67(7):754-9. doi: 10.1016/j.jclinepi.2014.01.002 [published Online First: 2014/04/09]
22. Bafeta A, Trinquart L, Seror R, et al. Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review. *BMJ (Clinical research ed)* 2013;347:f3675. doi: 10.1136/bmj.f3675 [published Online First: 2013/07/03]
23. Cullis PS, Gudlaugsdottir K, Andrews J. A systematic review of the quality of conduct and reporting of systematic reviews and meta-analyses in paediatric surgery. *PloS one* 2017;12(4):e0175213. doi: 10.1371/journal.pone.0175213 [published Online First: 2017/04/07]

- 1
2
3 24. Fleming PS, Seehra J, Polychronopoulou A, et al. Cochrane and non-Cochrane
4 systematic reviews in leading orthodontic journals: a quality paradigm?
5 *European journal of orthodontics* 2013;35(2):244-8. doi:
6 10.1093/ejo/cjs016 [published Online First: 2012/04/19]
7
8 25. Adie S, Ma D, Harris IA, et al. Quality of conduct and reporting of meta-
9 analyses of surgical interventions. *Annals of surgery* 2015;261(4):685-94.
10 doi: 10.1097/sla.0000000000000836 [published Online First:
11 2015/01/13]
12
13 26. Windsor B, Popovich I, Jordan V, et al. Methodological quality of systematic
14 reviews in subfertility: a comparison of Cochrane and non-Cochrane
15 systematic reviews in assisted reproductive technologies. *Human*
16 *reproduction (Oxford, England)* 2012;27(12):3460-6. doi:
17 10.1093/humrep/des342 [published Online First: 2012/10/05]
18
19 27. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic
20 review and meta-analysis protocols (PRISMA-P) 2015: elaboration and
21 explanation. *BMJ : British Medical Journal* 2015;349 doi:
22 10.1136/bmj.g7647
23
24 28. Page MJ, McKenzie JE, Kirkham J, et al. Bias due to selective inclusion and
25 reporting of outcomes and analyses in systematic reviews of randomised
26 trials of healthcare interventions. *The Cochrane database of systematic*
27 *reviews* 2014(10):Mr000035. doi: 10.1002/14651858.MR000035.pub2
28 [published Online First: 2014/10/02]
29
30 29. Stewart L, Moher D, Shekelle P. Why prospective registration of systematic
31 reviews makes sense. *Systematic reviews* 2012;1:7. doi: 10.1186/2046-
32 4053-1-7 [published Online First: 2012/05/17]
33
34 30. Murad M, Montori VM, Ioannidis JA, et al. How to read a systematic review and
35 meta-analysis and apply the results to patient care: Users' guides to the
36 medical literature. *JAMA* 2014;312(2):171-79. doi:
37 10.1001/jama.2014.5559
38
39 31. Dahm P. Raising the bar for systematic reviews with Assessment of Multiple
40 Systematic Reviews (AMSTAR). *BJU International* 2017;119(2):193-93. doi:
41 10.1111/bju.13754
42
43 32. Higgins JG, S. (editors). *Cochrane Handbook for Systematic Reviews of*
44 *Interventions* Version 5.1.0 [updated March 2011]. March 2011 ed: The
45 Cochrane Collaboration, 2011.
46
47 33. Julian PT Higgins TL, Jackie Chandler, David Tovey, Rachel Churchill.
48 *Methodological Expectations of Cochrane Intervention Reviews*. London:
49 Cochrane 2016.
50
51 34. Whiting P, Savović J, Higgins JPT, et al. ROBIS: A new tool to assess risk of bias
52 in systematic reviews was developed. *Journal of clinical*
53 *epidemiology*;69:225-34. doi: 10.1016/j.jclinepi.2015.06.005
54
55
56
57
58
59
60

Table 1: Baseline characteristics of the included Cochrane reviews and high-impact journal SRs

	Cochrane	High-impact journals								
	Cochrane reviews (n=346)	Total high-impact journal SRs (n=215)	J Natl Cancer Inst (n=56)	J Clin Oncol (n=56)	Lancet Oncology (n=53)	The BMJ (n=22)	Lancet (n=14)	JAMA (n=12)	CA Cancer J Clin (n=1)	Cancer Research (n=1)
Year first published (Number of SR (%))										
2011	45 (13.1)	45 (20.9)	9 (16.1)	14 (25)	13 (24.5)	2 (9.1)	4 (28.6)	3 (25)		
2012	60 (17.3)	50 (23.2)	20 (35.7)	11 (19.6)	11 (20.8)	4 (18.2)	1 (7.1)	3 (25)		
2013	80 (23.1)	31 (14.4)	7 (12.5)	8 (14.3)	8 (15.1)	5 (22.7)	2 (14.3)	1 (8.3)		
2014	59 (17.1)	51 (23.7)	11 (19.6)	10 (17.9)	15 (28.3)	7 (31.8)	4 (28.6)	4 (33.3)		
2015	69 (19.9)	32 (14.9)	6 (10.7)	11 (19.6)	5 (9.4)	4 (18.2)	3 (21.4)	1 (8.3)	1 (100)	1 (100)
2016	33 (9.5)	6 (2.8)	3 (5.4)	2 (3.6)	1 (1.9)					
Region (Number of SR (%))										
Europe	233 (67.3)	95 (44.2)	14 (25)	20 (35.7)	34 (64.2)	12 (54.5)	13 (92.9)	1 (8.3)	1 (100)	
North America	26 (7.5)	88 (40.9)	33 (58.9)	27 (48.2)	10 (18.9)	6 (27.3)	1 (7.1)	10 (83.3)		1 (100)
Asia	49 (14.2)	16 (7.4)	6 (10.7)	3 (5.4)	3 (5.7)	3 (13.6)		1 (8.3)		
Australia/ New Zealand	19 (5.5)	14 (6.5)	2 (3.6)	6 (10.7)	6 (11.3)					
South America	13 (3.8)	1 (0.5)	1 (1.8)							
Africa	6 (1.7)	1 (0.5)				1 (4.5)				
Review type (Number of SR (%))										
Study-level	331 (95.7)	147 (68.4)	39 (69.6)	40 (71.4)	35 (66)	19 (86.4)	1 (7.1)	11 (91.7)	1 (100)	1 (100)


	Cochrane	High-impact journals								
	Cochrane reviews (n=346)	Total high-impact journal SRs (n=215)	J Natl Cancer Inst (n=56)	J Clin Oncol (n=56)	Lancet Oncology (n=53)	The BMJ (n=22)	Lancet (n=14)	JAMA (n=12)	CA Cancer J Clin (n=1)	Cancer Research (n=1)
data										
IPD	3 (0.9)	67 (31.2)	17 (30.4)	15 (26.8)	18 (34)	3 (13.6)	13 (92.9)	1 (8.3)		
Both	12 (3.5)	1 (0.5)		1 (1.8)						
Network Meta-Analysis (Number of SR (%))	2 (0.6)	6 (2.8)	3 (5.4)		3 (5.7)					
Study type (Number of SR (%))										
RCT	264 (76.3)	75 (34.9)	15 (26.8)	21 (37.5)	14 (26.4)	7 (31.8)	12 (85.7)	5 (41.7)	1 (100)	
non-RCT	5 (1.4)	85 (39.5)	27 (48.2)	16 (28.6)	27 (50.9)	12 (54.5)	1 (7.1)	2 (16.7)		
Both	77 (22.3)	46 (21.4)	9 (16.1)	19 (33.9)	9 (17)	3 (13.6)	1 (7.1)	5 (41.7)		
Unclear		9 (4.2)	5 (8.9)		3 (5.7)					1 (100)
Population (Number of SR (%))										
Adult	318 (9.9)	151 (70.2)	39 (69.6)	43 (76.8)	32 (60.4)	14 (63.6)	13 (92.9)	9 (75)	1 (100)	
Paediatric	26 (7.5)	6 (2.8)	1 (1.8)	1 (1.8)	4 (7.5)					
Both	2 (0.6)	22 (10.2)	5 (8.9)	6 (10.7)	7 (13.2)	4 (18.2)				
Unclear		36 (16.7)	11 (19.6)	6 (10.7)	10 (18.9)	4 (18.2)	1 (7.1)	3 (25)		1 (100)
Included studies (Median (IQR))	6 (2-13)	18 (10-38,8)	20 (12-43.8)	16 (9-36.3)	24 (12.8-44.8)	16 (9.6-26.5)	16 (25-9.8)	16.5 (10.3-24.8)	14	37

	Cochrane	High-impact journals								
	Cochrane reviews (n=346)	Total high-impact journal SRs (n=215)	J Natl Cancer Inst (n=56)	J Clin Oncol (n=56)	Lancet Oncology (n=53)	The BMJ (n=22)	Lancet (n=14)	JAMA (n=12)	CA Cancer J Clin (n=1)	Cancer Research (n=1)
Included patients (Median (IQR))	1020 (194.5-2845)	7730 (3288-29423)	8216 (3288-35568)	4758,5 (184.5-11091.8)	4600 (3033-21137)	117597 (10903-890992.3)	21471.5 (13287.5-45195.8)	12813.5 (4075.5-48067.3)	3377	Not reported
Citations (Median (IQR))	3 (1-7)	46 (18,5-86,5)	30.5 (9.8-55.3)	48,5 (18-70.3)	40 (22-97)	40 (15-80.3)	157 (54-351.8)	101 (45.3-155.8)	8	15

SR= systematic review, IPD= Individual Patient Data, J Natl Cancer Inst= Journal of the National Cancer Institute, J Clin Oncol= Journal of Clinical Oncology, CA Cancer J Clin= A Cancer Journal for Clinicians, Cancer Res= Cancer Research, RCT=randomised controlled trial, IQR= interquartile range

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



30 Figure 1. PRISMA flow diagram of Cochrane reviews

31 45x32mm (300 x 300 DPI)




Figure 2. PRISMA flow diagram of high-impact journal SRs

34x43mm (300 x 300 DPI)




Figure 3. Forrest plot comparing to what extent Cochrane reviews and SRs published in high-impact journals meet criteria for methodological quality

89x32mm (300 x 300 DPI)

Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4. Distribution of Cochrane reviews and high-impact journal SRs by review question

63x50mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 5. Distribution of Cochrane reviews and high-impact journal SRs by disease

69x55mm (300 x 300 DPI)

View only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 6. Distribution of Cochrane reviews and high-impact journal SRs by intervention

66x53mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

[#6](#) Search (#4 or #7) Filters: Publication date from 2011/01/01 to 2016/05/31

For peer review only

Appendix table 2: Extracted items

Item	Extracted	Example
1.	Author	
2.	Title	
3.	Journal	Cochrane, A Cancer Journal for Clinicians, New England Journal of Medicine, The Lancet, JAMA, Lancet Oncology, Journal of Clinical Oncology, The BMJ, Nature Reviews Clinical Oncology, Journal of the National Cancer Institute, Cancer Research
4.	Year last updated	2011-2016
5.	Year first published	2011-2016
6.	Cochrane group	
7.	Region of corresponding author	Africa, Asia, Australia/ New Zealand, Europe, North America, South America
8.	Review type	SR based on trial-level data, Individual Patient Data SR, Both
9.	Network Meta-Analysis	Yes, No
10.	Included study type	RCTs, non-RCTs, Both
11.	Question type	Diagnosis, Epidemiology, Prevention,

Item	Extracted	Example
		Prognosis, Screening, Therapy
12.	Disease	Bladder, bones (incl. spine), brain (incl. CNS), breast, cancer in general, cervical, colorectal, endometrial, oesophagus, gastric, haematological (leukaemia, lymphoma, myeloma), head and neck, lung, melanoma, mixed (but not general, other (e.g. male breast cancer, liver metastases), ovarian, pancreas, prostate, renal, uterus
13.	Intervention	Behavioural (e.g. exercise, diet, smoking), chemotherapy, mixed interventions, “new drug” (targeted therapy and monoclonal antibodies), radiotherapy, supportive, surgery, thermal (e.g. hyperthermia, cryotherapy), not applicable (if diagnostic, prognostic, preventive, epidemiologic, screening)
14.	Population	Adult, paediatric, both
15.	Number of included studies	
16.	Number included patients	

Appendix table 3: Extracted quality indicators

Item	AMSTAR	This work
1.	Was an 'a priori' design provided	Was the review question established before the conduct of the review?
		Were the in- and exclusion criteria defined before the conduct of the review?
2.	Was there duplicate study selection and data extraction?	Was the study selection and data-extraction undertaken by two independently working authors?
		Was the consensus procedure described?
		Was the interobserver-agreement (quantitatively) assessed?
3.	Was a comprehensive literature search performed?	Were at least two electronic databases searched?
		Were the years included in the searches reported?
		Were the database searches supported by other sources?
4.	Was the status of publication (i.e. grey literature) used as an inclusion criterion?	Were reviews irrespective of publication status included?
		Were reviews in languages other than English

Item	AMSTAR	This work
		included?
5.	Was a list of studies (included and excluded) provided?	Was a list of included studies provided? Was a list of excluded studies provided?
6.	Were the characteristics of the included studies provided?	Were study characteristic of every included study included?
7.	Was the scientific quality of the included studies assessed and documented?	Was the quality of included studies included by available tools (e.g. Cochrane's Risk of Bias, ROBINS, Newcastle-Ottawa scale)
8.	Was the scientific quality of the included studies used appropriately in formulating conclusions?	If a Meta-analysis was performed: Was the study quality included into the analysis via sensitivity- or subgroup analysis?
9.	Were the methods used to combine the findings of studies appropriate?	Was possible heterogeneity assessed?
10.	Was the likelihood of publication bias assessed?	Was possible publication bias formally assessed?
11.	Was the conflict of interest included?	Were possible Conflicts of Interest regarding the review disclosed?

Item	AMSTAR	This work
		Were possible Conflicts of Interest of the included studies reported?

For peer review only

References

References of assessed reviews

Cochrane reviews

1. Abdel-Rahman Omar M, Elsayed Z. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma. Cochrane Database of Systematic Reviews 2016; (2).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011313.pub2/abstract>.
2. Abdul Razak Albiruni R, Li L, Bryant A, et al. Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease. Cochrane Database of Systematic Reviews 2011; (3).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007584.pub2/abstract>.
3. Aghoram R, Cai P, Dickinson James A. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database of Systematic Reviews 2012; (9).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002799.pub2/abstract>.
4. Akl Elie A, Kahale L, Terrenato I, et al. Oral anticoagulation in patients with cancer who have no therapeutic or prophylactic indication for anticoagulation. Cochrane Database of Systematic Reviews 2014; (7).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006466.pub5/abstract>.

- 1
2
3 5. Akl Elie A, Kahale Lara A, Ballout Rami A, et al. Parenteral anticoagulation in
4
5 ambulatory patients with cancer. Cochrane Database of Systematic Reviews
6
7 2014; (12).
8
9 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006652.pub4/abstract>
10
11
12
13
14
- 15 6. Akl Elie A, Kahale Lara A, Barba M, et al. Anticoagulation for the long-term treatment
16
17 of venous thromboembolism in patients with cancer. Cochrane Database of
18
19 Systematic Reviews 2014; (7).
20
21 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006650.pub4/abstract>
22
23
24
25
26
- 27 7. Akl Elie A, Kahale Lara A, Neumann I, et al. Anticoagulation for the initial treatment of
28
29 venous thromboembolism in patients with cancer. Cochrane Database of
30
31 Systematic Reviews 2014; (6).
32
33 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006649.pub6/abstract>
34
35
36
37
38
- 39 8. Akl Elie A, Kahale Lara A, Sperati F, et al. Low molecular weight heparin versus
40
41 unfractionated heparin for perioperative thromboprophylaxis in patients with
42
43 cancer. Cochrane Database of Systematic Reviews 2014; (6).
44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009447.pub2/abstract>
46
47
48
49
- 50 9. Akl Elie A, Ramly Elie P, Kahale Lara A, et al. Anticoagulation for people with cancer
51
52 and central venous catheters. Cochrane Database of Systematic Reviews 2014;
53
54 (10).
55
56 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006468.pub5/abstract>
57
58
59
60

- 1
2
3 10. Al Rawahi T, Lopes Alberto D, Bristow Robert E, et al. Surgical cytoreduction for
4 recurrent epithelial ovarian cancer. Cochrane Database of Systematic Reviews
5
6
7
8 2013; (2).
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008765.pub3/abstract>
11
12
13 t.
- 14
15 11. Alazzam Mi, Tidy J, Osborne R, et al. Chemotherapy for resistant or recurrent
16 gestational trophoblastic neoplasia. Cochrane Database of Systematic Reviews
17
18
19 2016; (1).
20
21 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008891.pub3/abstract>
22
23
24 t.
- 25
26
27 12. Amarasena Isuru U, Chatterjee S, Walters Julia AE, et al. Platinum versus non-
28 platinum chemotherapy regimens for small cell lung cancer. Cochrane Database
29
30
31 of Systematic Reviews 2015; (8).
32
33 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006849.pub3/abstract>
34
35
36 t.
- 37
38
39 13. Ang C, Bryant A, Barton Desmond PJ, et al. Exenterative surgery for recurrent
40 gynaecological malignancies. Cochrane Database of Systematic Reviews 2014;
41
42
43 (2).
44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010449.pub2/abstract>
46
47
48 t.
- 49
50
51 14. Ang C, Chan Karen KL, Bryant A, et al. Ultra-radical (extensive) surgery versus
52 standard surgery for the primary cytoreduction of advanced epithelial ovarian
53
54
55 cancer. Cochrane Database of Systematic Reviews 2011; (4).
56
57 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007697.pub2/abstract>
58
59
60 t.

- 1
2
3 15. Anglemeyer A, Agrawal Anurag K, Rutherford George W. Treatment of Kaposi sarcoma
4
5 in children with HIV-1 infection. Cochrane Database of Systematic Reviews 2014;
6
7 (1).
8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009826.pub2/abstract>
11
12
13
14
15 16. Arbyn M, Roelens J, Simoens C, et al. Human papillomavirus testing versus repeat
16
17 cytology for triage of minor cytological cervical lesions. Cochrane Database of
18
19 Systematic Reviews 2013; (3).
20
21
22 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008054.pub2/abstract>
23
24
25
26
27 17. Archampong D, Borowski D, Wille-Jørgensen P, et al. Workload and surgeon's
28
29 specialty for outcome after colorectal cancer surgery. Cochrane Database of
30
31 Systematic Reviews 2012; (3).
32
33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005391.pub3/abstract>
35
36
37
38
39 18. Arcidiacono Paolo G, Calori G, Carrara S, et al. Celiac plexus block for pancreatic
40
41 cancer pain in adults. Cochrane Database of Systematic Reviews 2011; (3).
42
43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007519.pub2/abstract>
45
46
47
48 19. Baalbergen A, Veenstra Y, Stalpers L. Primary surgery versus primary radiotherapy
49
50 with or without chemotherapy for early adenocarcinoma of the uterine cervix.
51
52 Cochrane Database of Systematic Reviews 2013; (1).
53
54
55 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006248.pub3/abstract>
56
57
58
59
60

- 1
2
3 20. Bala Malgorzata M, Riemsma Robert P, Wolff R, et al. Microwave coagulation for liver
4 metastases. Cochrane Database of Systematic Reviews 2013; (10).
5
6 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010163.pub2/abstract>
7
8
9
10
11
12 21. Bala Malgorzata M, Riemsma Robert P, Wolff R, et al. Cryotherapy for liver
13 metastases. Cochrane Database of Systematic Reviews 2013; (6).
14
15 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009058.pub2/abstract>
16
17
18
19
20
21
22 22. Balduzzi S, Mantarro S, Guarneri V, et al. Trastuzumab-containing regimens for
23 metastatic breast cancer. Cochrane Database of Systematic Reviews 2014; (6).
24
25 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006242.pub2/abstract>
26
27
28
29
30
31 23. Barone Damiano G, Lawrie Theresa A, Hart Michael G. Image guided surgery for the
32 resection of brain tumours. Cochrane Database of Systematic Reviews 2014; (1).
33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009685.pub2/abstract>
35
36
37
38
39
40 24. Bath-Hextall Fiona J, Matin Rubeta N, Wilkinson D, et al. Interventions for cutaneous
41 Bowen's disease. Cochrane Database of Systematic Reviews 2013; (6).
42
43 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007281.pub2/abstract>
44
45
46
47
48
49 25. Bauer K, Rancea M, Roloff V, et al. Rituximab, ofatumumab and other monoclonal
50 anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database of
51 Systematic Reviews 2012; (11).
52
53 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008079.pub2/abstract>
54
55
56
57
58
59
60

- 1
2
3 26. Bauer K, Skoetz N, Monsef I, et al. Comparison of first-line chemotherapy including
4
5 escalated BEACOPP versus chemotherapy including ABVD for people with early
6
7 unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database of
8
9 Systematic Reviews 2011; (5).
10
11 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007941.pub3/abstract>
12
13
14
15 t.
- 16
17 27. Bell Rae F, Eccleston C, Kalso Eija A. Ketamine as an adjuvant to opioids for cancer
18
19 pain. Cochrane Database of Systematic Reviews 2012; (6).
20
21 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003351.pub3/abstract>
22
23
24
25 t.
- 26
27 28. Bennett C, Green S, DeCaestecker J, et al. Surgery versus radical endotherapies for
28
29 early cancer and high-grade dysplasia in Barrett's oesophagus. Cochrane
30
31 Database of Systematic Reviews 2012; (11).
32
33 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007334.pub4/abstract>
34
35
36
37 t.
- 38
39 29. Bennett Michael H, Feldmeier J, Smee R, et al. Hyperbaric oxygenation for tumour
40
41 sensitisation to radiotherapy. Cochrane Database of Systematic Reviews 2012;
42
43 (4).
44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005007.pub3/abstract>
46
47
48
49 t.
- 50
51 30. Bergenthal N, Will A, Streckmann F, et al. Aerobic physical exercise for adult patients
52
53 with haematological malignancies. Cochrane Database of Systematic Reviews
54
55 2014; (11).
56
57 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009075.pub2/abstract>
58
59
60 t.

- 1
2
3 31. Bergner N, Monsef I, Illerhaus G, et al. Role of chemotherapy additional to high-dose
4 methotrexate for primary central nervous system lymphoma (PCNSL). Cochrane
5 Database of Systematic Reviews 2012; (11).
6
7
8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009355.pub2/abstract>
11
12
13
14
- 15 32. Bessell A, Glennon A-M, Furness S, et al. Interventions for the treatment of oral and
16 oropharyngeal cancers: surgical treatment. Cochrane Database of Systematic
17 Reviews 2011; (9).
18
19
20
21
22 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006205.pub3/abstract>
23
24
25
26
- 27 33. Best Lawrence MJ, Mughal M, Gurusamy Kurinchi S. Laparoscopic versus open
28 gastrectomy for gastric cancer. Cochrane Database of Systematic Reviews 2016;
29 (3).
30
31
32
33 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011389.pub2/abstract>
34
35
36
37
- 38 34. Best Lawrence MJ, Mughal M, Gurusamy Kurinchi S. Non-surgical versus surgical
39 treatment for oesophageal cancer. Cochrane Database of Systematic Reviews
40 2016; (3).
41
42
43
44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011498.pub2/abstract>
46
47
48
49
- 50 35. Billson Hazel A, Holland C, Curwell J, et al. Perioperative nutrition interventions for
51 women with ovarian cancer. Cochrane Database of Systematic Reviews 2013; (9).
52
53
54
55 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009884.pub2/abstract>
56
57
58
59
60

- 1
2
3 36. Bjelakovic G, Gluud Lise L, Nikolova D, et al. Vitamin D supplementation for
4 prevention of cancer in adults. Cochrane Database of Systematic Reviews 2014;
5
6
7 (6).
8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007469.pub2/abstract>
11
12
13
14
15 37. Bleeker G, Tytgat Godelieve AM, Adam Judit A, et al. 123I-MIBG scintigraphy and
16
17 18F-FDG-PET imaging for diagnosing neuroblastoma. Cochrane Database of
18 Systematic Reviews 2015; (9).
19
20
21 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009263.pub2/abstract>
22
23
24
25
26
27 38. Bourke L, Homer Kate E, Thaha Mohamed A, et al. Interventions for promoting
28
29 habitual exercise in people living with and beyond cancer. Cochrane Database of
30 Systematic Reviews 2013; (9).
31
32
33 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010192.pub2/abstract>
34
35
36
37
38
39 39. Braam Katja I, van der Torre P, Takken T, et al. Physical exercise training
40
41 interventions for children and young adults during and after treatment for
42
43 childhood cancer. Cochrane Database of Systematic Reviews 2016; (3).
44
45
46 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008796.pub3/abstract>
47
48
49
50
51 40. Bradt J, Shim M, Goodill Sherry W. Dance/movement therapy for improving
52
53 psychological and physical outcomes in cancer patients. Cochrane Database of
54 Systematic Reviews 2015; (1).
55
56
57 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007103.pub3/abstract>
58
59
60

- 1
2
3 41. Brockbank E, Kokka F, Bryant A, et al. Pre-treatment surgical para-aortic lymph node
4
5 assessment in locally advanced cervical cancer. Cochrane Database of Systematic
6
7 Reviews 2013; (3).
8
9 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008217.pub3/abstract>
10
11
12
13
14
15 42. Brocklehurst P, Kujan O, O'Malley Lucy A, et al. Screening programmes for the early
16
17 detection and prevention of oral cancer. Cochrane Database of Systematic
18
19 Reviews 2013; (11).
20
21 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004150.pub4/abstract>
22
23
24
25
26
27 43. Burdett S, Pignon Jean P, Tierney J, et al. Adjuvant chemotherapy for resected early-
28
29 stage non-small cell lung cancer. Cochrane Database of Systematic Reviews 2015;
30
31 (3). <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011430/abstract>.
32
33
34 44. Cakmakkaya Ozlem S, Kolodzie K, Apfel Christian C, et al. Anaesthetic techniques for
35
36 risk of malignant tumour recurrence. Cochrane Database of Systematic Reviews
37
38 2014; (11).
39
40 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008877.pub2/abstract>
41
42
43
44
45 45. Candy B, Jones L, Vickerstaff V, et al. Interventions for sexual dysfunction following
46
47 treatments for cancer in women. Cochrane Database of Systematic Reviews 2016;
48
49 (2).
50
51 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005540.pub3/abstract>
52
53
54
55
56
57 46. Carvalho Alan PV, Vital Flávia MR, Soares Bernardo GO. Exercise interventions for
58
59 shoulder dysfunction in patients treated for head and neck cancer. Cochrane
60

1
2
3 Database of Systematic Reviews 2012; (4).

4 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008693.pub2/abstract>
5
6
7
8 t.

9
10 47. Cavalheri V, Tahirah F, Nonoyama Mika L, et al. Exercise training undertaken by
11
12 people within 12 months of lung resection for non-small cell lung cancer.

13
14
15 Cochrane Database of Systematic Reviews 2013; (7).

16
17 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009955.pub2/abstract>
18
19
20 t.

21
22 48. Chan Benjamin KY, Wiseberg-Firtell Jill A, Jois Ramesh HS, et al. Localization

23
24 techniques for guided surgical excision of non-palpable breast lesions. Cochrane
25
26 Database of Systematic Reviews 2015; (12).

27
28 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009206.pub2/abstract>
29
30
31 t.

32
33 49. Chan Kelvin KW, Glenny A-M, Weldon Jo C, et al. Interventions for the treatment of

34
35 oral and oropharyngeal cancers: targeted therapy and immunotherapy. Cochrane
36
37 Database of Systematic Reviews 2015; (12).

38
39 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010341.pub2/abstract>
40
41
42
43 t.

44
45 50. Charoenkwan K, Kietpeerakool C. Retroperitoneal drainage versus no drainage after
46
47 pelvic lymphadenectomy for the prevention of lymphocyst formation in women

48
49 with gynaecological malignancies. Cochrane Database of Systematic Reviews
50
51 2016; (6).

52
53 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007387.pub4/abstract>
54
55
56
57 t.

- 1
2
3 51. Chen H, Li J, Cui T, et al. Adjuvant gonadotropin-releasing hormone analogues for the
4
5 prevention of chemotherapy induced premature ovarian failure in
6
7 premenopausal women. Cochrane Database of Systematic Reviews 2011; (11).
8
9 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008018.pub2/abstract>
10
11
12
13 t.
- 14
15 52. Chen X, Deng L, Jiang X, et al. Chinese herbal medicine for oesophageal cancer.
16
17 Cochrane Database of Systematic Reviews 2016; (1).
18
19 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004520.pub7/abstract>
20
21
22
23 t.
- 24
25 53. Cheuk Daniel KL, Chiang Alan KS, Chan Godfrey CF, et al. Urate oxidase for the
26
27 prevention and treatment of tumour lysis syndrome in children with cancer.
28
29 Cochrane Database of Systematic Reviews 2014; (3).
30
31 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006945.pub4/abstract>
32
33
34
35 t.
- 36
37 54. Cheuk Daniel KL, Chiang Alan KS, Lee Tsz L, et al. Vaccines for prophylaxis of viral
38
39 infections in patients with hematological malignancies. Cochrane Database of
40
41 Systematic Reviews 2011; (3).
42
43 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006505.pub2/abstract>
44
45
46
47 t.
- 48
49 55. Cirocchi R, Trastulli S, Abraha I, et al. Non-resection versus resection for an
50
51 asymptomatic primary tumour in patients with unresectable Stage IV colorectal
52
53 cancer. Cochrane Database of Systematic Reviews 2012; (8).
54
55 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008997.pub2/abstract>
56
57
58
59
60 t.

- 1
2
3 56. Cirocchi R, Trastulli S, Boselli C, et al. Radiofrequency ablation in the treatment of
4
5 liver metastases from colorectal cancer. Cochrane Database of Systematic
6
7 Reviews 2012; (6).
8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006317.pub3/abstract>
11
12
13
14
15 57. Clarke T, Galaal K, Bryant A, et al. Evaluation of follow-up strategies for patients with
16
17 epithelial ovarian cancer following completion of primary treatment. Cochrane
18
19 Database of Systematic Reviews 2014; (9).
20
21
22 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006119.pub3/abstract>
23
24
25
26
27 58. Cortés-Jofré M, Rueda J-R, Corsini-Muñoz G, et al. Drugs for preventing lung cancer in
28
29 healthy people. Cochrane Database of Systematic Reviews 2012; (10).
30
31
32 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002141.pub2/abstract>
33
34
35
36
37 59. Cousins Sarah E, Tempest E, Feuer David J. Surgery for the resolution of symptoms in
38
39 malignant bowel obstruction in advanced gynaecological and gastrointestinal
40
41 cancer. Cochrane Database of Systematic Reviews 2016; (1).
42
43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002764.pub2/abstract>
45
46
47
48
49 60. Coyne I, O'Mathúna Dónal P, Gibson F, et al. Interventions for promoting
50
51 participation in shared decision-making for children with cancer. Cochrane
52
53 Database of Systematic Reviews 2016; (11).
54
55
56 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008970.pub3/abstract>
57
58
59
60

- 1
2
3 61. Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in
4
5 adults. Cochrane Database of Systematic Reviews 2012; (11).
6
7 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006145.pub3/abstract>
8
9
10
11
12 62. Crighton Gemma L, Estcourt Lise J, Wood Erica M, et al. A therapeutic-only versus
13
14 prophylactic platelet transfusion strategy for preventing bleeding in patients
15
16 with haematological disorders after myelosuppressive chemotherapy or stem cell
17
18 transplantation. Cochrane Database of Systematic Reviews 2015; (9).
19
20 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010981.pub2/abstract>
21
22
23
24
25
26 63. Daly T, Hickey Brigid E, Lehman M, et al. Adjuvant radiotherapy following radical
27
28 prostatectomy for prostate cancer. Cochrane Database of Systematic Reviews
29
30 2011; (12).
31
32 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007234.pub2/abstract>
33
34
35
36
37
38 64. Day J, Yust-Katz S, Cachia D, et al. Interventions for the management of fatigue in
39
40 adults with a primary brain tumour. Cochrane Database of Systematic Reviews
41
42 2016; (4).
43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011376.pub2/abstract>
45
46
47
48
49
50 65. Day J, Zienius K, Gehring K, et al. Interventions for preventing and ameliorating
51
52 cognitive deficits in adults treated with cranial irradiation. Cochrane Database of
53
54 Systematic Reviews 2014; (12).
55
56 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011335.pub2/abstract>
57
58
59
60

- 1
2
3 66. de Boer Angela GEM, Taskila Tyna K, Tamminga Sietske J, et al. Interventions to
4 enhance return-to-work for cancer patients. Cochrane Database of Systematic
5
6
7
8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007569.pub3/abstract>
11
12
13
14
- 15 67. De Caluwé L, Van Nieuwenhove Y, Ceelen Wim P. Preoperative chemoradiation
16
17 versus radiation alone for stage II and III resectable rectal cancer. Cochrane
18
19 Database of Systematic Reviews 2013; (2).
20
21 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006041.pub3/abstract>
22
23
24
25
- 26 68. de Castria Tiago B, da Silva Edina MK, Gois Aecio FT, et al. Cisplatin versus
27
28 carboplatin in combination with third-generation drugs for advanced non-small
29
30 cell lung cancer. Cochrane Database of Systematic Reviews 2013; (8).
31
32 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009256.pub2/abstract>
33
34
35
36
- 37 69. de Zwart V, Gouw Samantha C, Meyer-Wentrup Friederike AG. Antibody therapies
38
39 for lymphoma in children. Cochrane Database of Systematic Reviews 2016; (1).
40
41 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011181.pub2/abstract>
42
43
44
45
- 46 70. Dear Rachel F, McGeechan K, Jenkins Marisa C, et al. Combination versus sequential
47
48 single agent chemotherapy for metastatic breast cancer. Cochrane Database of
49
50 Systematic Reviews 2013; (12).
51
52 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008792.pub2/abstract>
53
54
55
56
57
58
59
60

- 1
2
3 71. Deng L, Zhang J, Wu T, et al. Combination chemotherapy for primary treatment of
4
5 high-risk gestational trophoblastic tumour. Cochrane Database of Systematic
6
7 Reviews 2013; (1).
8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005196.pub4/abstract>
11
12
13 t.
- 14
15 72. Deva S, Jameson M. Histamine type 2 receptor antagonists as adjuvant treatment for
16
17 resected colorectal cancer. Cochrane Database of Systematic Reviews 2012; (8).
18
19 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007814.pub2/abstract>
20
21
22 t.
- 23
24 73. Diaz-Nieto R, Orti-Rodríguez R, Winslet M. Post-surgical chemotherapy versus
25
26 surgery alone for resectable gastric cancer. Cochrane Database of Systematic
27
28 Reviews 2013; (9).
29
30
31 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008415.pub2/abstract>
32
33
34 t.
- 35
36 74. Dominick S, Hickey M, Chin J, et al. Levonorgestrel intrauterine system for
37
38 endometrial protection in women with breast cancer on adjuvant tamoxifen.
39
40 Cochrane Database of Systematic Reviews 2015; (12).
41
42
43 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007245.pub3/abstract>
44
45
46 t.
- 47
48 75. Dong Z, Xu J, Wang Z, et al. Stents for the prevention of pancreatic fistula following
49
50 pancreaticoduodenectomy. Cochrane Database of Systematic Reviews 2016; (5).
51
52
53 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008914.pub3/abstract>
54
55
56 t.
- 57
58 76. D'Souza N, Darmanin G, Fedorowicz Z. Immediate versus delayed reconstruction
59
60 following surgery for breast cancer. Cochrane Database of Systematic Reviews

2011; (7).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008674.pub2/abstract>.

77. Edey Katharine A, Allan E, Murdoch John B, et al. Interventions for the treatment of Paget's disease of the vulva. Cochrane Database of Systematic Reviews 2013; (10).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009245.pub2/abstract>.

78. Elattar A, Bryant A, Winter-Roach Brett A, et al. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database of Systematic Reviews 2011; (8).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007565.pub2/abstract>.

79. Eleje George U, Eke Ahizechukwu C, Igberase Gabriel O, et al. Palliative interventions for controlling vaginal bleeding in advanced cervical cancer. Cochrane Database of Systematic Reviews 2015; (5).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011000.pub2/abstract>.

80. Eliakim-Raz N, Vinograd I, Zalmanovici Trestioreanu A, et al. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database of Systematic Reviews 2013; (10).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008983.pub2/abstract>.

81. Elias S, Al-Khayatt A, Porter Richard WJ, et al. Dental extractions prior to radiotherapy to the jaws for reducing post-radiotherapy dental complications.

1
2
3 Cochrane Database of Systematic Reviews 2013; (2).

4 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008857.pub2/abstract>
5
6
7
8 t.

9
10 82. Estcourt L, Stanworth S, Doree C, et al. Prophylactic platelet transfusion for
11 prevention of bleeding in patients with haematological disorders after
12 chemotherapy and stem cell transplantation. Cochrane Database of Systematic
13 Reviews 2012; (5).

14
15
16
17
18 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004269.pub3/abstract>
19
20
21
22 t.

23
24 83. Estcourt Lise J, Stanworth S, Doree C, et al. Different doses of prophylactic platelet
25 transfusion for preventing bleeding in people with haematological disorders after
26 myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database
27 of Systematic Reviews 2015; (10).

28
29
30
31
32 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010984.pub2/abstract>
33
34
35
36 t.

37
38 84. Estcourt Lise J, Stanworth Simon J, Doree C, et al. Granulocyte transfusions for
39 preventing infections in people with neutropenia or neutrophil dysfunction.
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Cochrane Database of Systematic Reviews 2015; (6).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005341.pub3/abstract>
t.

85. Everett T, Bryant A, Griffin Michelle F, et al. Interventions targeted at women to
encourage the uptake of cervical screening. Cochrane Database of Systematic
Reviews 2011; (5).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002834.pub2/abstract>
t.

- 1
2
3 86. Ezzo J, Manheimer E, McNeely Margaret L, et al. Manual lymphatic drainage for
4
5 lymphedema following breast cancer treatment. Cochrane Database of Systematic
6
7 Reviews 2015; (5).
8
9
10 [http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003475.pub2/abstrac](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003475.pub2/abstract)
11
12 [t.](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003475.pub2/abstract)
13
14
15 87. Farquhar C, Marjoribanks J, Lethaby A, et al. High-dose chemotherapy and
16
17 autologous bone marrow or stem cell transplantation versus conventional
18
19 chemotherapy for women with early poor prognosis breast cancer. Cochrane
20
21 Database of Systematic Reviews 2016; (5).
22
23
24 [http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003139.pub3/abstrac](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003139.pub3/abstract)
25
26 [t.](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003139.pub3/abstract)
27
28
29 88. Felbel S, Meerpohl Joerg J, Monsef I, et al. Yoga in addition to standard care for
30
31 patients with haematological malignancies. Cochrane Database of Systematic
32
33 Reviews 2014; (6).
34
35
36 [http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010146.pub2/abstrac](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010146.pub2/abstract)
37
38 [t.](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010146.pub2/abstract)
39
40
41 89. Ford Alexander C, Forman D, Hunt R, et al. Helicobacter pylori eradication for the
42
43 prevention of gastric neoplasia. Cochrane Database of Systematic Reviews 2015;
44
45 (7).
46
47
48 [http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005583.pub2/abstrac](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005583.pub2/abstract)
49
50 [t.](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005583.pub2/abstract)
51
52
53 90. Frost Jonathan A, Webster Katie E, Bryant A, et al. Lymphadenectomy for the
54
55 management of endometrial cancer. Cochrane Database of Systematic Reviews
56
57 2015; (9).
58
59
60

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007585.pub3/abstract>
4
5
6 t.

7
8 91. Fu J, Fang F, Xie L, et al. Prophylactic chemotherapy for hydatidiform mole to prevent
9
10 gestational trophoblastic neoplasia. Cochrane Database of Systematic Reviews
11
12 2012; (10).

13
14 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007289.pub2/abstract>
15
16
17 t.

18
19 92. Furness S, Glenny A-M, Worthington Helen V, et al. Interventions for the treatment of
20
21 oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database of
22
23 Systematic Reviews 2011; (4).

24
25 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006386.pub3/abstract>
26
27
28 t.

29
30 93. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in
31
32 afebrile neutropenic patients following chemotherapy. Cochrane Database of
33
34 Systematic Reviews 2012; (1).

35
36 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004386.pub3/abstract>
37
38
39 t.

40
41 94. Gaitskell K, Martinek I, Bryant A, et al. Angiogenesis inhibitors for the treatment of
42
43 ovarian cancer. Cochrane Database of Systematic Reviews 2011; (9).

44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007930.pub2/abstract>
46
47
48 t.

49
50 95. Galaal K, Al Moundhri M, Bryant A, et al. Adjuvant chemotherapy for advanced
51
52 endometrial cancer. Cochrane Database of Systematic Reviews 2014; (5).

53
54 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010681.pub2/abstract>
55
56
57 t.

- 1
2
3 96. Galaal K, Bryant A, Deane Katherine HO, et al. Interventions for reducing anxiety in
4
5 women undergoing colposcopy. Cochrane Database of Systematic Reviews 2011;
6
7 (12).
8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006013.pub3/abstract>
11
12
13
14
15 97. Galaal K, Bryant A, Fisher Ann D, et al. Laparoscopy versus laparotomy for the
16
17 management of early stage endometrial cancer. Cochrane Database of Systematic
18
19 Reviews 2012; (9).
20
21 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006655.pub2/abstract>
22
23
24
25
26 98. Galaal K, van der Heijden E, Godfrey K, et al. Adjuvant radiotherapy and/or
27
28 chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database of
29
30 Systematic Reviews 2013; (2).
31
32 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006812.pub3/abstract>
33
34
35
36
37 99. Galway K, Black A, Cantwell M, et al. Psychosocial interventions to improve quality of
38
39 life and emotional wellbeing for recently diagnosed cancer patients. Cochrane
40
41 Database of Systematic Reviews 2012; (11).
42
43 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007064.pub2/abstract>
44
45
46
47
48 100. Gartlehner G, Thaler K, Chapman A, et al. Mammography in combination with
49
50 breast ultrasonography versus mammography for breast cancer screening in
51
52 women at average risk. Cochrane Database of Systematic Reviews 2013; (4).
53
54 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009632.pub2/abstract>
55
56
57
58
59
60

- 1
2
3 101. Gbabe Oluwatoyin F, Okwundu Charles I, Dedicoat M, et al. Treatment of severe or
4
5 progressive Kaposi's sarcoma in HIV-infected adults. Cochrane Database of
6
7 Systematic Reviews 2014; (9).
8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003256.pub2/abstract>
11
12
13
14
15 102. George R, Jeba J, Ramkumar G, et al. Interventions for the treatment of metastatic
16
17 extradural spinal cord compression in adults. Cochrane Database of Systematic
18
19 Reviews 2015; (9).
20
21
22 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006716.pub3/abstract>
23
24
25
26
27 103. Gherzi D, Willson Melina L, Chan Matthew Ming K, et al. Taxane-containing
28
29 regimens for metastatic breast cancer. Cochrane Database of Systematic Reviews
30
31 2015; (6).
32
33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003366.pub3/abstract>
35
36
37
38
39 104. Goodwin A, Parker S, Gherzi D, et al. Post-operative radiotherapy for ductal
40
41 carcinoma in situ of the breast. Cochrane Database of Systematic Reviews 2013;
42
43 (11).
44
45
46 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000563.pub7/abstract>
47
48
49
50
51 105. Goossen Ginette M, Kremer Leontien CM, van de Wetering Marianne D. Influenza
52
53 vaccination in children being treated with chemotherapy for cancer. Cochrane
54
55 Database of Systematic Reviews 2013; (8).
56
57
58 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006484.pub3/abstract>
59
60

- 1
2
3 106. Gordijn Maartje S, Rensen N, Gemke Reinoud JBJ, et al. Hypothalamic-pituitary-
4
5 adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for
6
7 childhood acute lymphoblastic leukaemia. Cochrane Database of Systematic
8
9 Reviews 2015; (8).
10
11 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008727.pub3/abstract>
12
13
14
15
16
17 107. Gøtzsche Peter C, Johansen Helle K. Routine versus selective antifungal
18
19 administration for control of fungal infections in patients with cancer. Cochrane
20
21 Database of Systematic Reviews 2014; (9).
22
23 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000026.pub2/abstract>
24
25
26
27
28
29 108. Gøtzsche Peter C, Jørgensen Karsten J. Screening for breast cancer with
30
31 mammography. Cochrane Database of Systematic Reviews 2013; (6).
32
33 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001877.pub5/abstract>
34
35
36
37
38
39 109. Grabosch Shannon M, Shariff Osman M, Wulff Judith L, et al. Non-steroidal anti-
40
41 inflammatory agents to induce regression and prevent the progression of cervical
42
43 intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2014; (4).
44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004121.pub3/abstract>
46
47
48
49
50 110. Grande Antonio J, Silva V, Riera R, et al. Exercise for cancer cachexia in adults.
51
52 Cochrane Database of Systematic Reviews 2014; (11).
53
54 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010804.pub2/abstract>
55
56
57
58
59
60

- 1
2
3 111. Gupta Aditya K, Paquet M, Villanueva E, et al. Interventions for actinic keratoses.
4
5 Cochrane Database of Systematic Reviews 2012; (12).
6
7 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004415.pub2/abstract>
8
9
10
11
12 112. Gurion R, Belnik-Plitman Y, Gafer-Gvili A, et al. Colony-stimulating factors for
13
14 prevention and treatment of infectious complications in patients with acute
15
16 myelogenous leukemia. Cochrane Database of Systematic Reviews 2012; (6).
17
18 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008238.pub3/abstract>
19
20
21
22
23
24 113. Gurumurthy M, Bryant A, Shanbhag S. Effectiveness of different treatment
25
26 modalities for the management of adult-onset granulosa cell tumours of the
27
28 ovary (primary and recurrent). Cochrane Database of Systematic Reviews 2014;
29
30 (4).
31
32 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006912.pub2/abstract>
33
34
35
36
37
38 114. Gurusamy Kurinchi S, Kumar S, Davidson Brian R. Prophylactic gastrojejunostomy
39
40 for unresectable periampullary carcinoma. Cochrane Database of Systematic
41
42 Reviews 2013; (2).
43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008533.pub3/abstract>
45
46
47
48
49
50 115. Gurusamy Kurinchi S, Kumar S, Davidson Brian R, et al. Resection versus other
51
52 treatments for locally advanced pancreatic cancer. Cochrane Database of
53
54 Systematic Reviews 2014; (2).
55
56 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010244.pub2/abstract>
57
58
59
60

- 1
2
3 116. Gurusamy Kurinchi S, Pallari E, Midya S, et al. Laparoscopic versus open transhiatal
4 oesophagectomy for oesophageal cancer. Cochrane Database of Systematic
5
6 oesophagectomy for oesophageal cancer. Cochrane Database of Systematic
7
8 Reviews 2016; (3).
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011390.pub2/abstract>
11
12
13 t.
- 14
15 117. Hadley G, Derry S, Moore RA, et al. Transdermal fentanyl for cancer pain. Cochrane
16
17 Database of Systematic Reviews 2013; (10).
18
19 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010270.pub2/abstract>
20
21
22 t.
- 23
24 118. Haldar K, Gaitskell K, Bryant A, et al. Epidermal growth factor receptor blockers for
25
26 the treatment of ovarian cancer. Cochrane Database of Systematic Reviews 2011;
27
28 (10).
29
30 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007927.pub3/abstract>
31
32
33 t.
- 34
35 119. Hart Michael G, Garside R, Rogers G, et al. Chemotherapy wafers for high grade
36
37 glioma. Cochrane Database of Systematic Reviews 2011; (3).
38
39 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007294.pub2/abstract>
40
41
42 t.
- 43
44 120. Hart Michael G, Garside R, Rogers G, et al. Temozolomide for high grade glioma.
45
46 Cochrane Database of Systematic Reviews 2013; (4).
47
48 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007415.pub2/abstract>
49
50
51 t.
- 52
53
54 121. Hartmann T, Hübel K, Monsef I, et al. Additional plerixafor to granulocyte colony-
55
56 stimulating factors for haematopoietic stem cell mobilisation for autologous
57
58 transplantation in people with malignant lymphoma or multiple myeloma.
59
60

1
2
3 Cochrane Database of Systematic Reviews 2015; (10).

4 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010615.pub2/abstract>
5
6
7
8 t.

9
10 122. Helm CW, Lorenz Douglas J, Meyer Nicholas J, et al. Retinoids for preventing the
11 progression of cervical intra-epithelial neoplasia. Cochrane Database of
12 Systematic Reviews 2013; (6).

13
14
15
16 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003296.pub3/abstract>
17
18
19 t.

20
21 123. Henschke N, Maher Christopher G, Ostelo Raymond WJG, et al. Red flags to screen
22 for malignancy in patients with low-back pain. Cochrane Database of Systematic
23 Reviews 2013; (2).

24
25
26
27 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008686.pub2/abstract>
28
29
30 t.

31
32 124. Henson Caroline C, Burden S, Davidson Susan E, et al. Nutritional interventions for
33 reducing gastrointestinal toxicity in adults undergoing radical pelvic
34 radiotherapy. Cochrane Database of Systematic Reviews 2013; (11).

35
36
37
38 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009896.pub2/abstract>
39
40
41 t.

42
43 125. Herbst C, Monsef I, Specht L, et al. Chemotherapy alone versus chemotherapy plus
44 radiotherapy for adults with early stage Hodgkin lymphoma. Cochrane Database
45 of Systematic Reviews 2011; (4).

46
47
48
49 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007110.pub3/abstract>
50
51
52 t.

53
54 126. Hickey Brigid E, Francis Daniel P, Lehman M. Sequencing of chemotherapy and
55 radiotherapy for early breast cancer. Cochrane Database of Systematic Reviews
56
57
58
59
60

1
2
3 2013; (4).

4
5 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005212.pub3/abstract>
6
7
8 t.

9
10 127. Hilgart Jennifer S, Coles B, Iredale R. Cancer genetic risk assessment for individuals
11
12 at risk of familial breast cancer. Cochrane Database of Systematic Reviews 2012;
13
14 (2).

15
16 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003721.pub3/abstract>
17
18
19 t.

20
21 128. Holme Ø, Bretthauer M, Fretheim A, et al. Flexible sigmoidoscopy versus faecal
22
23 occult blood testing for colorectal cancer screening in asymptomatic individuals.
24
25 Cochrane Database of Systematic Reviews 2013; (9).

26
27 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009259.pub2/abstract>
28
29
30 t.

31
32 129. Holtick U, Albrecht M, Chemnitz Jens M, et al. Bone marrow versus peripheral blood
33
34 allogeneic haematopoietic stem cell transplantation for haematological
35
36 malignancies in adults. Cochrane Database of Systematic Reviews 2014; (4).

37
38 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010189.pub2/abstract>
39
40
41 t.

42
43 130. Hurlow A, Bennett Michael I, Robb Karen A, et al. Transcutaneous electric nerve
44
45 stimulation (TENS) for cancer pain in adults. Cochrane Database of Systematic
46
47 Reviews 2012; (3).

48
49 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006276.pub3/abstract>
50
51
52 t.

53
54 131. Hüttner Felix J, Fitzmaurice C, Schwarzer G, et al. Pylorus-preserving
55
56 pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy
57
58
59
60

(classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database of Systematic Reviews 2016; (2).

<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006053.pub6/abstract>.

132. Hutzschenreuter F, Monsef I, Kreuzer K-A, et al. Granulocyte and granulocyte-macrophage colony stimulating factors for newly diagnosed patients with myelodysplastic syndromes. Cochrane Database of Systematic Reviews 2016; (2).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009310.pub2/abstract>.

133. Ilic D, Forbes Kristian M, Hased C. Lycopene for the prevention of prostate cancer. Cochrane Database of Systematic Reviews 2011; (11).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008007.pub2/abstract>.

134. Ilic D, Misso Marie L. Screening for testicular cancer. Cochrane Database of Systematic Reviews 2011; (2).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007853.pub2/abstract>.

135. Ilic D, Neuberger Molly M, Djulbegovic M, et al. Screening for prostate cancer. Cochrane Database of Systematic Reviews 2013; (1).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004720.pub3/abstract>.

136. Itchaki G, Gafter-Gvili A, Lahav M, et al. Anthracycline-containing regimens for treatment of follicular lymphoma in adults. Cochrane Database of Systematic Reviews 2013; (7).

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008909.pub2/abstract>
4
5
6 t.

7
8 137. Jaaback K, Johnson N, Lawrie Theresa A. Intraperitoneal chemotherapy for the
9
10 initial management of primary epithelial ovarian cancer. Cochrane Database of
11
12 Systematic Reviews 2016; (1).

13
14
15 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005340.pub4/abstract>
16
17
18 t.

19
20 138. Jassim Ghufuran A, Whitford David L, Hickey A, et al. Psychological interventions for
21
22 women with non-metastatic breast cancer. Cochrane Database of Systematic
23
24 Reviews 2015; (5).

25
26
27 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008729.pub2/abstract>
28
29
30 t.

31
32 139. Jin H, Leng Q, Li C. Dietary flavonoid for preventing colorectal neoplasms. Cochrane
33
34 Database of Systematic Reviews 2012; (8).

35
36
37 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009350.pub2/abstract>
38
39
40 t.

41
42 140. Jin X, Ruiz Beguerie J, Sze Daniel M-y, et al. Ganoderma lucidum (Reishi mushroom)
43
44 for cancer treatment. Cochrane Database of Systematic Reviews 2016; (4).

45
46
47 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007731.pub3/abstract>
48
49
50 t.

51
52 141. Johansen Helle K, Gøtzsche Peter C. Amphotericin B versus fluconazole for
53
54 controlling fungal infections in neutropenic cancer patients. Cochrane Database
55
56 of Systematic Reviews 2014; (9).

57
58
59 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000239.pub2/abstract>
60
61
62 t.

- 1
2
3 142. Johansen Helle K, Gøtzsche Peter C. Amphotericin B lipid soluble formulations
4
5 versus amphotericin B in cancer patients with neutropenia. Cochrane Database of
6
7 Systematic Reviews 2014; (9).
8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000969.pub2/abstract>
11
12
13 t.
- 14
15 143. Johnson N, Bryant A, Miles T, et al. Adjuvant chemotherapy for endometrial cancer
16
17 after hysterectomy. Cochrane Database of Systematic Reviews 2011; (10).
18
19 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003175.pub2/abstract>
20
21
22 t.
- 23
24 144. Jones Daniel J, Bunn F, Bell-Syer Sophie V. Prophylactic antibiotics to prevent
25
26 surgical site infection after breast cancer surgery. Cochrane Database of
27
28 Systematic Reviews 2014; (3).
29
30 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005360.pub4/abstract>
31
32
33 t.
- 34
35 145. Jones G, Cleves A, Wilt Timothy J, et al. Intravesical gemcitabine for non-muscle
36
37 invasive bladder cancer. Cochrane Database of Systematic Reviews 2012; (1).
38
39 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009294.pub2/abstract>
40
41
42
43 t.
- 44
45 146. Jørgensen Karsten J, Gøtzsche Peter C, Dalbøge Christina S, et al. Voriconazole
46
47 versus amphotericin B or fluconazole in cancer patients with neutropenia.
48
49 Cochrane Database of Systematic Reviews 2014; (2).
50
51 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004707.pub3/abstract>
52
53
54
55 t.
- 56
57 147. Kaushik S, Pepas L, Nordin A, et al. Surgical interventions for high-grade vulval
58
59 intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2014; (3).
60

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007928.pub3/abstract>
4
5
6 t.

7
8 148. Kerrigan S, Grant R. Antiepileptic drugs for treating seizures in adults with brain
9
10 tumours. Cochrane Database of Systematic Reviews 2011; (8).

11
12 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008586.pub2/abstract>
13
14
15 t.

16
17 149. Khan F, Amatya B, Ng L, et al. Multidisciplinary rehabilitation for follow-up of
18
19 women treated for breast cancer. Cochrane Database of Systematic Reviews
20
21 2012; (12).

22
23 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009553.pub2/abstract>
24
25
26 t.

27
28 150. Khan F, Amatya B, Ng L, et al. Multidisciplinary rehabilitation after primary brain
29
30 tumour treatment. Cochrane Database of Systematic Reviews 2015; (8).

31
32 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009509.pub3/abstract>
33
34
35 t.

36
37 151. Kharfan-Dabaja M, Mhaskar R, Reljic T, et al. Mycophenolate mofetil versus
38
39 methotrexate for prevention of graft-versus-host disease in people receiving
40
41 allogeneic hematopoietic stem cell transplantation. Cochrane Database of
42
43 Systematic Reviews 2014; (7).

44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010280.pub2/abstract>
46
47
48 t.

49
50 152. Khasraw M, Ameratunga Malaka S, Grant R, et al. Antiangiogenic therapy for high-
51
52 grade glioma. Cochrane Database of Systematic Reviews 2014; (9).

53
54 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008218.pub3/abstract>
55
56
57 t.

- 1
2
3 153. Kidane B, Coughlin S, Vogt K, et al. Preoperative chemotherapy for resectable
4
5 thoracic esophageal cancer. Cochrane Database of Systematic Reviews 2015; (5).
6
7 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001556.pub3/abstract>
8
9
10
11
12
13 154. Kietpeerakool C, Supoken A, Laopaiboon M, et al. Effectiveness of tranexamic acid in
14
15 reducing blood loss during cytoreductive surgery for advanced ovarian cancer.
16
17 Cochrane Database of Systematic Reviews 2016; (1).
18
19 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011732.pub2/abstract>
20
21
22
23
24 155. Knijnenburg Sebastiaan L, Mulder Renée L, Schouten-Van Meeteren Antoinette YN,
25
26 et al. Early and late renal adverse effects after potentially nephrotoxic treatment
27
28 for childhood cancer. Cochrane Database of Systematic Reviews 2013; (10).
29
30 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008944.pub2/abstract>
31
32
33
34
35
36 156. Kokka F, Bryant A, Brockbank E, et al. Surgical treatment of stage IA2 cervical
37
38 cancer. Cochrane Database of Systematic Reviews 2014; (5).
39
40 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010870.pub2/abstract>
41
42
43
44
45
46 157. Kokka F, Bryant A, Brockbank E, et al. Hysterectomy with radiotherapy or
47
48 chemotherapy or both for women with locally advanced cervical cancer.
49
50 Cochrane Database of Systematic Reviews 2015; (4).
51
52 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010260.pub2/abstract>
53
54
55
56
57 158. Kong A, Johnson N, Kitchener Henry C, et al. Adjuvant radiotherapy for stage I
58
59 endometrial cancer. Cochrane Database of Systematic Reviews 2012; (4).
60

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003916.pub4/abstract>
4
5
6 t.

7
8 159. Kucukmetin A, Biliatis I, Naik R, et al. Laparoscopically assisted radical vaginal
9
10 hysterectomy versus radical abdominal hysterectomy for the treatment of early
11
12 cervical cancer. Cochrane Database of Systematic Reviews 2013; (10).

13
14
15 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006651.pub3/abstract>
16
17
18 t.

19
20 160. Kunath F, Grobe Henrik R, Rücker G, et al. Non-steroidal antiandrogen
21
22 monotherapy compared with luteinising hormone-releasing hormone agonists or
23
24 surgical castration monotherapy for advanced prostate cancer. Cochrane
25
26 Database of Systematic Reviews 2014; (6).

27
28
29 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009266.pub2/abstract>
30
31
32 t.

33
34 161. Kyrgidis A, Tzellos T, Mocellin S, et al. Sentinel lymph node biopsy followed by
35
36 lymph node dissection for localised primary cutaneous melanoma. Cochrane
37
38 Database of Systematic Reviews 2015; (5).

39
40
41 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010307.pub2/abstract>
42
43
44 t.

45
46 162. Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after
47
48 conservative treatment for cervical intraepithelial neoplasia. Cochrane Database
49
50 of Systematic Reviews 2015; (9).

51
52
53 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008478.pub2/abstract>
54
55
56 t.

57
58 163. Lanceley A, Fiander A, McCormack M, et al. Follow-up protocols for women with
59
60 cervical cancer after primary treatment. Cochrane Database of Systematic

1
2
3 Reviews 2013; (11).

4
5 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008767.pub2/abstract>
6
7
8 t.

9
10 164. Lawal Aramide O, Musekiwa A, Grobler L. Interferon after surgery for women with
11 advanced (Stage II-IV) epithelial ovarian cancer. Cochrane Database of Systematic
12 Reviews 2013; (6).

13
14
15 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009620.pub2/abstract>
16
17
18 t.

19
20 165. Lawrie Theresa A, Bryant A, Cameron A, et al. Pegylated liposomal doxorubicin for
21 relapsed epithelial ovarian cancer. Cochrane Database of Systematic Reviews
22 2013; (7).

23
24 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006910.pub2/abstract>
25
26
27 t.

28
29 166. Lawrie Theresa A, Nordin A, Chakrabarti M, et al. Medical and surgical
30 interventions for the treatment of usual-type vulval intraepithelial neoplasia.
31 Cochrane Database of Systematic Reviews 2016; (1).

32
33 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011837.pub2/abstract>
34
35
36 t.

37
38 167. Lawrie Theresa A, Patel A, Martin-Hirsch Pierre PL, et al. Sentinel node assessment
39 for diagnosis of groin lymph node involvement in vulval cancer. Cochrane
40 Database of Systematic Reviews 2014; (6).

41
42 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010409.pub2/abstract>
43
44
45 t.

46
47 168. Lawrie Theresa A, Rabbie R, Thoma C, et al. Pegylated liposomal doxorubicin for
48 first-line treatment of epithelial ovarian cancer. Cochrane Database of Systematic
49
50

1
2
3 Reviews 2013; (10).

4
5 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010482.pub2/abstract>
6
7
8 t.

9
10 169. Lawrie Theresa A, Winter-Roach Brett A, Heus P, et al. Adjuvant (post-surgery)
11 chemotherapy for early stage epithelial ovarian cancer. Cochrane Database of
12 Systematic Reviews 2015; (12).

13
14
15 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004706.pub5/abstract>
16
17
18 t.

19
20 170. Lecavalier-Barsoum M, Quon H, Abdulkarim B. Adjuvant treatment of anaplastic
21 oligodendrogliomas and oligoastrocytomas. Cochrane Database of Systematic
22 Reviews 2014; (5).

23
24
25 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007104.pub2/abstract>
26
27
28 t.

29
30 171. Lee Siew H, Grant R, Kennedy C, et al. Positioning and spinal bracing for pain relief
31 in metastatic spinal cord compression in adults. Cochrane Database of Systematic
32 Reviews 2015; (9).

33
34
35 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007609.pub3/abstract>
36
37
38 t.

39
40 172. Leffers N, Daemen T, Helfrich W, et al. Antigen-specific active immunotherapy for
41 ovarian cancer. Cochrane Database of Systematic Reviews 2014; (9).

42
43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007287.pub3/abstract>
45
46
47 t.

48
49 173. Li X, Xu S, Tan Y, et al. The effects of idarubicin versus other anthracyclines for
50 induction therapy of patients with newly diagnosed leukaemia. Cochrane
51 Database of Systematic Reviews 2015; (6).

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010432.pub2/abstract>
4
5
6 t.

7
8 174. Liu R, Wang X, Tian Jin H, et al. High dose rate versus low dose rate intracavity
9
10 brachytherapy for locally advanced uterine cervix cancer. Cochrane Database of
11
12 Systematic Reviews 2014; (10).

13
14
15 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007563.pub3/abstract>
16
17
18 t.

19
20 175. Loeffen Erik AH, te Poele Esther M, Tissing Wim JE, et al. Very early discharge
21
22 versus early discharge versus non-early discharge in children with cancer and
23
24 febrile neutropenia. Cochrane Database of Systematic Reviews 2016; (2).

25
26
27 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008382.pub2/abstract>
28
29
30 t.

31
32 176. Lu D, Wang X, Shi G. Perioperative enhanced recovery programmes for
33
34 gynaecological cancer patients. Cochrane Database of Systematic Reviews 2015;
35
36 (3).

37
38
39 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008239.pub4/abstract>
40
41
42 t.

43
44 177. Macaya A, Muñoz-Santos C, Balaguer A, et al. Interventions for anal canal
45
46 intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2012; (12).

47
48
49 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009244.pub2/abstract>
50
51
52 t.

53
54 178. Macey R, Walsh T, Brocklehurst P, et al. Diagnostic tests for oral cancer and
55
56 potentially malignant disorders in patients presenting with clinically evident
57
58 lesions. Cochrane Database of Systematic Reviews 2015; (5).

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010276.pub2/abstract>
4
5
6 t.

7
8 179. Manser R, Lethaby A, Irving Louis B, et al. Screening for lung cancer. Cochrane
9
10 Database of Systematic Reviews 2013; (6).

11
12 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001991.pub3/abstract>
13
14
15 t.

16
17 180. Mao C, Fu X-H, Yuan J-Q, et al. Interleukin-2 as maintenance therapy for children
18
19 and adults with acute myeloid leukaemia in first complete remission. Cochrane
20
21 Database of Systematic Reviews 2015; (11).

22
23 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010248.pub2/abstract>
24
25
26 t.

27
28
29 181. Mao C, Yang Z-Y, He B-F, et al. Toremifene versus tamoxifen for advanced breast
30
31 cancer. Cochrane Database of Systematic Reviews 2012; (7).

32
33 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008926.pub2/abstract>
34
35
36 t.

37
38 182. Martí-Carvajal Arturo J, Anand V, Solà I. Treatment for disseminated intravascular
39
40 coagulation in patients with acute and chronic leukemia. Cochrane Database of
41
42 Systematic Reviews 2015; (6).

43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008562.pub3/abstract>
45
46
47 t.

48
49
50 183. Martin-Hirsch Pierre PL, Bryant A. Interventions for preventing blood loss during
51
52 the treatment of cervical intraepithelial neoplasia. Cochrane Database of
53
54 Systematic Reviews 2013; (12).

55
56 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001421.pub3/abstract>
57
58
59 t.

- 1
2
3 184. Martin-Hirsch Pierre PL, Bryant A, Keep Sarah L, et al. Adjuvant progestagens for
4
5 endometrial cancer. Cochrane Database of Systematic Reviews 2011; (6).
6
7 [http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001040.pub2/abstrac](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001040.pub2/abstract)
8
9 [t.](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001040.pub2/abstract)
10
11
12 185. Martin-Hirsch Pierre PL, Paraskevaidis E, Bryant A, et al. Surgery for cervical
13
14 intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2013; (12).
15
16 [http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001318.pub3/abstrac](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001318.pub3/abstract)
17
18 [t.](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001318.pub3/abstract)
19
20
21 186. Masterson L, Moualed D, Masood A, et al. De-escalation treatment protocols for
22
23 human papillomavirus-associated oropharyngeal squamous cell carcinoma.
24
25 Cochrane Database of Systematic Reviews 2014; (2).
26
27 [http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010271.pub2/abstrac](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010271.pub2/abstract)
28
29 [t.](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010271.pub2/abstract)
30
31
32 187. McCarthy K, Pearson K, Fulton R, et al. Pre-operative chemoradiation for non-
33
34 metastatic locally advanced rectal cancer. Cochrane Database of Systematic
35
36 Reviews 2012; (12).
37
38 [http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008368.pub2/abstrac](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008368.pub2/abstract)
39
40 [t.](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008368.pub2/abstract)
41
42
43 188. Mei L, Chen H, Wei Dong M, et al. Maintenance chemotherapy for ovarian cancer.
44
45 Cochrane Database of Systematic Reviews 2013; (6).
46
47 [http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007414.pub3/abstrac](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007414.pub3/abstract)
48
49 [t.](http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007414.pub3/abstract)
50
51
52 189. Mhaskar R, Clark Otavio Augusto C, Lyman G, et al. Colony-stimulating factors for
53
54 chemotherapy-induced febrile neutropenia. Cochrane Database of Systematic
55
56 Reviews 2014; (10).
57
58
59
60

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003039.pub2/abstract>
4
5
6 t.

7
8 190. Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma:
9
10 a network meta-analysis. Cochrane Database of Systematic Reviews 2012; (5).

11
12 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003188.pub3/abstract>
13
14
15 t.

16
17 191. Mhaskar R, Wao H, Miladinovic B, et al. The role of iron in the management of
18
19 chemotherapy-induced anemia in cancer patients receiving erythropoiesis-
20
21 stimulating agents. Cochrane Database of Systematic Reviews 2016; (2).

22
23 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009624.pub2/abstract>
24
25
26 t.

27
28 192. Mical P, Borok S, Vidal L, et al. Empirical antibiotics targeting gram-positive
29
30 bacteria for the treatment of febrile neutropenic patients with cancer. Cochrane
31
32 Database of Systematic Reviews 2014; (6).

33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003914.pub4/abstract>
35
36
37 t.

38
39 193. Michiels Erna MC, Schouten-Van Meeteren Antoinette YN, Doz F, et al.

40
41
42 Chemotherapy for children with medulloblastoma. Cochrane Database of
43
44 Systematic Reviews 2015; (1).

45
46 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006678.pub2/abstract>
47
48
49 t.

50
51 194. Milazzo S, Horneber M. Laetrile treatment for cancer. Cochrane Database of
52
53 Systematic Reviews 2015; (4).

54
55 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005476.pub4/abstract>
56
57
58 t.
59
60

- 1
2
3 195. Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic
4
5 radiotherapy. Cochrane Database of Systematic Reviews 2014; (9).
6
7 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007291.pub3/abstract>
8
9
10
11
12 196. Mishra Shiraz I, Scherer Roberta W, Geigle Paula M, et al. Exercise interventions on
13
14 health-related quality of life for cancer survivors. Cochrane Database of
15
16 Systematic Reviews 2012; (8).
17
18 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007566.pub2/abstract>
19
20
21
22
23 197. Mishra Shiraz I, Scherer Roberta W, Snyder C, et al. Exercise interventions on
24
25 health-related quality of life for people with cancer during active treatment.
26
27 Cochrane Database of Systematic Reviews 2012; (8).
28
29 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008465.pub2/abstract>
30
31
32
33
34
35 198. Mocellin S, Lens Marko B, Pasquali S, et al. Interferon alpha for the adjuvant
36
37 treatment of cutaneous melanoma. Cochrane Database of Systematic Reviews
38
39 2013; (6).
40
41 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008955.pub2/abstract>
42
43
44
45
46
47 199. Mocellin S, McCulloch P, Kazi H, et al. Extent of lymph node dissection for
48
49 adenocarcinoma of the stomach. Cochrane Database of Systematic Reviews 2015;
50
51 (8).
52
53 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001964.pub4/abstract>
54
55
56
57
58
59
60

- 1
2
3 200. Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for
4 the preoperative locoregional staging of primary gastric cancer. Cochrane
5 Database of Systematic Reviews 2015; (2).
6
7
8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009944.pub2/abstract>
11
12
13
14
15 201. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early
16 breast cancer. Cochrane Database of Systematic Reviews 2012; (4).
17
18
19 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006243.pub2/abstract>
20
21
22
23
24 202. Molassiotis A, Bailey C, Caress A, et al. Interventions for cough in cancer. Cochrane
25 Database of Systematic Reviews 2015; (5).
26
27
28 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007881.pub3/abstract>
29
30
31
32
33 203. Moore Philippa M, Rivera Mercado S, Grez Artigues M, et al. Communication skills
34 training for healthcare professionals working with people who have cancer.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57 204. Morrison J, Haldar K, Kehoe S, et al. Chemotherapy versus surgery for initial
58 treatment in advanced ovarian epithelial cancer. Cochrane Database of
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
200. Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. Cochrane Database of Systematic Reviews 2015; (2).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009944.pub2/abstract>
201. Moja L, Tagliabue L, Balduzzi S, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database of Systematic Reviews 2012; (4).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006243.pub2/abstract>
202. Molassiotis A, Bailey C, Caress A, et al. Interventions for cough in cancer. Cochrane Database of Systematic Reviews 2015; (5).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007881.pub3/abstract>
203. Moore Philippa M, Rivera Mercado S, Grez Artigues M, et al. Communication skills training for healthcare professionals working with people who have cancer. Cochrane Database of Systematic Reviews 2013; (3).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003751.pub3/abstract>
204. Morrison J, Haldar K, Kehoe S, et al. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database of Systematic Reviews 2012; (8).
<http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005343.pub3/abstract>
205. Moschetti I, Cinquini M, Lambertini M, et al. Follow-up strategies for women treated for early breast cancer. Cochrane Database of Systematic Reviews 2016; (5).

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001768.pub3/abstract>
4
5
6 t.

7
8 206. Muchtar E, Vidal L, Ram R, et al. The role of maintenance therapy in acute
9
10 promyelocytic leukemia in the first complete remission. Cochrane Database of
11
12 Systematic Reviews 2013; (3).

13
14 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009594.pub2/abstract>
15
16
17 t.

18
19 207. Mulder Renée L, Paulides M, Langer T, et al. Cyclophosphamide versus ifosfamide
20
21 for paediatric and young adult bone and soft tissue sarcoma patients. Cochrane
22
23 Database of Systematic Reviews 2015; (9).

24
25 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006300.pub4/abstract>
26
27
28 t.

29
30 208. Mulder Renée L, van Dalen Elvira C, Van den Hof M, et al. Hepatic late adverse
31
32 effects after antineoplastic treatment for childhood cancer. Cochrane Database of
33
34 Systematic Reviews 2011; (7).

35
36 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008205.pub2/abstract>
37
38
39 t.

40
41 209. Mustafa M, Carson-Stevens A, Gillespie D, et al. Psychological interventions for
42
43 women with metastatic breast cancer. Cochrane Database of Systematic Reviews
44
45 2013; (6).

46
47 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004253.pub4/abstract>
48
49
50 t.

51
52 210. Nagorni A, Bjelakovic G, Petrovic B. Narrow band imaging versus conventional
53
54 white light colonoscopy for the detection of colorectal polyps. Cochrane Database
55
56 of Systematic Reviews 2012; (1).

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008361.pub2/abstract>
4
5
6 t.

7
8 211. Nama V, Nordin A, Bryant A. Patient-reported outcome measures for follow-up after
9
10 gynaecological cancer treatment. Cochrane Database of Systematic Reviews
11
12 2013; (11).

13
14 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010299.pub2/abstract>
15
16
17 t.

18
19 212. Narayanan K, Hadid Omar H, Barnes Eric A. Mohs micrographic surgery versus
20
21 surgical excision for periocular basal cell carcinoma. Cochrane Database of
22
23 Systematic Reviews 2014; (12).

24
25 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007041.pub4/abstract>
26
27
28 t.

29
30 213. Naumann-Winter F, Greb A, Borchmann P, et al. First-line tandem high-dose
31
32 chemotherapy and autologous stem cell transplantation versus single high-dose
33
34 chemotherapy and autologous stem cell transplantation in multiple myeloma, a
35
36 systematic review of controlled studies. Cochrane Database of Systematic
37
38 Reviews 2012; (10).

39
40
41 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004626.pub3/abstract>
42
43
44 t.

45
46 214. Nicholson Brian D, Shinkins B, Pathiraja I, et al. Blood CEA levels for detecting
47
48 recurrent colorectal cancer. Cochrane Database of Systematic Reviews 2015;
49
50 (12).

51
52 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011134.pub2/abstract>
53
54
55
56 t.

- 1
2
3 215. Nugent B, Lewis S, O'Sullivan Joe M. Enteral feeding methods for nutritional
4 management in patients with head and neck cancers being treated with
5 radiotherapy and/or chemotherapy. Cochrane Database of Systematic Reviews
6 2013; (1).
7
8 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007904.pub3/abstract>
9
10
11
12
13
14
15
16
17 216. O'Connor A, McNamara D, O'Moráin Colm A. Surveillance of gastric intestinal
18 metaplasia for the prevention of gastric cancer. Cochrane Database of Systematic
19 Reviews 2013; (9).
20
21 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009322.pub2/abstract>
22
23
24
25
26
27
28
29 217. Okebe Joseph U, Skoetz N, Meremikwu Martin M, et al. Therapeutic interventions
30 for Burkitt lymphoma in children. Cochrane Database of Systematic Reviews
31 2011; (7).
32
33 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005198.pub3/abstract>
34
35
36
37
38
39
40 218. Oliveri Roberto S, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for
41 unresectable hepatocellular carcinoma. Cochrane Database of Systematic
42 Reviews 2011; (3).
43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004787.pub2/abstract>
45
46
47
48
49
50
51
52 219. Ostuzzi G, Matcham F, Dauchy S, et al. Antidepressants for the treatment of
53 depression in people with cancer. Cochrane Database of Systematic Reviews
54 2015; (6).
55
56
57
58
59
60

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011006.pub2/abstract>
4
5
6 t.

7
8 220. Pachler J, Wille-Jørgensen P. Quality of life after rectal resection for cancer, with or
9
10 without permanent colostomy. Cochrane Database of Systematic Reviews 2012;
11
12 (12).

13
14
15 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004323.pub4/abstract>
16
17
18 t.

19
20 221. Paley Carole A, Johnson Mark I, Tashani Osama A, et al. Acupuncture for cancer pain
21
22 in adults. Cochrane Database of Systematic Reviews 2015; (10).

23
24 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007753.pub3/abstract>
25
26
27 t.

28
29 222. Parahoo K, McDonough S, McCaughan E, et al. Psychosocial interventions for men
30
31 with prostate cancer. Cochrane Database of Systematic Reviews 2013; (12).

32
33 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008529.pub3/abstract>
34
35
36 t.

37
38 223. Patil Chirag G, Pricola K, Sarmiento JM, et al. Whole brain radiation therapy (WBRT)
39
40 alone versus WBRT and radiosurgery for the treatment of brain metastases.
41
42 Cochrane Database of Systematic Reviews 2012; (9).

43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006121.pub3/abstract>
45
46
47 t.

48
49 224. Paul M, Dickstein Y, Schlesinger A, et al. Beta-lactam versus beta-lactam-
50
51 aminoglycoside combination therapy in cancer patients with neutropenia.
52
53 Cochrane Database of Systematic Reviews 2013; (6).

54
55 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003038.pub2/abstract>
56
57
58 t.

- 1
2
3 225. Peinemann F, Bartel C, Grouven U. First-line allogeneic hematopoietic stem cell
4
5 transplantation of HLA-matched sibling donors compared with first-line
6
7 ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe
8
9 aplastic anemia. Cochrane Database of Systematic Reviews 2013; (7).
10
11 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006407.pub2/abstract>
12
13
14
15 t.
- 16
17 226. Peinemann F, Enk H, Smith Lesley A. Autologous hematopoietic stem cell
18
19 transplantation following high-dose chemotherapy for nonrhabdomyosarcoma
20
21 soft tissue sarcomas. Cochrane Database of Systematic Reviews 2013; (4).
22
23 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008216.pub5/abstract>
24
25
26
27 t.
- 28
29 227. Peinemann F, Grouven U, Hemkens Lars G, et al. Low-dose rate brachytherapy for
30
31 men with localized prostate cancer. Cochrane Database of Systematic Reviews
32
33 2011; (7).
34
35 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008871.pub2/abstract>
36
37
38
39 t.
- 40
41 228. Peinemann F, Kahangire Doreen A, van Dalen Elvira C, et al. Rapid COJEC versus
42
43 standard induction therapies for high-risk neuroblastoma. Cochrane Database of
44
45 Systematic Reviews 2015; (5).
46
47 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010774.pub2/abstract>
48
49
50
51 t.
- 52
53 229. Peinemann F, van Dalen Elvira C, Kahangire Doreen A, et al. Retinoic acid post
54
55 consolidation therapy for high-risk neuroblastoma patients treated with
56
57 autologous hematopoietic stem cell transplantation. Cochrane Database of
58
59 Systematic Reviews 2015; (1).
60

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010685.pub2/abstract>
4
5
6 t.

7
8 230. Pelayo Alvarez M, Westeel V, Cortés-Jofré M, et al. Chemotherapy versus best
9
10 supportive care for extensive small cell lung cancer. Cochrane Database of
11
12 Systematic Reviews 2013; (11).

13
14
15 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001990.pub3/abstract>
16
17
18 t.

19
20 231. Peng L, Min S, Zejun Z, et al. Spinal cord stimulation for cancer-related pain in
21
22 adults. Cochrane Database of Systematic Reviews 2015; (6).

23
24 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009389.pub3/abstract>
25
26
27 t.

28
29 232. Pepas L, Kaushik S, Nordin A, et al. Medical interventions for high-grade vulval
30
31 intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2015; (8).

32
33 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007924.pub3/abstract>
34
35
36 t.

37
38 233. Petersen Sune H, Harling H, Kirkeby Lene T, et al. Postoperative adjuvant
39
40 chemotherapy in rectal cancer operated for cure. Cochrane Database of
41
42 Systematic Reviews 2012; (3).

43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004078.pub2/abstract>
45
46
47 t.

48
49 234. Phillips Robert S, Friend Amanda J, Gibson F, et al. Antiemetic medication for
50
51 prevention and treatment of chemotherapy-induced nausea and vomiting in
52
53 childhood. Cochrane Database of Systematic Reviews 2016; (2).

54
55 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007786.pub3/abstract>
56
57
58 t.
59
60

- 1
2
3 235. Pidala J, Djulbegovic B, Anasetti C, et al. Allogeneic hematopoietic cell
4
5 transplantation for adult acute lymphoblastic leukemia (ALL) in first complete
6
7 remission. Cochrane Database of Systematic Reviews 2011; (10).
8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008818.pub2/abstract>
11
12
13 t.
- 14
15 236. Preston Nancy J, Hurlow A, Brine J, et al. Blood transfusions for anaemia in patients
16
17 with advanced cancer. Cochrane Database of Systematic Reviews 2012; (2).
18
19 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009007.pub2/abstract>
20
21
22 t.
- 23
24 237. Rai Bhavan P, Shelley M, Coles B, et al. Surgical management for upper urinary tract
25
26 transitional cell carcinoma. Cochrane Database of Systematic Reviews 2011; (4).
27
28 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007349.pub2/abstract>
29
30
31 t.
- 32
33 238. Rancea M, Monsef I, von Tresckow B, et al. High-dose chemotherapy followed by
34
35 autologous stem cell transplantation for patients with relapsed/refractory
36
37 Hodgkin lymphoma. Cochrane Database of Systematic Reviews 2013; (6).
38
39 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009411.pub2/abstract>
40
41
42 t.
- 43
44 239. Rao Ahsan M, Ahmed I. Laparoscopic versus open liver resection for benign and
45
46 malignant hepatic lesions in adults. Cochrane Database of Systematic Reviews
47
48 2013; (5).
49
50 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010162.pub2/abstract>
51
52
53 t.
- 54
55
56
57 240. Ratnavelu Nithya DG, Brown Andrew P, Mallett S, et al. Intraoperative frozen
58
59 section analysis for the diagnosis of early stage ovarian cancer in suspicious
60

1
2
3 pelvic masses. Cochrane Database of Systematic Reviews 2016; (3).

4 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010360.pub2/abstract>
5
6
7
8 t.

9
10 241. Reid J, Mills M, Cantwell M, et al. Thalidomide for managing cancer cachexia.

11
12 Cochrane Database of Systematic Reviews 2012; (4).

13 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008664.pub2/abstract>
14
15
16
17 t.

18
19 242. Renner P, Milazzo S, Liu Jian P, et al. Primary prophylactic colony-stimulating

20
21 factors for the prevention of chemotherapy-induced febrile neutropenia in breast
22
23 cancer patients. Cochrane Database of Systematic Reviews 2012; (10).

24
25 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007913.pub2/abstract>
26
27
28
29 t.

30
31 243. Resende Heloisa M, Jacob Luiz Felipe P, Quinellato Luciano V, et al. Combination

32
33 chemotherapy versus single-agent chemotherapy during preoperative

34
35 chemoradiation for resectable rectal cancer. Cochrane Database of Systematic
36
37 Reviews 2015; (10).

38
39 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008531.pub2/abstract>
40
41
42
43 t.

44
45 244. Reveiz L, Rueda J-R, Cardona Andrés F. Palliative endobronchial brachytherapy for

46
47 non-small cell lung cancer. Cochrane Database of Systematic Reviews 2012; (12).

48
49 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004284.pub3/abstract>
50
51
52
53 t.

54
55 245. Reveiz L, Rueda J-R, Cardona Andrés F. Chemotherapy for brain metastases from

56
57 small cell lung cancer. Cochrane Database of Systematic Reviews 2012; (6).

58
59
60

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007464.pub2/abstract>
4
5
6 t.

7
8 246. Riemsma Robert P, Bala Malgorzata M, Wolff R, et al. Percutaneous ethanol
9
10 injection for liver metastases. Cochrane Database of Systematic Reviews 2013;
11
12 (5).

13
14 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008717.pub2/abstract>
15
16
17 t.

18
19 247. Riemsma Robert P, Bala Malgorzata M, Wolff R, et al. Electro-coagulation for liver
20
21 metastases. Cochrane Database of Systematic Reviews 2013; (5).

22
23 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009497.pub2/abstract>
24
25
26 t.

27
28 248. Riemsma Robert P, Bala Malgorzata M, Wolff R, et al. Transarterial
29
30 (chemo)embolisation versus no intervention or placebo intervention for liver
31
32 metastases. Cochrane Database of Systematic Reviews 2013; (4).

33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009498.pub3/abstract>
35
36
37 t.

38
39 249. Riviere D, Gurusamy Kurinchi S, Kooby David A, et al. Laparoscopic versus open
40
41 distal pancreatectomy for pancreatic cancer. Cochrane Database of Systematic
42
43 Reviews 2016; (4).

44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011391.pub2/abstract>
46
47
48 t.

49
50 250. Rizzuto I, Behrens Renee F, Smith Lesley A. Risk of ovarian cancer in women treated
51
52 with ovarian stimulating drugs for infertility. Cochrane Database of Systematic
53
54 Reviews 2013; (8).

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008215.pub2/abstract>
4
5
6 t.

7
8 251. Robertson L, Yeoh Su E, Stansby G, et al. Effect of testing for cancer on cancer- and
9
10 venous thromboembolism (VTE)-related mortality and morbidity in patients
11
12 with unprovoked VTE. Cochrane Database of Systematic Reviews 2015; (3).

13
14
15 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010837.pub2/abstract>
16
17
18 t.

19
20 252. Rogers L, Siu Shing Shun N, Luesley D, et al. Radiotherapy and chemoradiation after
21
22 surgery for early cervical cancer. Cochrane Database of Systematic Reviews 2012;
23
24 (5).

25
26
27 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007583.pub3/abstract>
28
29
30 t.

31
32 253. Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Perioperative
33
34 chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of
35
36 the stomach, gastroesophageal junction, and lower esophagus. Cochrane
37
38 Database of Systematic Reviews 2013; (5).

39
40
41 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008107.pub2/abstract>
42
43
44 t.

45
46 254. Rooney Alasdair G, Grant R. Pharmacological treatment of depression in patients
47
48 with a primary brain tumour. Cochrane Database of Systematic Reviews 2013;
49
50 (5).

51
52
53 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006932.pub3/abstract>
54
55
56 t.

57
58 255. Roqué i Figuls M, Martinez-Zapata Maria J, Scott-Brown M, et al. Radioisotopes for
59
60 metastatic bone pain. Cochrane Database of Systematic Reviews 2011; (3).

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003347.pub3/abstract>
4
5
6 t.

7
8 256. Rosa D, Medeiros L, Edelweiss MI, et al. Adjuvant platinum-based chemotherapy for
9
10 early stage cervical cancer. Cochrane Database of Systematic Reviews 2012; (11).

11
12 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005342.pub4/abstract>
13
14
15 t.

16
17 257. Rueda J-R, Solà I, Pascual A, et al. Non-invasive interventions for improving well-
18
19 being and quality of life in patients with lung cancer. Cochrane Database of
20
21 Systematic Reviews 2011; (9).

22
23 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD004282.pub3/abstract>
24
25
26 t.

27
28
29 258. Rutten Marianne J, Leeflang Mariska MG, Kenter Gemma G, et al. Laparoscopy for
30
31 diagnosing resectability of disease in patients with advanced ovarian cancer.
32
33 Cochrane Database of Systematic Reviews 2014; (2).

34
35 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009786.pub2/abstract>
36
37
38 t.

39
40 259. Rydzewska L, Tierney J, Vale Claire L, et al. Neoadjuvant chemotherapy plus surgery
41
42 versus surgery for cervical cancer. Cochrane Database of Systematic Reviews
43
44 2012; (12).

45
46 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007406.pub3/abstract>
47
48
49 t.

50
51
52 260. Salhofer I, Will A, Monsef I, et al. Meditation for adults with haematological
53
54 malignancies. Cochrane Database of Systematic Reviews 2016; (2).

55
56 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011157.pub2/abstract>
57
58
59 t.

- 1
2
3 261. Samuel M, Khin Lay W, Brennan Victoria K, et al. Timing of breast surgery in
4
5 premenopausal breast cancer patients. Cochrane Database of Systematic Reviews
6
7 2011; (5).
8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003720.pub2/abstract>
11
12
13
14
15 262. Santos Fábio N, de Castria Tiago B, Cruz Marcelo RS, et al. Chemotherapy for
16
17 advanced non-small cell lung cancer in the elderly population. Cochrane Database
18
19 of Systematic Reviews 2015; (10).
20
21
22 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010463.pub2/abstract>
23
24
25
26
27 263. Sarmiento JM, Venteicher Andrew S, Patil Chirag G. Early versus delayed
28
29 postoperative radiotherapy for treatment of low-grade gliomas. Cochrane
30
31 Database of Systematic Reviews 2015; (6).
32
33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009229.pub2/abstract>
35
36
37
38
39 264. Scatchard K, Forrest Jennifer L, Flubacher M, et al. Chemotherapy for metastatic and
40
41 recurrent cervical cancer. Cochrane Database of Systematic Reviews 2012; (10).
42
43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006469.pub2/abstract>
45
46
47
48 265. Schaaf M, Reiser M, Borchmann P, et al. High-dose therapy with autologous stem
49
50 cell transplantation versus chemotherapy or immuno-chemotherapy for follicular
51
52 lymphoma in adults. Cochrane Database of Systematic Reviews 2012; (1).
53
54
55 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007678.pub2/abstract>
56
57
58
59
60

- 1
2
3 266. Schlaak M, Pickenhain J, Theurich S, et al. Allogeneic stem cell transplantation
4
5 versus conventional therapy for advanced primary cutaneous T-cell lymphoma.
6
7 Cochrane Database of Systematic Reviews 2013; (8).
8
9 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008908.pub3/abstract>
10
11
12
13
14
15 267. Schmidt-Hansen M, Baldwin David R, Hasler E, et al. PET-CT for assessing
16
17 mediastinal lymph node involvement in patients with suspected resectable non-
18
19 small cell lung cancer. Cochrane Database of Systematic Reviews 2014; (11).
20
21 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009519.pub2/abstract>
22
23
24
25
26
27 268. Schmidt-Hansen M, Bennett Michael I, Arnold S, et al. Oxycodone for cancer-related
28
29 pain. Cochrane Database of Systematic Reviews 2015; (2).
30
31 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003870.pub5/abstract>
32
33
34
35
36 269. Schmidt-Hansen M, Bromham N, Taubert M, et al. Buprenorphine for treating
37
38 cancer pain. Cochrane Database of Systematic Reviews 2015; (3).
39
40 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009596.pub4/abstract>
41
42
43
44
45 270. Schoot Reineke A, Kremer Leontien CM, van de Wetering Marianne D, et al.
46
47 Systemic treatments for the prevention of venous thrombo-embolic events in
48
49 paediatric cancer patients with tunnelled central venous catheters. Cochrane
50
51 Database of Systematic Reviews 2013; (9).
52
53 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009160.pub2/abstract>
54
55
56
57
58
59
60

- 1
2
3 271. Schoot Reineke A, van Dalen Elvira C, van Ommen Cornelia H, et al. Antibiotic and
4
5 other lock treatments for tunnelled central venous catheter-related infections in
6
7 children with cancer. Cochrane Database of Systematic Reviews 2013; (6).
8
9 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008975.pub2/abstract>
10
11
12
13
14
15 272. Scott David A, Mills M, Black A, et al. Multidimensional rehabilitation programmes
16
17 for adult cancer survivors. Cochrane Database of Systematic Reviews 2013; (3).
18
19 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007730.pub2/abstract>
20
21
22
23
24 273. Scott K, Hayden Patrick J, Will A, et al. Bortezomib for the treatment of multiple
25
26 myeloma. Cochrane Database of Systematic Reviews 2016; (4).
27
28 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010816.pub2/abstract>
29
30
31
32
33 274. Semple C, Parahoo K, Norman A, et al. Psychosocial interventions for patients with
34
35 head and neck cancer. Cochrane Database of Systematic Reviews 2013; (7).
36
37 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009441.pub2/abstract>
38
39
40
41
42
43 275. Shang Pan F, Kwong J, Wang Zhi P, et al. Intravesical Bacillus Calmette-Guérin
44
45 versus epirubicin for Ta and T1 bladder cancer. Cochrane Database of Systematic
46
47 Reviews 2011; (5).
48
49 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006885.pub2/abstract>
50
51
52
53
54 276. Sharif Fyeza NJ, Oliver R, Sweet C, et al. Interventions for the treatment of
55
56 keratocystic odontogenic tumours. Cochrane Database of Systematic Reviews
57
58 2015; (11).
59
60

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008464.pub3/abstract>
4
5
6 t.

7
8 277. Shelley M, Cleves A, Wilt Timothy J, et al. Gemcitabine for unresectable, locally
9
10 advanced or metastatic bladder cancer. Cochrane Database of Systematic
11
12 Reviews 2011; (4).

13
14 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008976.pub2/abstract>
15
16
17 t.

18
19 278. Shepherd Jonathan P, Frampton Geoff K, Harris P. Interventions for encouraging
20
21 sexual behaviours intended to prevent cervical cancer. Cochrane Database of
22
23 Systematic Reviews 2011; (4).

24
25 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001035.pub2/abstract>
26
27
28 t.

29
30 279. Shylasree TS, Bryant A, Athavale R. Chemotherapy and/or radiotherapy in
31
32 combination with surgery for ovarian carcinosarcoma. Cochrane Database of
33
34 Systematic Reviews 2013; (2).

35
36 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006246.pub2/abstract>
37
38
39 t.

40
41 280. Shylasree TS, Bryant A, Howells Robert EJ. Chemoradiation for advanced primary
42
43 vulval cancer. Cochrane Database of Systematic Reviews 2011; (4).

44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003752.pub3/abstract>
46
47
48 t.

49
50 281. Sickinger M-T, von Tresckow B, Kobe C, et al. Positron emission tomography-
51
52 adapted therapy for first-line treatment in individuals with Hodgkin lymphoma.
53
54 Cochrane Database of Systematic Reviews 2015; (1).

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010533.pub2/abstract>
4
5
6 t.

7
8 282. Skoetz N, Bauer K, Elter T, et al. Alemtuzumab for patients with chronic
9
10 lymphocytic leukaemia. Cochrane Database of Systematic Reviews 2012; (2).

11
12 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008078.pub2/abstract>
13
14
15 t.

16
17 283. Skoetz N, Bohlius J, Engert A, et al. Prophylactic antibiotics or G(M)-CSF for the
18
19 prevention of infections and improvement of survival in cancer patients receiving
20
21 myelotoxic chemotherapy. Cochrane Database of Systematic Reviews 2015; (12).

22
23 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007107.pub3/abstract>
24
25
26 t.

27
28
29 284. Smith Lesley A, Azariah F, Lavender Verna TC, et al. Cannabinoids for nausea and
30
31 vomiting in adults with cancer receiving chemotherapy. Cochrane Database of
32
33 Systematic Reviews 2015; (11).

34
35 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009464.pub2/abstract>
36
37
38 t.

39
40 285. Song H, Zhu J, Lu D. Long-term proton pump inhibitor (PPI) use and the
41
42 development of gastric pre-malignant lesions. Cochrane Database of Systematic
43
44 Reviews 2014; (12).

45
46 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010623.pub2/abstract>
47
48
49 t.

50
51
52 286. Soon Yu Y, Tham Ivan Weng K, Lim Keith H, et al. Surgery or radiosurgery plus
53
54 whole brain radiotherapy versus surgery or radiosurgery alone for brain
55
56 metastases. Cochrane Database of Systematic Reviews 2014; (3).

57
58
59
60

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009454.pub2/abstract>
4
5
6 t.

7
8 287. Spanjersberg Willem R, Reurings J, Keus F, et al. Fast track surgery versus
9
10 conventional recovery strategies for colorectal surgery. Cochrane Database of
11
12 Systematic Reviews 2011; (2).

13
14 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007635.pub2/abstract>
15
16
17 t.

18
19 288. Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ.
20
21 Cochrane Database of Systematic Reviews 2012; (10).

22
23 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007847.pub2/abstract>
24
25
26 t.

27
28 289. Stevens R, Macbeth F, Toy E, et al. Palliative radiotherapy regimens for patients
29
30 with thoracic symptoms from non-small cell lung cancer. Cochrane Database of
31
32 Systematic Reviews 2015; (1).

33
34 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002143.pub4/abstract>
35
36
37 t.

38
39 290. Straube C, Derry S, Jackson Kenneth C, et al. Codeine, alone and with paracetamol
40
41 (acetaminophen), for cancer pain. Cochrane Database of Systematic Reviews
42
43 2014; (9).

44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006601.pub4/abstract>
46
47
48 t.

49
50 291. Stuver Martijn M, ten Tusscher Marieke R, Agasi-Idenburg Carla S, et al.
51
52 Conservative interventions for preventing clinically detectable upper-limb
53
54 lymphoedema in patients who are at risk of developing lymphoedema after
55
56 breast cancer therapy. Cochrane Database of Systematic Reviews 2015; (2).
57
58
59
60

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009765.pub2/abstract>
4
5
6 t.

7
8 292. Taefi A, Abrishami A, Nasser-Moghaddam S, et al. Surgical resection versus liver
9
10 transplant for patients with hepatocellular carcinoma. Cochrane Database of
11
12 Systematic Reviews 2013; (6).

13
14
15 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006935.pub2/abstract>
16
17
18 t.

19
20 293. Tangjitgamol S, Katanyoo K, Laopaiboon M, et al. Adjuvant chemotherapy after
21
22 concurrent chemoradiation for locally advanced cervical cancer. Cochrane
23
24 Database of Systematic Reviews 2014; (12).

25
26
27 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010401.pub2/abstract>
28
29
30 t.

31
32 294. Theurich S, Fischmann H, Shimabukuro-Vornhagen A, et al. Polyclonal anti-
33
34 thymocyte globulins for the prophylaxis of graft-versus-host disease after
35
36 allogeneic stem cell or bone marrow transplantation in adults. Cochrane
37
38 Database of Systematic Reviews 2012; (9).

39
40
41 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009159.pub2/abstract>
42
43
44 t.

45
46 295. Thomson David R, Sadideen H, Furniss D. Wound drainage after axillary dissection
47
48 for carcinoma of the breast. Cochrane Database of Systematic Reviews 2013;
49
50 (10).

51
52
53 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006823.pub2/abstract>
54
55
56 t.

57
58 296. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with
59
60 cancer. Cochrane Database of Systematic Reviews 2012; (12).

1
2
3 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003407.pub5/abstract>
4
5
6 t.

7
8 297. Torres Maria FS, Porfirio Gustavo JM, Carvalho Alan PV, et al. Non-invasive positive
9
10 pressure ventilation for prevention of complications after pulmonary resection in
11
12 lung cancer patients. Cochrane Database of Systematic Reviews 2015; (9).

13
14
15 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010355.pub2/abstract>
16
17
18 t.

19
20 298. Tou S, Malik Ali I, Wexner Steven D, et al. Energy source instruments for
21
22 laparoscopic colectomy. Cochrane Database of Systematic Reviews 2011; (5).

23
24 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007886.pub2/abstract>
25
26
27 t.

28
29 299. Tsao May N, Lloyd N, Wong Rebecca KS, et al. Whole brain radiotherapy for the
30
31 treatment of newly diagnosed multiple brain metastases. Cochrane Database of
32
33 Systematic Reviews 2012; (4).

34
35
36 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003869.pub3/abstract>
37
38
39 t.

40
41 300. Tzellos T, Kyrgidis A, Mocellin S, et al. Interventions for melanoma in situ, including
42
43 lentigo maligna. Cochrane Database of Systematic Reviews 2014; (12).

44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010308.pub2/abstract>
46
47
48 t.

49
50 301. Vale Claire L, Tierney J, Bull Sarah J, et al. Chemotherapy for advanced, recurrent or
51
52 metastatic endometrial carcinoma. Cochrane Database of Systematic Reviews
53
54 2012; (8).

55
56
57 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003915.pub4/abstract>
58
59
60 t.

- 1
2
3 302. van Dalen Elvira C, Caron Huib N, Dickinson Heather O, et al. Cardioprotective
4
5 interventions for cancer patients receiving anthracyclines. Cochrane Database of
6
7 Systematic Reviews 2011; (6).
8
9 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003917.pub4/abstract>
10
11
12
13
14
15 303. van Dalen Elvira C, de Lijster Manou S, Leijssen Lieve GJ, et al. Minimally invasive
16
17 surgery versus open surgery for the treatment of solid abdominal and thoracic
18
19 neoplasms in children. Cochrane Database of Systematic Reviews 2015; (1).
20
21 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008403.pub3/abstract>
22
23
24
25
26
27 304. van Dalen Elvira C, Mank A, Leclercq E, et al. Low bacterial diet versus control diet
28
29 to prevent infection in cancer patients treated with chemotherapy causing
30
31 episodes of neutropenia. Cochrane Database of Systematic Reviews 2016; (4).
32
33 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006247.pub3/abstract>
34
35
36
37
38
39 305. van Dalen Elvira C, Raphaël Martine F, Caron Huib N, et al. Treatment including
40
41 anthracyclines versus treatment not including anthracyclines for childhood
42
43 cancer. Cochrane Database of Systematic Reviews 2014; (9).
44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006647.pub4/abstract>
46
47
48
49
50
51 306. van Dalen Elvira C, van As Jorrit W, de Camargo B. Methotrexate for high-grade
52
53 osteosarcoma in children and young adults. Cochrane Database of Systematic
54
55 Reviews 2011; (5).
56
57 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006325.pub3/abstract>
58
59
60

- 1
2
3 307. van Dalen Elvira C, van der Pal Helena JH, Kremer Leontien CM. Different dosage
4
5 schedules for reducing cardiotoxicity in people with cancer receiving
6
7 anthracycline chemotherapy. Cochrane Database of Systematic Reviews 2016;
8
9 (3).
10
11 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005008.pub4/abstract>
12
13
14
15
16
17 308. van de Wetering Fleur T, Verleye L, Andreyev HJN, et al. Non-surgical interventions
18
19 for late rectal problems (proctopathy) of radiotherapy in people who have
20
21 received radiotherapy to the pelvis. Cochrane Database of Systematic Reviews
22
23 2016; (4).
24
25 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003455.pub2/abstract>
26
27
28
29
30
31 309. van de Wetering Marianne D, van Woensel Job BM, Lawrie Theresa A. Prophylactic
32
33 antibiotics for preventing Gram positive infections associated with long-term
34
35 central venous catheters in oncology patients. Cochrane Database of Systematic
36
37 Reviews 2013; (11).
38
39 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003295.pub3/abstract>
40
41
42
43
44
45 310. van der Heijden E, Lopes Alberto D, Bryant A, et al. Follow-up strategies after
46
47 treatment (large loop excision of the transformation zone (LLETZ)) for cervical
48
49 intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test.
50
51 Cochrane Database of Systematic Reviews 2015; (1).
52
53 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010757.pub2/abstract>
54
55
56
57
58
59
60

- 1
2
3 311. van der Velden J, Fons G, Lawrie Theresa A. Primary groin irradiation versus
4
5 primary groin surgery for early vulvar cancer. Cochrane Database of Systematic
6
7 Reviews 2011; (5).
8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002224.pub2/abstract>
11
12
13 t.
- 14
15 312. Veeravagu A, Chang Steven D, Black Keith L, et al. Biopsy versus resection for the
16
17 management of low-grade gliomas. Cochrane Database of Systematic Reviews
18
19 2013; (4).
20
21
22 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009319.pub3/abstract>
23
24
25 t.
- 26
27 313. Vennix S, Pelzers L, Bouvy N, et al. Laparoscopic versus open total mesorectal
28
29 excision for rectal cancer. Cochrane Database of Systematic Reviews 2014; (4).
30
31
32 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005200.pub3/abstract>
33
34
35 t.
- 36
37 314. Vidal L, Ben dor I, Paul M, et al. Oral versus intravenous antibiotic treatment for
38
39 febrile neutropenia in cancer patients. Cochrane Database of Systematic Reviews
40
41 2013; (10).
42
43
44 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003992.pub3/abstract>
45
46
47 t.
- 48
49 315. Vidal L, Gafter-Gvili A, Gurion R, et al. Bendamustine for patients with indolent B
50
51 cell lymphoid malignancies including chronic lymphocytic leukaemia. Cochrane
52
53 Database of Systematic Reviews 2012; (9).
54
55
56 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009045.pub2/abstract>
57
58
59 t.
60

- 1
2
3 316. Vinceti M, Dennert G, Crespi Catherine M, et al. Selenium for preventing cancer.
4
5 Cochrane Database of Systematic Reviews 2014; (3).
6
7 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005195.pub3/abstract>
8
9
10
11
12 317. Wagner Anna D, Thomssen C, Haerting J, et al. Vascular-endothelial-growth-factor
13
14 (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast
15
16 cancer. Cochrane Database of Systematic Reviews 2012; (7).
17
18 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008941.pub2/abstract>
19
20
21
22
23
24 318. Walsh T, Liu Joseph LY, Brocklehurst P, et al. Clinical assessment to screen for the
25
26 detection of oral cavity cancer and potentially malignant disorders in apparently
27
28 healthy adults. Cochrane Database of Systematic Reviews 2013; (11).
29
30
31 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010173.pub2/abstract>
32
33
34
35
36 319. Wang Z, Chen J, Su K, et al. Abdominal drainage versus no drainage post-
37
38 gastrectomy for gastric cancer. Cochrane Database of Systematic Reviews 2015;
39
40 (5).
41
42 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008788.pub3/abstract>
43
44
45
46
47
48 320. Ward Evelyn J, Henry Lisa M, Friend Amanda J, et al. Nutritional support in children
49
50 and young people with cancer undergoing chemotherapy. Cochrane Database of
51
52 Systematic Reviews 2015; (8).
53
54 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003298.pub3/abstract>
55
56
57
58
59
60

- 1
2
3 321. Warner L, Chudasama J, Kelly Charles G, et al. Radiotherapy versus open surgery
4
5 versus endolaryngeal surgery (with or without laser) for early laryngeal
6
7 squamous cell cancer. Cochrane Database of Systematic Reviews 2014; (12).
8
9 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD002027.pub2/abstract>
10
11
12
13 t.
- 14
15 322. Weberschock T, Strametz R, Lorenz M, et al. Interventions for mycosis fungoides.
16
17 Cochrane Database of Systematic Reviews 2012; (9).
18
19 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008946.pub2/abstract>
20
21
22
23 t.
- 24
25 323. Wei Mao L, Kang D, Gu L, et al. Chemotherapy for thymic carcinoma and advanced
26
27 thymoma in adults. Cochrane Database of Systematic Reviews 2013; (8).
28
29 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008588.pub2/abstract>
30
31
32
33 t.
- 34
35 324. Weis S, Franke A, Berg T, et al. Percutaneous ethanol injection or percutaneous
36
37 acetic acid injection for early hepatocellular carcinoma. Cochrane Database of
38
39 Systematic Reviews 2015; (1).
40
41 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006745.pub3/abstract>
42
43
44
45 t.
- 46
47 325. Weis S, Franke A, Mössner J, et al. Radiofrequency (thermal) ablation versus no
48
49 intervention or other interventions for hepatocellular carcinoma. Cochrane
50
51 Database of Systematic Reviews 2013; (12).
52
53 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003046.pub3/abstract>
54
55
56
57 t.
- 58
59 326. Weitz M, Strahm B, Meerpohl Joerg J, et al. Extracorporeal photopheresis versus
60
61 alternative treatment for chronic graft-versus-host disease after haematopoietic

1
2
3 stem cell transplantation in paediatric patients. Cochrane Database of Systematic
4
5 Reviews 2015; (12).

6
7 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009898.pub3/abstract>
8
9
10 t.

11
12 327. Weitz M, Strahm B, Meerpohl Joerg J, et al. Extracorporeal photopheresis versus
13
14 standard treatment for acute graft-versus-host disease after haematopoietic stem
15
16 cell transplantation in paediatric patients. Cochrane Database of Systematic
17
18 Reviews 2015; (12).

19
20
21 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009759.pub3/abstract>
22
23
24 t.

25
26 328. Wiffen Philip J, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or
27
28 codeine on patient consciousness, appetite and thirst when used to treat cancer
29
30 pain. Cochrane Database of Systematic Reviews 2014; (5).

31
32
33 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011056.pub2/abstract>
34
35
36 t.

37
38 329. Wiffen Philip J, Derry S, Naessens K, et al. Oral tapentadol for cancer pain. Cochrane
39
40 Database of Systematic Reviews 2015; (9).

41
42
43 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD011460.pub2/abstract>
44
45
46 t.

47
48 330. Wiffen Philip J, Wee B, Moore RA. Oral morphine for cancer pain. Cochrane
49
50 Database of Systematic Reviews 2016; (4).

51
52
53 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003868.pub4/abstract>
54
55
56 t.

57
58 331. Wiggins Alison J, Cass Gemma KS, Bryant A, et al. Poly(ADP-ribose) polymerase
59
60 (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database of

1
2
3 Systematic Reviews 2015; (5).

4 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007929.pub3/abstract>
5
6
7
8 t.

9
10 332. Williams C, Bryant A. Short versus long duration infusions of paclitaxel for any
11
12 advanced adenocarcinoma. Cochrane Database of Systematic Reviews 2011; (5).

13 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003911.pub2/abstract>
14
15
16
17 t.

18
19 333. Wolf E, Milazzo S, Boehm K, et al. Thymic peptides for treatment of cancer patients.
20
21 Cochrane Database of Systematic Reviews 2011; (2).

22 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003993.pub3/abstract>
23
24
25
26 t.

27
28
29 334. Wong Matthew HF, Stockler Martin R, Pavlakis N. Bisphosphonates and other bone
30
31 agents for breast cancer. Cochrane Database of Systematic Reviews 2012; (2).

32 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003474.pub3/abstract>
33
34
35
36 t.

37
38 335. Woo Yin L, Kyrgiou M, Bryant A, et al. Centralisation of services for gynaecological
39
40 cancer. Cochrane Database of Systematic Reviews 2012; (3).

41 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007945.pub2/abstract>
42
43
44
45 t.

46
47 336. Worthington Helen V, Clarkson Jan E, Bryan G, et al. Interventions for preventing
48
49 oral mucositis for patients with cancer receiving treatment. Cochrane Database of
50
51 Systematic Reviews 2011; (4).

52 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD000978.pub5/abstract>
53
54
55
56
57 t.

- 1
2
3 337. Wulaningsih W, Wardhana A, Watkins J, et al. Irinotecan chemotherapy combined
4
5 with fluoropyrimidines versus irinotecan alone for overall survival and
6
7 progression-free survival in patients with advanced and/or metastatic colorectal
8
9 cancer. Cochrane Database of Systematic Reviews 2016; (2).
10
11 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008593.pub3/abstract>
12
13
14
15 t.
- 16
17 338. Yalçın B, Kremer Leontien CM, van Dalen Elvira C. High-dose chemotherapy and
18
19 autologous haematopoietic stem cell rescue for children with high-risk
20
21 neuroblastoma. Cochrane Database of Systematic Reviews 2015; (10).
22
23 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006301.pub4/abstract>
24
25
26
27 t.
- 28
29 339. Yang J, Zhu L, Wu Z, et al. Chinese herbal medicines for induction of remission in
30
31 advanced or late gastric cancer. Cochrane Database of Systematic Reviews 2013;
32
33 (4).
34
35 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005096.pub4/abstract>
36
37
38
39 t.
- 40
41 340. Yang S, Wu S, Huang Y, et al. Screening for oesophageal cancer. Cochrane Database
42
43 of Systematic Reviews 2012; (12).
44
45 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007883.pub2/abstract>
46
47
48
49 t.
- 50
51 341. Yang S, Wu S, Zhou J, et al. Screening for nasopharyngeal cancer. Cochrane Database
52
53 of Systematic Reviews 2015; (11).
54
55 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008423.pub2/abstract>
56
57
58
59
60 t.

- 1
2
3 342. Yang Z-Y, Liu L, Mao C, et al. Chemotherapy with cetuximab versus chemotherapy
4 alone for chemotherapy-naive advanced non-small cell lung cancer. Cochrane
5 Database of Systematic Reviews 2014; (11).
6
7
8
9
10 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009948.pub2/abstract>
11
12
13
14
15 343. Yuan Y, Zeng X, Hu Y, et al. Omentoplasty for oesophagostomy after
16 oesophagectomy. Cochrane Database of Systematic Reviews 2014; (10).
17
18
19 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008446.pub3/abstract>
20
21
22
23
24 344. Zacher J, Kasenda B, Engert A, et al. The role of additional radiotherapy for primary
25 central nervous system lymphoma. Cochrane Database of Systematic Reviews
26 2014; (6).
27
28
29
30
31 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009211.pub2/abstract>
32
33
34
35
36 345. Zani Emerson L, Clark Otavio Augusto C, Rodrigues Netto Jr N. Antibiotic
37 prophylaxis for transrectal prostate biopsy. Cochrane Database of Systematic
38 Reviews 2011; (5).
39
40
41
42 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006576.pub2/abstract>
43
44
45
46
47
48 346. Zhong Jian H, Li Le Q, Wu Liu C. Lamivudine with or without adefovir
49 dipivoxil for postoperative hepatocellular carcinoma. Cochrane Database of
50 Systematic Reviews 2011; (12).
51 <http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008713.pub2/abstract>
52
53
54
55

56 *High impact journal SRs*
57
58
59
60

- 1
2
3 1. Menarche, menopause, and breast cancer risk: individual participant meta-analysis,
4 including 118 964 women with breast cancer from 117 epidemiological studies. The
5
6 Lancet Oncology 2012;13(11):1141-51.
7
8
9
- 10
11 2. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and
12
13 meta-analysis of individual participant data. Lancet (London, England)
14
15 2014;383(9928):1561-71.
16
17
- 18
19 3. Endometrial cancer and oral contraceptives: an individual participant meta-analysis
20
21 of 27 276 women with endometrial cancer from 36 epidemiological studies. The Lancet
22
23 Oncology 2015;16(9):1061-70.
24
25
- 26
27 4. Ahmed M, Purushotham AD, Douek M. Novel techniques for sentinel lymph node
28
29 biopsy in breast cancer: a systematic review. The Lancet Oncology 2014;15(8):e351-62.
30
31
- 32
33 5. Al Khabori M, de Almeida JR, Guyatt GH, et al. Autologous stem cell transplantation in
34
35 follicular lymphoma: a systematic review and meta-analysis. Journal of the National
36
37 Cancer Institute 2012;104(1):18-28.
38
39
- 40
41 6. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and
42
43 metastasis: a systematic comparison of evidence from observational studies versus
44
45 randomised trials. The Lancet Oncology 2012;13(5):518-27.
46
47
- 48
49 7. Amir E, Seruga B, Niraula S, et al. Toxicity of adjuvant endocrine therapy in
50
51 postmenopausal breast cancer patients: a systematic review and meta-analysis. Journal
52
53 of the National Cancer Institute 2011;103(17):1299-309.
54
55
56
57
58
59
60

- 1
2
3 8. Arbyn M, Verdoodt F, Snijders PJ, et al. Accuracy of human papillomavirus testing on
4 self-collected versus clinician-collected samples: a meta-analysis. *The Lancet Oncology*
5
6 2014;15(2):172-83.
7
8
9
- 10
11 9. Aune D, Chan DS, Lau R, et al. Dietary fibre, whole grains, and risk of colorectal cancer:
12 systematic review and dose-response meta-analysis of prospective studies. *BMJ (Clinical*
13
14 research ed) 2011;343:d6617.
15
16
17
- 18
19 10. Bach, Smith-Bindman R, Wood DE, et al. Benefits and harms of CT screening for lung
20 cancer: a systematic review. *Jama* 2012;307(22):2418-29.
21
22
23
- 24
25 11. Baldwin C, Spiro A, Ahern R, et al. Oral nutritional interventions in malnourished
26 patients with cancer: a systematic review and meta-analysis. *Journal of the National*
27
28 Cancer Institute 2012;104(5):371-85.
29
30
31
- 32
33 12. Ballard-Barbash R, Friedenreich CM, Courneya KS, et al. Physical activity,
34 biomarkers, and disease outcomes in cancer survivors: a systematic review. *Journal of*
35
36 the National Cancer Institute 2012;104(11):815-40.
37
38
39
- 40
41 13. Bangalore S, Kumar S, Kjeldsen SE, et al. Antihypertensive drugs and risk of cancer:
42 network meta-analyses and trial sequential analyses of 324,168 participants from
43
44 randomised trials. *The Lancet Oncology* 2011;12(1):65-82.
45
46
47
- 48
49 14. Bao Y, Michaud DS, Spiegelman D, et al. Folate intake and risk of pancreatic cancer:
50 pooled analysis of prospective cohort studies. *Journal of the National Cancer Institute*
51
52 2011;103(24):1840-50.
53
54
55
56
57
58
59
60

- 1
2
3 15. Beral V, Gaitskell K, Hermon C, et al. Ovarian cancer and smoking: individual
4 participant meta-analysis including 28,114 women with ovarian cancer from 51
5 epidemiological studies. *The Lancet Oncology* 2012;13(9):946-56.
6
7
8
9
10
11 16. Beral V, Gaitskell K, Hermon C, et al. Menopausal hormone use and ovarian cancer
12 risk: individual participant meta-analysis of 52 epidemiological studies. *Lancet (London,*
13 *England)* 2015;385(9980):1835-42.
14
15
16
17
18
19 17. Biagi JJ, Raphael MJ, Mackillop WJ, et al. Association between time to initiation of
20 adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-
21 analysis. *Jama* 2011;305(22):2335-42.
22
23
24
25
26
27 18. Blanchard P, Bourhis J, Lacas B, et al. Taxane-cisplatin-fluorouracil as induction
28 chemotherapy in locally advanced head and neck cancers: an individual patient data
29 meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group.
30 *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
31 2013;31(23):2854-60.
32
33
34
35
36
37
38
39
40 19. Blanchard P, Lee A, Marguet S, et al. Chemotherapy and radiotherapy in
41 nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. *The Lancet*
42 *Oncology* 2015;16(6):645-55.
43
44
45
46
47
48 20. Blanke CD, Bot BM, Thomas DM, et al. Impact of young age on treatment efficacy and
49 safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line
50 phase III chemotherapy trials. *Journal of clinical oncology : official journal of the*
51 *American Society of Clinical Oncology* 2011;29(20):2781-6.
52
53
54
55
56
57
58 21. Blumenthal GM, Karuri SW, Zhang H, et al. Overall response rate, progression-free
59 survival, and overall survival with targeted and standard therapies in advanced non-
60

1
2
3 small-cell lung cancer: US Food and Drug Administration trial-level and patient-level
4 analyses. *Journal of clinical oncology : official journal of the American Society of Clinical*
5
6
7
8 *Oncology* 2015;33(9):1008-14.
9

10
11 22. Boehmer U, Cooley TP, Clark MA. Cancer and men who have sex with men: a
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

systematic review. *The Lancet Oncology* 2012;13(12):e545-53.

23. Bolton KL, Chenevix-Trench G, Goh C, et al. Association between BRCA1 and BRCA2
mutations and survival in women with invasive epithelial ovarian cancer. *Jama*
2012;307(4):382-90.

24. Boniol M, Autier P, Boyle P, et al. Cutaneous melanoma attributable to sunbed use:
systematic review and meta-analysis. *BMJ (Clinical research ed)* 2012;345:e4757.

25. Bourhis J, Blanchard P, Maillard E, et al. Effect of amifostine on survival among
patients treated with radiotherapy: a meta-analysis of individual patient data. *Journal of*
clinical oncology : official journal of the American Society of Clinical Oncology
2011;29(18):2590-7.

26. Bowers DC, Nathan PC, Constine L, et al. Subsequent neoplasms of the CNS among
survivors of childhood cancer: a systematic review. *The Lancet Oncology*
2013;14(8):e321-8.

27. Boyle T, Keegel T, Bull F, et al. Physical activity and risks of proximal and distal colon
cancers: a systematic review and meta-analysis. *Journal of the National Cancer Institute*
2012;104(20):1548-61.

- 1
2
3 28. Brasme JF, Morfouace M, Grill J, et al. Delays in diagnosis of paediatric cancers: a
4 systematic review and comparison with expert testimony in lawsuits. *The Lancet*
5
6
7
8 *Oncology* 2012;13(10):e445-59.
9
10
11 29. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening
12
13
14
15
16
17
18
19
20
21
22 30. Breugom AJ, Swets M, Bosset JF, et al. Adjuvant chemotherapy after preoperative
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
30. Breugom AJ, Swets M, Bosset JF, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. *The Lancet Oncology* 2015;16(2):200-7.
31. Brinton LA, Cook MB, McCormack V, et al. Anthropometric and hormonal risk factors for male breast cancer: male breast cancer pooling project results. *Journal of the National Cancer Institute* 2014;106(3):djt465.
32. Castellsague X, Diaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. *The Lancet Oncology* 2011;12(11):1023-31.
33. Castillo JJ, Dalia S, Shum H. Meta-analysis of the association between cigarette smoking and incidence of Hodgkin's Lymphoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2011;29(29):3900-6.
34. Chatzinasiou F, Lill CM, Kypreou K, et al. Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. *Journal of the National Cancer Institute* 2011;103(16):1227-35.

- 1
2
3 35. Chellapandian D, Lehrnbecher T, Phillips B, et al. Bronchoalveolar lavage and lung
4 biopsy in patients with cancer and hematopoietic stem-cell transplantation recipients: a
5 systematic review and meta-analysis. *Journal of clinical oncology : official journal of the*
6
7
8
9
10 American Society of Clinical Oncology 2015;33(5):501-9.
11
12
13 36. Chen LS, Hung RJ, Baker T, et al. CHRNA5 risk variant predicts delayed smoking
14 cessation and earlier lung cancer diagnosis--a meta-analysis. *Journal of the National*
15
16
17
18
19
20
21
22 37. Choueiri TK, Mayer EL, Je Y, et al. Congestive heart failure risk in patients with breast
23 cancer treated with bevacizumab. *Journal of clinical oncology : official journal of the*
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
60 38. Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific
death: systematic review and meta-analysis of observational cohort and randomised
intervention studies. *BMJ (Clinical research ed)* 2014;348:g1903.
39. Church DN, Stelloo E, Nout RA, et al. Prognostic significance of POLE proofreading
mutations in endometrial cancer. *Journal of the National Cancer Institute*
2015;107(1):402.
40. Coleman R, Powles T, Paterson A, et al. Adjuvant bisphosphonate treatment in early
breast cancer: meta-analyses of individual patient data from randomised trials. *Lancet*
(London, England) 2015;386(10001):1353-61.
41. Collins M, Wilhelm M, Conyers R, et al. Benefits and adverse events in younger versus
older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a
meta-analysis. *Journal of clinical oncology : official journal of the American Society of*
Clinical Oncology 2013;31(18):2303-12.

- 1
2
3 42. Coory M, White VM, Johnson KS, et al. Systematic review of quality improvement
4
5 interventions directed at cancer specialists. *Journal of clinical oncology : official journal*
6
7 *of the American Society of Clinical Oncology* 2013;31(12):1583-91.
8
9
10
11 43. Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term
12
13 clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet (London, England)*
14
15 2014;384(9938):164-72.
16
17
18
19 44. Crowe FL, Appleby PN, Travis RC, et al. Circulating fatty acids and prostate cancer
20
21 risk: individual participant meta-analysis of prospective studies. *Journal of the National*
22
23 *Cancer Institute* 2014;106(9).
24
25
26
27 45. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in
28
29 prevention of breast cancer: an updated meta-analysis of individual participant data.
30
31 *Lancet (London, England)* 2013;381(9880):1827-34.
32
33
34
35 46. Dabestani S, Marconi L, Hofmann F, et al. Local treatments for metastases of renal
36
37 cell carcinoma: a systematic review. *The Lancet Oncology* 2014;15(12):e549-61.
38
39
40
41 47. D'Amico AV, Chen MH, de Castro M, et al. Surrogate endpoints for prostate cancer-
42
43 specific mortality after radiotherapy and androgen suppression therapy in men with
44
45 localised or locally advanced prostate cancer: an analysis of two randomised trials. *The*
46
47 *Lancet Oncology* 2012;13(2):189-95.
48
49
50
51 48. Darby S, McGale P, Correa C, et al. Effect of radiotherapy after breast-conserving
52
53 surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of
54
55 individual patient data for 10,801 women in 17 randomised trials. *Lancet (London,*
56
57 *England)* 2011;378(9804):1707-16.
58
59
60

- 1
2
3 49. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and
4
5 other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of
6
7 randomised trials. *Lancet (London, England)* 2011;378(9793):771-84.
8
9
10
11 50. de Jong MC, Kors WA, de Graaf P, et al. Trilateral retinoblastoma: a systematic review
12
13 and meta-analysis. *The Lancet Oncology* 2014;15(10):1157-67.
14
15
16
17 51. De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative
18
19 stimulation brain mapping on glioma surgery outcome: a meta-analysis. *Journal of*
20
21 *clinical oncology : official journal of the American Society of Clinical Oncology*
22
23 2012;30(20):2559-65.
24
25
26
27 52. Deppen SA, Blume JD, Kensinger CD, et al. Accuracy of FDG-PET to diagnose lung
28
29 cancer in areas with infectious lung disease: a meta-analysis. *Jama* 2014;312(12):1227-
30
31 36.
32
33
34
35 53. Di Leo A, Desmedt C, Bartlett JM, et al. HER2 and TOP2A as predictive markers for
36
37 anthracycline-containing chemotherapy regimens as adjuvant treatment of breast
38
39 cancer: a meta-analysis of individual patient data. *The Lancet Oncology*
40
41 2011;12(12):1134-42.
42
43
44
45 54. DiSipio T, Rye S, Newman B, et al. Incidence of unilateral arm lymphoedema after
46
47 breast cancer: a systematic review and meta-analysis. *The Lancet Oncology*
48
49 2013;14(6):500-15.
50
51
52
53 55. dos Santos LV, Souza FH, Brunetto AT, et al. Neurokinin-1 receptor antagonists for
54
55 chemotherapy-induced nausea and vomiting: a systematic review. *Journal of the*
56
57 *National Cancer Institute* 2012;104(17):1280-92.
58
59
60

- 1
2
3 56. Dowsett M, Forbes JF, Bradley R, et al. Aromatase inhibitors versus tamoxifen in
4 early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet*
5
6 (London, England) 2015;386(10001):1341-52.
7
8
9
10
11 57. Eisen T, Sternberg CN, Robert C, et al. Targeted therapies for renal cell carcinoma:
12 review of adverse event management strategies. *Journal of the National Cancer Institute*
13
14 2012;104(2):93-113.
15
16
17
18
19 58. Eliassen AH, Hendrickson SJ, Brinton LA, et al. Circulating carotenoids and risk of
20 breast cancer: pooled analysis of eight prospective studies. *Journal of the National*
21
22 *Cancer Institute* 2012;104(24):1905-16.
23
24
25
26
27 59. Engelhardt EG, Garvelink MM, de Haes JH, et al. Predicting and communicating the
28 risk of recurrence and death in women with early-stage breast cancer: a systematic
29 review of risk prediction models. *Journal of clinical oncology : official journal of the*
30
31 *American Society of Clinical Oncology* 2014;32(3):238-50. doi:
32
33 10.1200/jco.2013.50.3417
34
35
36
37
38
39
40 60. Faller H, Schuler M, Richard M, et al. Effects of psycho-oncologic interventions on
41 emotional distress and quality of life in adult patients with cancer: systematic review
42 and meta-analysis. *Journal of clinical oncology : official journal of the American Society*
43
44 *of Clinical Oncology* 2013;31(6):782-93.
45
46
47
48
49
50 61. Fokom-Domgue J, Combescure C, Fokom-Defo V, et al. Performance of alternative
51 strategies for primary cervical cancer screening in sub-Saharan Africa: systematic
52 review and meta-analysis of diagnostic test accuracy studies. *BMJ (Clinical research ed)*
53
54 2015;351:h3084.
55
56
57
58
59
60

1
2
3 62. Fong DY, Ho JW, Hui BP, et al. Physical activity for cancer survivors: meta-analysis of
4
5 randomised controlled trials. *BMJ (Clinical research ed)* 2012;344:e70.
6
7

8
9 63. Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to
10
11 prevent gastric cancer in healthy asymptomatic infected individuals: systematic review
12
13 and meta-analysis of randomised controlled trials. *BMJ (Clinical research ed)*
14
15 2014;348:g3174.
16
17

18
19 64. Freese KE, Kokai L, Edwards RP, et al. Adipose-derived stems cells and their role in
20
21 human cancer development, growth, progression, and metastasis: a systematic review.
22
23 *Cancer research* 2015;75(7):1161-8.
24
25

26
27 65. Friebel TM, Domchek SM, Rebbeck TR. Modifiers of cancer risk in BRCA1 and BRCA2
28
29 mutation carriers: systematic review and meta-analysis. *Journal of the National Cancer*
30
31 *Institute* 2014;106(6):dju091.
32
33

34
35 66. Garcia MK, McQuade J, Haddad R, et al. Systematic review of acupuncture in cancer
36
37 care: a synthesis of the evidence. *Journal of clinical oncology : official journal of the*
38
39 *American Society of Clinical Oncology* 2013;31(7):952-60.
40
41

42
43 67. Gardner JR, Livingston PM, Fraser SF. Effects of exercise on treatment-related
44
45 adverse effects for patients with prostate cancer receiving androgen-deprivation
46
47 therapy: a systematic review. *Journal of clinical oncology : official journal of the*
48
49 *American Society of Clinical Oncology* 2014;32(4):335-46.
50
51

52
53 68. Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic
54
55 breast cancer: a systematic review and meta-analysis of randomized clinical trials.
56
57 *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
58
59 2011;29(16):2144-9.
60

- 1
2
3 69. Ghesquieres H, Slager SL, Jardin F, et al. Genome-Wide Association Study of Event-
4 Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
5 Journal of clinical oncology : official journal of the American Society of Clinical Oncology
6 2015;33(33):3930-7.
7
8
9
10
11
12
13 70. Greco MT, Roberto A, Corli O, et al. Quality of cancer pain management: an update of
14 a systematic review of undertreatment of patients with cancer. Journal of clinical
15 oncology : official journal of the American Society of Clinical Oncology
16 2014;32(36):4149-54.
17
18
19
20
21
22
23 71. Green J, Cairns BJ, Casabonne D, et al. Height and cancer incidence in the Million
24 Women Study: prospective cohort, and meta-analysis of prospective studies of height
25 and total cancer risk. The Lancet Oncology 2011;12(8):785-94.
26
27
28
29
30
31
32 72. Gupta S, Hunsberger S, Boerner SA, et al. Meta-analysis of the relationship between
33 dose and benefit in phase I targeted agent trials. Journal of the National Cancer Institute
34 2012;104(24):1860-6.
35
36
37
38
39
40 73. Hamaker ME, Jonker JM, de Rooij SE, et al. Frailty screening methods for predicting
41 outcome of a comprehensive geriatric assessment in elderly patients with cancer: a
42 systematic review. The Lancet Oncology 2012;13(10):e437-44.
43
44
45
46
47
48 74. Hart SL, Hoyt MA, Diefenbach M, et al. Meta-analysis of efficacy of interventions for
49 elevated depressive symptoms in adults diagnosed with cancer. Journal of the National
50 Cancer Institute 2012;104(13):990-1004.
51
52
53
54
55
56 75. Hayes JH, Barry MJ. Screening for prostate cancer with the prostate-specific antigen
57 test: a review of current evidence. Jama 2014;311(11):1143-9.
58
59
60

1
2
3 76. Heikkila K, Nyberg ST, Theorell T, et al. Work stress and risk of cancer: meta-analysis
4
5 of 5700 incident cancer events in 116,000 European men and women. *BMJ (Clinical*
6
7 *research ed)* 2013;346:f165.
8
9

10
11 77. Heine JJ, Scott CG, Sellers TA, et al. A novel automated mammographic density
12
13 measure and breast cancer risk. *Journal of the National Cancer Institute*
14
15 2012;104(13):1028-37.
16
17

18
19 78. Heleno B, Thomsen MF, Rodrigues DS, et al. Quantification of harms in cancer
20
21 screening trials: literature review. *BMJ (Clinical research ed)* 2013;347:f5334.
22
23

24
25 79. Henson KE, Jagsi R, Cutter D, et al. Inferring the Effects of Cancer Treatment:
26
27 Divergent Results From Early Breast Cancer Trialists' Collaborative Group Meta-
28
29 Analyses of Randomized Trials and Observational Data From SEER Registries. *Journal of*
30
31 *clinical oncology : official journal of the American Society of Clinical Oncology* 2016.
32
33

34
35 80. Henson LA, Gao W, Higginson IJ, et al. Emergency department attendance by patients
36
37 with cancer in their last month of life: a systematic review and meta-analysis. *Journal of*
38
39 *clinical oncology : official journal of the American Society of Clinical Oncology*
40
41 2015;33(4):370-6.
42
43

44
45 81. Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to
46
47 induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis
48
49 of individual patient data from randomised controlled trials. *The Lancet Oncology*
50
51 2014;15(9):986-96.
52
53

54
55 82. Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant
56
57 pleural mesothelioma: an individual patient data meta-analysis. *Journal of clinical*
58
59
60

1
2
3 oncology : official journal of the American Society of Clinical Oncology
4
5 2012;30(13):1541-9.
6
7

8
9 83. Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract
10
11 cancer: a systematic review and meta-analysis. Journal of clinical oncology : official
12
13 journal of the American Society of Clinical Oncology 2012;30(16):1934-40.
14
15

16
17 84. Hornberger J, Alvarado MD, Rebecca C, et al. Clinical validity/utility, change in
18
19 practice patterns, and economic implications of risk stratifiers to predict outcomes for
20
21 early-stage breast cancer: a systematic review. Journal of the National Cancer Institute
22
23 2012;104(14):1068-79.
24
25

26
27 85. Horowitz NA, Benyamini N, Wohlfart K, et al. Reproductive organ involvement in
28
29 non-Hodgkin lymphoma during pregnancy: a systematic review. The Lancet Oncology
30
31 2013;14(7):e275-82.
32
33

34
35 86. Houssami N, Turner R, Macaskill P, et al. An individual person data meta-analysis of
36
37 preoperative magnetic resonance imaging and breast cancer recurrence. Journal of
38
39 clinical oncology : official journal of the American Society of Clinical Oncology
40
41 2014;32(5):392-401.
42
43

44
45 87. Howard-Anderson J, Ganz PA, Bower JE, et al. Quality of life, fertility concerns, and
46
47 behavioral health outcomes in younger breast cancer survivors: a systematic review.
48
49 Journal of the National Cancer Institute 2012;104(5):386-405.
50
51

52
53 88. Hurwitz HI, Saltz LB, Van Cutsem E, et al. Venous thromboembolic events with
54
55 chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II
56
57 and III studies. Journal of clinical oncology : official journal of the American Society of
58
59 Clinical Oncology 2011;29(13):1757-64.
60

- 1
2
3 89. Jenkins MA, Dowty JG, Ait Ouakrim D, et al. Short-term risk of colorectal cancer in
4 individuals with lynch syndrome: a meta-analysis. *Journal of clinical oncology : official*
5
6 *journal of the American Society of Clinical Oncology* 2015;33(4):326-31.
7
8
9
10
11 90. Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast
12 cancer survivors previously treated with standard-dose chemotherapy. *Journal of*
13
14 *clinical oncology : official journal of the American Society of Clinical Oncology*
15
16 2012;30(29):3578-87.
17
18
19
20
21 91. Joensuu H, Vehtari A, Riihimaki J, et al. Risk of recurrence of gastrointestinal stromal
22 tumour after surgery: an analysis of pooled population-based cohorts. *The Lancet*
23
24 *Oncology* 2012;13(3):265-74.
25
26
27
28
29 92. Jung S, Spiegelman D, Baglietto L, et al. Fruit and vegetable intake and risk of breast
30 cancer by hormone receptor status. *Journal of the National Cancer Institute*
31
32 2013;105(3):219-36.
33
34
35
36
37 93. Kamangar F, Shakeri R, Malekzadeh R, et al. Opium use: an emerging risk factor for
38 cancer? *The Lancet Oncology* 2014;15(2):e69-77.
39
40
41
42
43 94. Keum N, Greenwood DC, Lee DH, et al. Adult weight gain and adiposity-related
44 cancers: a dose-response meta-analysis of prospective observational studies. *Journal of*
45
46 *the National Cancer Institute* 2015;107(2).
47
48
49
50
51 95. Kiely BE, Soon YY, Tattersall MH, et al. How long have I got? Estimating typical, best-
52 case, and worst-case scenarios for patients starting first-line chemotherapy for
53
54 metastatic breast cancer: a systematic review of recent randomized trials. *Journal of*
55
56 *clinical oncology : official journal of the American Society of Clinical Oncology*
57
58 2011;29(4):456-63.
59
60

- 1
2
3 96. Knoll GA, Kokolo MB, Mallick R, et al. Effect of sirolimus on malignancy and survival
4 after kidney transplantation: systematic review and meta-analysis of individual patient
5 data. *BMJ (Clinical research ed)* 2014;349:g6679.
6
7
8
9
10
11 97. Kolaheer F, Jang SL, Corriveau A, et al. Knowledge, attitudes, and behaviours
12 towards cancer screening in indigenous populations: a systematic review. *The Lancet*
13 *Oncology* 2014;15(11):e504-16.
14
15
16
17
18
19 98. Kong A, Johnson N, Kitchener HC, et al. Adjuvant radiotherapy for stage I endometrial
20 cancer: an updated Cochrane systematic review and meta-analysis. *Journal of the*
21 *National Cancer Institute* 2012;104(21):1625-34.
22
23
24
25
26
27 99. Kotecha RS, Pascoe EM, Rushing EJ, et al. Meningiomas in children and adolescents: a
28 meta-analysis of individual patient data. *The Lancet Oncology* 2011;12(13):1229-39.
29
30
31
32
33 100. Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of
34 patient-reported outcome measures toward improvement of patient outcomes,
35 processes of care, and health service outcomes in cancer care? A systematic review of
36 controlled trials. *Journal of clinical oncology : official journal of the American Society of*
37 *Clinical Oncology* 2014;32(14):1480-501.
38
39
40
41
42
43
44
45 101. Kubben PL, ter Meulen KJ, Schijns OE, et al. Intraoperative MRI-guided resection of
46 glioblastoma multiforme: a systematic review. *The Lancet Oncology* 2011;12(11):1062-
47 70.
48
49
50
51
52
53 102. Kumar N, Chen Y, Zaw AS, et al. Use of intraoperative cell-salvage for autologous
54 blood transfusions in metastatic spine tumour surgery: a systematic review. *The Lancet*
55 *Oncology* 2014;15(1):e33-41.
56
57
58
59
60

- 1
2
3 103. Kyrgiou M, Mitra A, Arbyn M, et al. Fertility and early pregnancy outcomes after
4 treatment for cervical intraepithelial neoplasia: systematic review and meta-analysis.
5
6
7
8 BMJ (Clinical research ed) 2014;349:g6192.
9
10
11 104. Lallas A, Kyrgidis A, Ferrara G, et al. Atypical Spitz tumours and sentinel lymph
12 node biopsy: a systematic review. *The Lancet Oncology* 2014;15(4):e178-83.
13
14
15
16 105. Lansbury L, Bath-Hextall F, Perkins W, et al. Interventions for non-metastatic
17 squamous cell carcinoma of the skin: systematic review and pooled analysis of
18
19
20
21
22
23
24
25 106. Laurie SA, Ho AL, Fury MG, et al. Systemic therapy in the management of metastatic
26 or locally recurrent adenoid cystic carcinoma of the salivary glands: a systematic review.
27
28
29
30
31
32
33
34 107. Lavigne E, Holowaty EJ, Pan SY, et al. Breast cancer detection and survival among
35 women with cosmetic breast implants: systematic review and meta-analysis of
36
37
38
39
40
41
42
43
44
45
46
47
48
49 108. Lee CK, Brown C, Gralla RJ, et al. Impact of EGFR inhibitor in non-small cell lung
50 cancer on progression-free and overall survival: a meta-analysis. *Journal of the National*
51
52
53
54
55
56
57
58
59
60
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

- 1
2
3 110. Lee JK, Hahn S, Kim DW, et al. Epidermal growth factor receptor tyrosine kinase
4 inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-
5 type epidermal growth factor receptor: a meta-analysis. *Jama* 2014;311(14):1430-7.
6
7
8
9
10
11 111. Lee L, Cheung WY, Atkinson E, et al. Impact of comorbidity on chemotherapy use
12 and outcomes in solid tumors: a systematic review. *Journal of clinical oncology : official*
13 *journal of the American Society of Clinical Oncology* 2011;29(1):106-17.
14
15
16
17
18
19 112. Lee SJ, Boscardin WJ, Stijacic-Cenzer I, et al. Time lag to benefit after screening for
20 breast and colorectal cancer: meta-analysis of survival data from the United States,
21 Sweden, United Kingdom, and Denmark. *BMJ (Clinical research ed)* 2013;346:e8441.
22
23
24
25
26
27 113. Liao WC, Chien KL, Lin YL, et al. Adjuvant treatments for resected pancreatic
28 adenocarcinoma: a systematic review and network meta-analysis. *The Lancet Oncology*
29 2013;14(11):1095-103.
30
31
32
33
34
35 114. Liao WC, Tu YK, Wu MS, et al. Blood glucose concentration and risk of pancreatic
36 cancer: systematic review and dose-response meta-analysis. *BMJ (Clinical research ed)*
37 2015;349:g7371.
38
39
40
41
42
43 115. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. *The*
44 *Lancet Oncology* 2013;14(6):e218-28.
45
46
47
48
49 116. Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients
50 with rheumatoid arthritis treated with biologic therapy: a meta-analysis. *Jama*
51 2012;308(9):898-908.
52
53
54
55
56
57
58
59
60

- 1
2
3 117. Lockett T, Goldstein D, Butow PN, et al. Psychological morbidity and quality of life
4 of ethnic minority patients with cancer: a systematic review and meta-analysis. The
5
6 Lancet Oncology 2011;12(13):1240-8.
7
8
9
10
11 118. Ma Y, Zhang P, Wang F, et al. Association between vitamin D and risk of colorectal
12 cancer: a systematic review of prospective studies. Journal of clinical oncology : official
13 journal of the American Society of Clinical Oncology 2011;29(28):3775-82.
14
15
16
17
18 119. Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and
19 associated neoplastic lesions in men who have sex with men: a systematic review and
20 meta-analysis. The Lancet Oncology 2012;13(5):487-500.
21
22
23
24
25
26
27 120. Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients with muscle-
28 invasive bladder cancer after selective bladder-preserving combined-modality therapy:
29 a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506,
30 9706, 9906, and 0233. Journal of clinical oncology : official journal of the American
31 Society of Clinical Oncology 2014;32(34):3801-9.
32
33
34
35
36
37
38
39
40 121. Maltoni M, Scarpi E, Rosati M, et al. Palliative sedation in end-of-life care and
41 survival: a systematic review. Journal of clinical oncology : official journal of the
42 American Society of Clinical Oncology 2012;30(12):1378-83.
43
44
45
46
47
48 122. Manceau G, Karoui M, Werner A, et al. Comparative outcomes of rectal cancer
49 surgery between elderly and non-elderly patients: a systematic review. The Lancet
50 Oncology 2012;13(12):e525-36.
51
52
53
54
55
56 123. Marinovich ML, Houssami N, Macaskill P, et al. Meta-analysis of magnetic resonance
57 imaging in detecting residual breast cancer after neoadjuvant therapy. Journal of the
58 National Cancer Institute 2013;105(5):321-33.
59
60

1
2
3 124. Markar SR, Wiggins T, Ni M, et al. Assessment of the quality of surgery within
4
5 randomised controlled trials for the treatment of gastro-oesophageal cancer: a
6
7 systematic review. *The Lancet Oncology* 2015;16(1):e23-31.
8
9

10
11 125. Martin-Doyle W, Leow JJ, Orsola A, et al. Improving selection criteria for early
12
13 cystectomy in high-grade t1 bladder cancer: a meta-analysis of 15,215 patients. *Journal*
14
15 *of clinical oncology : official journal of the American Society of Clinical Oncology*
16
17 2015;33(6):643-50.
18
19

20
21 126. Mauguen A, Le Pechoux C, Saunders MI, et al. Hyperfractionated or accelerated
22
23 radiotherapy in lung cancer: an individual patient data meta-analysis. *Journal of clinical*
24
25 *oncology : official journal of the American Society of Clinical Oncology*
26
27 2012;30(22):2788-97.
28
29

30
31 127. McGale P, Taylor C, Correa C, et al. Effect of radiotherapy after mastectomy and
32
33 axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-
34
35 analysis of individual patient data for 8135 women in 22 randomised trials. *Lancet*
36
37 (London, England) 2014;383(9935):2127-35.
38
39

40
41 128. Meulendijks D, Henricks LM, Sonke GS, et al. Clinical relevance of DPYD variants
42
43 c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-
44
45 associated toxicity: a systematic review and meta-analysis of individual patient data. *The*
46
47 *Lancet Oncology* 2015;16(16):1639-50.
48
49

50
51 129. Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and
52
53 adjustment disorder in oncological, haematological, and palliative-care settings: a meta-
54
55 analysis of 94 interview-based studies. *The Lancet Oncology* 2011;12(2):160-74.
56
57
58
59
60

- 1
2
3 130. Mitchell AJ, Ferguson DW, Gill J, et al. Depression and anxiety in long-term cancer
4 survivors compared with spouses and healthy controls: a systematic review and meta-
5 analysis. *The Lancet Oncology* 2013;14(8):721-32.
6
7
8
9
10
11 131. Mocellin S, Pilati P, Briarava M, et al. Breast Cancer Chemoprevention: A Network
12 Meta-Analysis of Randomized Controlled Trials. *Journal of the National Cancer Institute*
13 2016;108(2).
14
15
16
17
18
19 132. Mocellin S, Verdi D, Pooley KA, et al. Telomerase reverse transcriptase locus
20 polymorphisms and cancer risk: a field synopsis and meta-analysis. *Journal of the*
21 *National Cancer Institute* 2012;104(11):840-54.
22
23
24
25
26
27 133. Moorman PG, Havrilesky LJ, Gierisch JM, et al. Oral contraceptives and risk of
28 ovarian cancer and breast cancer among high-risk women: a systematic review and
29 meta-analysis. *Journal of clinical oncology : official journal of the American Society of*
30 *Clinical Oncology* 2013;31(33):4188-98.
31
32
33
34
35
36
37 134. Myers ER, Moorman P, Gierisch JM, et al. Benefits and Harms of Breast Cancer
38 Screening: A Systematic Review. *Jama* 2015;314(15):1615-34.
39
40
41
42
43 135. Nagayama A, Hayashida T, Jinno H, et al. Comparative effectiveness of neoadjuvant
44 therapy for HER2-positive breast cancer: a network meta-analysis. *Journal of the*
45 *National Cancer Institute* 2014;106(9).
46
47
48
49
50
51 136. Nair VS, Maeda LS, Ioannidis JP. Clinical outcome prediction by microRNAs in
52 human cancer: a systematic review. *Journal of the National Cancer Institute*
53 2012;104(7):528-40.
54
55
56
57
58
59
60

- 1
2
3 137. Ndiaye C, Mena M, Alemany L, et al. HPV DNA, E6/E7 mRNA, and p16INK4a
4
5 detection in head and neck cancers: a systematic review and meta-analysis. *The Lancet*
6
7 *Oncology* 2014;15(12):1319-31.
8
9
10
11 138. Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with
12
13 cardiovascular death in patients with prostate cancer: a meta-analysis of randomized
14
15 trials. *Jama* 2011;306(21):2359-66.
16
17
18
19 139. Niraula S, Amir E, Vera-Badillo F, et al. Risk of incremental toxicities and associated
20
21 costs of new anticancer drugs: a meta-analysis. *Journal of clinical oncology : official*
22
23 *journal of the American Society of Clinical Oncology* 2014;32(32):3634-42.
24
25
26
27 140. Niraula S, Le LW, Tannock IF. Treatment of prostate cancer with intermittent
28
29 versus continuous androgen deprivation: a systematic review of randomized trials.
30
31 *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
32
33 2013;31(16):2029-36.
34
35
36
37 141. Niraula S, Seruga B, Ocana A, et al. The price we pay for progress: a meta-analysis of
38
39 harms of newly approved anticancer drugs. *Journal of clinical oncology : official journal*
40
41 *of the American Society of Clinical Oncology* 2012;30(24):3012-9.
42
43
44
45 142. Oba K, Paoletti X, Alberts S, et al. Disease-free survival as a surrogate for overall
46
47 survival in adjuvant trials of gastric cancer: a meta-analysis. *Journal of the National*
48
49 *Cancer Institute* 2013;105(21):1600-7.
50
51
52
53 143. Ocana A, Vera-Badillo F, Seruga B, et al. HER3 overexpression and survival in solid
54
55 tumors: a meta-analysis. *Journal of the National Cancer Institute* 2013;105(4):266-73.
56
57
58
59
60

- 1
2
3 144. Ohri N, Shen X, Dicker AP, et al. Radiotherapy protocol deviations and clinical
4
5 outcomes: a meta-analysis of cooperative group clinical trials. *Journal of the National*
6
7 *Cancer Institute* 2013;105(6):387-93.
8
9
10
11 145. Oostendorp LJ, Stalmeier PF, Donders AR, et al. Efficacy and safety of palliative
12
13 chemotherapy for patients with advanced breast cancer pretreated with anthracyclines
14
15 and taxanes: a systematic review. *The Lancet Oncology* 2011;12(11):1053-61.
16
17
18
19 146. O'Sullivan CC, Bradbury I, Campbell C, et al. Efficacy of Adjuvant Trastuzumab for
20
21 Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer
22
23 and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials. *Journal*
24
25 *of clinical oncology : official journal of the American Society of Clinical Oncology*
26
27 2015;33(24):2600-8.
28
29
30
31
32 147. Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast
33
34 cancer screening decisions. *Jama* 2014;311(13):1327-35.
35
36
37
38 148. Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with
39
40 lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual
41
42 patient data. *The Lancet Oncology* 2014;15(3):333-42.
43
44
45
46 149. Patel SH, Wang Z, Wong WW, et al. Charged particle therapy versus photon therapy
47
48 for paranasal sinus and nasal cavity malignant diseases: a systematic review and meta-
49
50 analysis. *The Lancet Oncology* 2014;15(9):1027-38.
51
52
53
54 150. Peairs KS, Barone BB, Snyder CF, et al. Diabetes mellitus and breast cancer
55
56 outcomes: a systematic review and meta-analysis. *Journal of clinical oncology : official*
57
58 *journal of the American Society of Clinical Oncology* 2011;29(1):40-6.
59
60

- 1
2
3 151. Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and
4 risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies.
5
6 The Lancet Oncology 2012;13(4):385-94.
7
8
9
10
11 152. Peto R, Davies C, Godwin J, et al. Comparisons between different polychemotherapy
12 regimens for early breast cancer: meta-analyses of long-term outcome among 100,000
13 women in 123 randomised trials. Lancet (London, England) 2012;379(9814):432-44.
14
15
16
17
18 153. Pettersson A, Graff RE, Ursin G, et al. Mammographic density phenotypes and risk of
19 breast cancer: a meta-analysis. Journal of the National Cancer Institute 2014;106(5).
20
21
22
23
24 154. Phi XA, Houssami N, Obdeijn IM, et al. Magnetic resonance imaging improves breast
25 screening sensitivity in BRCA mutation carriers age \geq 50 years: evidence from an
26 individual patient data meta-analysis. Journal of clinical oncology : official journal of the
27 American Society of Clinical Oncology 2015;33(4):349-56.
28
29
30
31
32 155. Pilarski R, Burt R, Kohlman W, et al. Cowden syndrome and the PTEN hamartoma
33 tumor syndrome: systematic review and revised diagnostic criteria. Journal of the
34 National Cancer Institute 2013;105(21):1607-16.
35
36
37
38
39
40
41
42
43 156. Playdon MC, Bracken MB, Sanft TB, et al. Weight Gain After Breast Cancer Diagnosis
44 and All-Cause Mortality: Systematic Review and Meta-Analysis. Journal of the National
45 Cancer Institute 2015;107(12):djv275.
46
47
48
49
50
51 157. Potter S, Brigic A, Whiting PF, et al. Reporting clinical outcomes of breast
52 reconstruction: a systematic review. Journal of the National Cancer Institute
53
54
55
56 2011;103(1):31-46.
57
58
59
60

- 1
2
3 158. Proverbs-Singh T, Chiu SK, Liu Z, et al. Arterial thromboembolism in cancer patients
4 treated with cisplatin: a systematic review and meta-analysis. *Journal of the National*
5
6
7
8
9
10
11 159. Puts MT, Hardt J, Monette J, et al. Use of geriatric assessment for older adults in the
12
13
14
15
16
17
18
19 160. Raaschou-Nielsen O, Andersen ZJ, Beelen R, et al. Air pollution and lung cancer
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
161. Rahbari NN, Bork U, Motschall E, et al. Molecular detection of tumor cells in regional lymph nodes is associated with disease recurrence and poor survival in node-negative colorectal cancer: a systematic review and meta-analysis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2012;30(1):60-70.
162. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. *Jama* 2011;305(5):487-94.
163. Rao R, Euhus D, Mayo HG, et al. Axillary node interventions in breast cancer: a systematic review. *Jama* 2013;310(13):1385-94.
164. Rebolj M, Bonde J, Njor SH, et al. Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. *BMJ (Clinical research ed)* 2011;342:d2757.

- 1
2
3 165. Richards CJ, Je Y, Schutz FA, et al. Incidence and risk of congestive heart failure in
4 patients with renal and nonrenal cell carcinoma treated with sunitinib. *Journal of clinical*
5
6
7
8 oncology : official journal of the American Society of Clinical Oncology
9
10 2011;29(25):3450-6.
11
12
13 166. Riester M, Wei W, Waldron L, et al. Risk prediction for late-stage ovarian cancer by
14 meta-analysis of 1525 patient samples. *Journal of the National Cancer Institute*
15
16
17 2014;106(5).
18
19
20
21 167. Rooney AG, Carson A, Grant R. Depression in cerebral glioma patients: a systematic
22 review of observational studies. *Journal of the National Cancer Institute*
23
24
25 2011;103(1):61-76.
26
27
28
29 168. Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine
30 and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic
31 review, and meta-analysis. *Journal of clinical oncology : official journal of the American*
32
33
34
35
36
37 Society of Clinical Oncology 2014;32(10):1031-9.
38
39
40 169. Rossi A, Chiodini P, Sun JM, et al. Six versus fewer planned cycles of first-line
41 platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and
42
43
44
45 meta-analysis of individual patient data. *The Lancet Oncology* 2014;15(11):1254-62.
46
47
48 170. Rossi A, Di Maio M, Chiodini P, et al. Carboplatin- or cisplatin-based chemotherapy
49 in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual
50
51
52
53 patient data. *Journal of clinical oncology : official journal of the American Society of*
54
55
56
57
58
59
60
Clinical Oncology 2012;30(14):1692-8.

- 1
2
3 171. Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of
4 death due to cancer: analysis of individual patient data from randomised trials. *Lancet*
5
6 (London, England) 2011;377(9759):31-41.
7
8
9
10
11 172. Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer
12 incidence, mortality, and non-vascular death: analysis of the time course of risks and
13 benefits in 51 randomised controlled trials. *Lancet* (London, England)
14
15 2012;379(9826):1602-12.
16
17
18
19
20
21 173. Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer
22 metastasis: a study of incident cancers during randomised controlled trials. *Lancet*
23 (London, England) 2012;379(9826):1591-601.
24
25
26
27
28
29
30 174. Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term Survival Data
31 From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic
32 Melanoma. *Journal of clinical oncology : official journal of the American Society of*
33
34
35
36
37
38
39
40 175. Schmid D, Leitzmann MF. Television viewing and time spent sedentary in relation
41 to cancer risk: a meta-analysis. *Journal of the National Cancer Institute* 2014;106(7).
42
43
44
45
46 176. Schmoll HJ, Twelves C, Sun W, et al. Effect of adjuvant capecitabine or fluorouracil,
47 with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect
48 of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from
49 four randomised controlled trials. *The Lancet Oncology* 2014;15(13):1481-92.
50
51
52
53
54
55
56 177. Schottker B, Jorde R, Peasey A, et al. Vitamin D and mortality: meta-analysis of
57 individual participant data from a large consortium of cohort studies from Europe and
58 the United States. *BMJ (Clinical research ed)* 2014;348:g3656.
59
60

1
2
3 178. Schutz FA, Je Y, Richards CJ, et al. Meta-analysis of randomized controlled trials for
4 the incidence and risk of treatment-related mortality in patients with cancer treated
5 with vascular endothelial growth factor tyrosine kinase inhibitors. *Journal of clinical*
6
7
8
9
10
11
12
13 7.

14
15
16 179. Seng S, Liu Z, Chiu SK, et al. Risk of venous thromboembolism in patients with
17
18
19
20
21
22
23 2012;30(35):4416-26.

24
25
26 180. Shaikh F, Dupuis LL, Alexander S, et al. Cardioprotection and Second Malignant
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

180. Shaikh F, Dupuis LL, Alexander S, et al. Cardioprotection and Second Malignant
Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline
Chemotherapy: A Systematic Review and Meta-Analysis. *Journal of the National Cancer
Institute* 2016;108(4).

181. Sheinfeld Gorin S, Krebs P, Badr H, et al. Meta-analysis of psychosocial interventions
to reduce pain in patients with cancer. *Journal of clinical oncology : official journal of the
American Society of Clinical Oncology* 2012;30(5):539-47.

182. Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant
chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated
meta-analysis. *The Lancet Oncology* 2011;12(7):681-92.

183. Skoetz N, Trelle S, Rancea M, et al. Effect of initial treatment strategy on survival of
patients with advanced-stage Hodgkin's lymphoma: a systematic review and network
meta-analysis. *The Lancet Oncology* 2013;14(10):943-52.

1
2
3 184. Sonneveld P, Goldschmidt H, Rosinol L, et al. Bortezomib-based versus
4 nonbortezomib-based induction treatment before autologous stem-cell transplantation
5 in patients with previously untreated multiple myeloma: a meta-analysis of phase III
6 randomized, controlled trials. *Journal of clinical oncology : official journal of the*
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

184. Sonneveld P, Goldschmidt H, Rosinol L, et al. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2013;31(26):3279-87.

185. Spratt DE, Gordon Spratt EA, Wu S, et al. Efficacy of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2014;32(28):3144-55.

186. Tang V, Boscardin WJ, Stijacic-Cenzer I, et al. Time to benefit for colorectal cancer screening: survival meta-analysis of flexible sigmoidoscopy trials. *BMJ (Clinical research ed)* 2015;350:h1662.

187. Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. *Journal of the National Cancer Institute* 2014;106(6):dju124.

188. Teulings HE, Limpens J, Jansen SN, et al. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2015;33(7):773-81.

189. Theodoratou E, Montazeri Z, Hawken S, et al. Systematic meta-analyses and field synopsis of genetic association studies in colorectal cancer. *Journal of the National Cancer Institute* 2012;104(19):1433-57.

- 1
2
3 190. Thosani N, Thosani SN, Kumar S, et al. Reduced risk of colorectal cancer with use of
4 oral bisphosphonates: a systematic review and meta-analysis. *Journal of clinical*
5
6 oncology : official journal of the American Society of Clinical Oncology 2013;31(5):623-
7
8 30.
9
10
11
12
13 191. Trabert B, Ness RB, Lo-Ciganic WH, et al. Aspirin, nonaspirin nonsteroidal anti-
14
15 inflammatory drug, and acetaminophen use and risk of invasive epithelial ovarian
16
17 cancer: a pooled analysis in the Ovarian Cancer Association Consortium. *Journal of the*
18
19 National Cancer Institute 2014;106(2):djt431.
20
21
22
23 192. Tsilidis KK, Kasimis JC, Lopez DS, et al. Type 2 diabetes and cancer: umbrella review
24
25 of meta-analyses of observational studies. *BMJ (Clinical research ed)* 2015;350:g7607.
26
27
28
29 193. Vale CL, Burdett S, Ryzewska LH, et al. Addition of docetaxel or bisphosphonates
30
31 to standard of care in men with localised or metastatic, hormone-sensitive prostate
32
33 cancer: a systematic review and meta-analyses of aggregate data. *The Lancet Oncology*
34
35 2016;17(2):243-56.
36
37
38
39 194. Valery PC, Moore SP, Meiklejohn J, et al. International variations in childhood
40
41 cancer in indigenous populations: a systematic review. *The Lancet Oncology*
42
43 2014;15(2):e90-e103.
44
45
46
47 195. Valsecchi ME, Silbermins D, de Rosa N, et al. Lymphatic mapping and sentinel lymph
48
49 node biopsy in patients with melanoma: a meta-analysis. *Journal of clinical oncology :*
50
51 official journal of the American Society of Clinical Oncology 2011;29(11):1479-87.
52
53
54
55 196. van der Pas MH, Meijer S, Hoekstra OS, et al. Sentinel-lymph-node procedure in
56
57 colon and rectal cancer: a systematic review and meta-analysis. *The Lancet Oncology*
58
59 2011;12(6):540-50.
60

- 1
2
3 197. Vera-Badillo FE, Templeton AJ, de Gouveia P, et al. Androgen receptor expression
4 and outcomes in early breast cancer: a systematic review and meta-analysis. *Journal of*
5
6 the National Cancer Institute 2014;106(1):djt319.
7
8
9
10
11 198. Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of
12
13 patients with follicular lymphoma: an updated systematic review and meta-analysis of
14
15 randomized trials. *Journal of the National Cancer Institute* 2011;103(23):1799-806.
16
17
18
19 199. Violette PD, Agoritsas T, Alexander P, et al. Decision aids for localized prostate
20
21 cancer treatment choice: Systematic review and meta-analysis. *CA: a cancer journal for*
22
23 clinicians 2015;65(3):239-51.
24
25
26
27 200. Vollset SE, Clarke R, Lewington S, et al. Effects of folic acid supplementation on
28
29 overall and site-specific cancer incidence during the randomised trials: meta-analyses of
30
31 data on 50,000 individuals. *Lancet (London, England)* 2013;381(9871):1029-36.
32
33
34
35 201. Vora A, Andreano A, Pui CH, et al. Influence of Cranial Radiotherapy on Outcome in
36
37 Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy.
38
39 *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
40
41 2016.
42
43
44
45 202. Waldron L, Haibe-Kains B, Culhane AC, et al. Comparative meta-analysis of
46
47 prognostic gene signatures for late-stage ovarian cancer. *Journal of the National Cancer*
48
49 *Institute* 2014;106(5).
50
51
52
53 203. Wang HT, Yao YH, Li BG, et al. Neuroendocrine Prostate Cancer (NEPC) progressing
54
55 from conventional prostatic adenocarcinoma: factors associated with time to
56
57 development of NEPC and survival from NEPC diagnosis-a systematic review and pooled
58
59
60

1
2
3 analysis. Journal of clinical oncology : official journal of the American Society of Clinical
4
5 Oncology 2014;32(30):3383-90.
6
7

8
9 204. Wang SY, Chu H, Shamliyan T, et al. Network meta-analysis of margin threshold for
10
11 women with ductal carcinoma in situ. Journal of the National Cancer Institute
12
13 2012;104(7):507-16.
14
15

16
17 205. Wang X, Ouyang Y, Liu J, et al. Fruit and vegetable consumption and mortality from
18
19 all causes, cardiovascular disease, and cancer: systematic review and dose-response
20
21 meta-analysis of prospective cohort studies. BMJ (Clinical research ed) 2014;349:g4490.
22
23

24
25 206. Wang Y, Yang F, Shen Y, et al. Maintenance Therapy With Immunomodulatory
26
27 Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. Journal of the
28
29 National Cancer Institute 2016;108(3).
30
31

32
33 207. Wehner MR, Shive ML, Chren MM, et al. Indoor tanning and non-melanoma skin
34
35 cancer: systematic review and meta-analysis. BMJ (Clinical research ed)
36
37 2012;345:e5909.
38
39

40
41 208. Winter AC, Rice MS, Fortner RT, et al. Migraine and breast cancer risk: a prospective
42
43 cohort study and meta-analysis. Journal of the National Cancer Institute
44
45 2015;107(1):381.
46
47

48
49 209. Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for
50
51 the staging and surveillance of melanoma patients: a meta-analysis. Journal of the
52
53 National Cancer Institute 2011;103(2):129-42.
54
55

- 1
2
3 210. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors
4 with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium
5 studies. *Journal of the National Cancer Institute* 2011;103(3):250-63.
6
7
8
9
10
11 211. Yothers G, Sargent DJ, Wolmark N, et al. Outcomes among black patients with stage
12 II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials.
13 *Journal of the National Cancer Institute* 2011;103(20):1498-506.
14
15
16
17
18 212. Zhang B, Beeghly-Fadiel A, Long J, et al. Genetic variants associated with breast-
19 cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological
20 evidence. *The Lancet Oncology* 2011;12(5):477-88.
21
22
23
24
25
26
27 213. Zhang B, Shu XO, Delahanty RJ, et al. Height and Breast Cancer Risk: Evidence From
28 Prospective Studies and Mendelian Randomization. *Journal of the National Cancer*
29 *Institute* 2015;107(11).
30
31
32
33
34
35 214. Zhao FH, Lewkowitz AK, Chen F, et al. Pooled analysis of a self-sampling HPV DNA
36 Test as a cervical cancer primary screening method. *Journal of the National Cancer*
37 *Institute* 2012;104(3):178-88.
38
39
40
41
42
43 215. Zheng JS, Hu XJ, Zhao YM, et al. Intake of fish and marine n-3 polyunsaturated fatty
44 acids and risk of breast cancer: meta-analysis of data from 21 independent prospective
45 cohort studies. *BMJ (Clinical research ed)* 2013;346:f3706.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



PRISMA 2009 Checklist

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6 and Appendix
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	7
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	7-8
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	8
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8



PRISMA 2009 Checklist

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	NA
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	NA
RESULTS			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	9 and flow diagrams
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	NA
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	NA
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	9-12 and forest plot
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	NA
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	NA
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	NA
DISCUSSION			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	13-16
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	13-14
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	15-16
FUNDING			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	18

From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed1000097

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

For more information, visit: www.prisma-statement.org



PRISMA 2009 Checklist

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47